BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-S64. [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012] [Cited by in Crossref: 1011] [Cited by in F6Publishing: 958] [Article Influence: 168.5] [Reference Citation Analysis]
Number Citing Articles
1 Mobasheri N, Ghahremani L, Fallahzadeh Abarghooee E, Hassanzadeh J, Apte U. Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial Based on the Theory of Planned Behavior. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/3465980] [Reference Citation Analysis]
2 Sun H, Fang D, Wang H, Wang J, Yuan Y, Huang S, Ma H, Gu T, Bi Y. The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity. Hepatol Int 2022. [PMID: 36071305 DOI: 10.1007/s12072-022-10409-5] [Reference Citation Analysis]
3 Albadawy R, Hasanin AH, Agwa SHA, Hamady S, Aboul-Ela YM, Raafat MH, Kamar SS, Othman M, Yahia YA, Matboli M. Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death. Int J Mol Sci 2022;23:10148. [PMID: 36077546 DOI: 10.3390/ijms231710148] [Reference Citation Analysis]
4 Hu H, Han Y, Cao C, He Y. The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. J Transl Med 2022;20:398. [PMID: 36064712 DOI: 10.1186/s12967-022-03611-4] [Reference Citation Analysis]
5 Thomas CE, Yu YC, Luu HN, Wang R, Paragomi P, Behari J, Yuan JM. Neutrophil-lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Cancer Med 2022. [PMID: 36052483 DOI: 10.1002/cam4.5185] [Reference Citation Analysis]
6 Li Y, Huang X, Yang G, Xu K, Yin Y, Brecchia G, Yin J. CD36 favours fat sensing and transport to govern lipid metabolism. Prog Lipid Res 2022;:101193. [PMID: 36055468 DOI: 10.1016/j.plipres.2022.101193] [Reference Citation Analysis]
7 Zhang W, Wang J, Wang L, Shi R, Chu C, Shi Z, Liu P, Li Y, Liu X, Liu Z. Alternate-day fasting prevents non-alcoholic fatty liver disease and working memory impairment in diet-induced obese mice. J Nutr Biochem 2022;:109146. [PMID: 36049672 DOI: 10.1016/j.jnutbio.2022.109146] [Reference Citation Analysis]
8 Shao M, Lu Y, Xiang H, Wang J, Ji G, Wu T. Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine. Front Pharmacol 2022;13:971561. [DOI: 10.3389/fphar.2022.971561] [Reference Citation Analysis]
9 Sandvik ECS, Aasarød KM, Johnsen G, Hoff DAL, Kulseng B, Hyldmo ÅA, Græslie H, Nymo S, Sandvik J, Fossmark R. The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores-An 11.6-Year Follow-Up Study. J Clin Med 2022;11:4910. [PMID: 36013149 DOI: 10.3390/jcm11164910] [Reference Citation Analysis]
10 Yi M, Peng W, Feng X, Teng F, Tang Y, Kong Q, Chen Z. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment Pharmacol Ther 2022. [PMID: 35989292 DOI: 10.1111/apt.17165] [Reference Citation Analysis]
11 Qiao P, Jia Y, Ma A, He J, Shao C, Li X, Wang S, Yang B, Zhou H. Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice. Front Pharmacol 2022;13:934136. [DOI: 10.3389/fphar.2022.934136] [Reference Citation Analysis]
12 Hadjihambi A, Konstantinou C, Klohs J, Monsorno K, Le Guennec A, Donnelly C, Cox J, Kusumbe A, Hosford PS, Soffientini U, Lecca S, Mameli M, Jalan R, Paolicelli RC, Pellerin L. Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction. J Hepatol 2022:S0168-8278(22)03008-2. [PMID: 35995127 DOI: 10.1016/j.jhep.2022.08.008] [Reference Citation Analysis]
13 Nasiri-Ansari N, Androutsakos T, Flessa CM, Kyrou I, Siasos G, Randeva HS, Kassi E, Papavassiliou AG. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells 2022;11:2511. [PMID: 36010588 DOI: 10.3390/cells11162511] [Reference Citation Analysis]
14 Cheng Q, Zhang J, Fang J, Ding H, Xu Y, Lu X, Zhang W. Untargeted metabolomics reveals the role of AQP9 in nonalcoholic fatty liver disease in a mice model. Int J Biol Macromol 2022;219:864-75. [PMID: 35961555 DOI: 10.1016/j.ijbiomac.2022.08.023] [Reference Citation Analysis]
15 Chew NW, Chong B, Ng CH, Kong G, Chin YH, Xiao W, Lee M, Dan YY, Muthiah MD, Foo R. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Front Genet 2022;13:971484. [DOI: 10.3389/fgene.2022.971484] [Reference Citation Analysis]
16 Byrne CD, Targher G. Time to consider a holistic approach to the treatment of non-alcoholic fatty liver disease in obese young people? Gut 2022:gutjnl-2022-328316. [PMID: 35944926 DOI: 10.1136/gutjnl-2022-328316] [Reference Citation Analysis]
17 Jitrukthai S, Kositamongkol C, Boonchai P, Mepramoon E, Ariyakunaphan P, Nimitpunya P, Srivanichakorn W, Chaisathaphol T, Washirasaksiri C, Auesomwang C, Sitasuwan T, Tinmanee R, Sayabovorn N, Charatcharoenwitthaya P, Phisalprapa P. Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome. J Clin Med 2022;11:4627. [PMID: 35956240 DOI: 10.3390/jcm11154627] [Reference Citation Analysis]
18 Naseri K, Saadati S, Yari Z, Askari B, Mafi D, Hoseinian P, Asbaghi O, Hekmatdoost A, de Courten B. Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2022;14:3224. [PMID: 35956400 DOI: 10.3390/nu14153224] [Reference Citation Analysis]
19 Fröhlich E, Wahl R. Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease. Metabolites 2022;12:718. [DOI: 10.3390/metabo12080718] [Reference Citation Analysis]
20 Pal SC, Eslam M, Mendez-Sanchez N. Detangling the interrelations between MAFLD, insulin resistance, and key hormones. Hormones (Athens) 2022. [PMID: 35921046 DOI: 10.1007/s42000-022-00391-w] [Reference Citation Analysis]
21 Jiang W, Mao X, Liu Z, Zhang T, Jin L, Chen X. Global Burden of Nonalcoholic Fatty Liver Disease, 1990 to 2019: Findings From the Global Burden of Disease Study 2019. J Clin Gastroenterol 2022. [PMID: 35921320 DOI: 10.1097/MCG.0000000000001739] [Reference Citation Analysis]
22 Gu Y, Duan S, Ding M, Zheng Q, Fan G, Li X, Li Y, Liu C, Sun R, Liu R. Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPARα and INSIG/SREBP1c pathway. Phytomedicine 2022;103:154219. [PMID: 35691075 DOI: 10.1016/j.phymed.2022.154219] [Reference Citation Analysis]
23 Mei Y, Hu H, Deng L, Sun X, Tan W. Therapeutic effects of isosteviol sodium on non-alcoholic fatty liver disease by regulating autophagy via Sirt1/AMPK pathway. Sci Rep 2022;12:12857. [PMID: 35896572 DOI: 10.1038/s41598-022-16119-0] [Reference Citation Analysis]
24 Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut 2022:gutjnl-2022-327672. [PMID: 35879047 DOI: 10.1136/gutjnl-2022-327672] [Reference Citation Analysis]
25 Tan L, Shin S. Effects of oily fish and its fatty acid intake on non-alcoholic fatty liver disease development among South Korean adults. Front Nutr 2022;9:876909. [DOI: 10.3389/fnut.2022.876909] [Reference Citation Analysis]
26 Yue S, Tan Y, Zhang L, Zhang B, Jiang F, Ji G, Liu B, Wang R. Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway. Front Endocrinol 2022;13:885039. [DOI: 10.3389/fendo.2022.885039] [Reference Citation Analysis]
27 Ilieva M, Dao J, Miller HE, Madsen JH, Bishop AJR, Kauppinen S, Uchida S. Systematic Analysis of Long Non-Coding RNA Genes in Nonalcoholic Fatty Liver Disease. ncRNA 2022;8:56. [DOI: 10.3390/ncrna8040056] [Reference Citation Analysis]
28 Hu W, Gao W, Liu Z, Fang Z, Wang H, Zhao J, Zhang H, Lu W, Chen W. Specific Strains of Faecalibacterium prausnitzii Ameliorate Nonalcoholic Fatty Liver Disease in Mice in Association with Gut Microbiota Regulation. Nutrients 2022;14:2945. [DOI: 10.3390/nu14142945] [Reference Citation Analysis]
29 Han AL, Lee HK. Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease. Metabolites 2022;12:664. [DOI: 10.3390/metabo12070664] [Reference Citation Analysis]
30 Zhang Z, Xun Y, Rong S, Yan L, SoRelle JA, Li X, Tang M, Keller K, Ludwig S, Moresco EMY, Beutler B. Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity. Nat Commun 2022;13:4136. [PMID: 35842425 DOI: 10.1038/s41467-022-31812-4] [Reference Citation Analysis]
31 Zhao W, Mori H, Tomiga Y, Tanaka K, Perveen R, Mine K, Inadomi C, Yoshioka W, Kubotsu Y, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Zhao Y, Ozaki I, Nagafuchi S, Kawaguchi A, Aishima S, Anzai K, Takahashi H. HSPA8 Single-Nucleotide Polymorphism Is Associated with Serum HSC70 Concentration and Carotid Artery Atherosclerosis in Nonalcoholic Fatty Liver Disease. Genes (Basel) 2022;13:1265. [PMID: 35886046 DOI: 10.3390/genes13071265] [Reference Citation Analysis]
32 Lonardo A, Mantovani A, Petta S, Carraro A, Byrne CD, Targher G. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. Nat Rev Endocrinol 2022. [PMID: 35840803 DOI: 10.1038/s41574-022-00711-5] [Reference Citation Analysis]
33 Booijink R, Salgado-Polo F, Jamieson C, Perrakis A, Bansal R. A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis. EMBO Mol Med 2022;:e16333. [PMID: 35833384 DOI: 10.15252/emmm.202216333] [Reference Citation Analysis]
34 Samimi S, Rajabzadeh S, Rabizadeh S, Nakhjavani M, Nakhaei P, Avanaki FA, Esteghamati A. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes. Eur J Med Res 2022;27:112. [PMID: 35818084 DOI: 10.1186/s40001-022-00731-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Sheen YJ, Hsu CC, Kung PT, Chiu LT, Tsai WC. Impact of chronic hepatitis on cardiovascular events among type 2 diabetes patients in Taiwan pay-for-performance program. Sci Rep 2022;12:11720. [PMID: 35810252 DOI: 10.1038/s41598-022-15827-x] [Reference Citation Analysis]
36 Ishikawa H, Hayakawa M, Baatartsogt N, Kakizawa N, Ohto-Ozaki H, Maruyama T, Miura K, Suzuki K, Rikiyama T, Ohmori T. IκBζ regulates the development of nonalcoholic fatty liver disease through the attenuation of hepatic steatosis in mice. Sci Rep 2022;12:11634. [PMID: 35804007 DOI: 10.1038/s41598-022-15840-0] [Reference Citation Analysis]
37 Wang R, Xue F, Wang L, Shi G, Qian G, Yang N, Chen X. Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States. J Clin Lab Anal 2022;:e24590. [PMID: 35808891 DOI: 10.1002/jcla.24590] [Reference Citation Analysis]
38 Li Y, Cen CQ, Liu B, Zhou L, Huang XM, Liu GY. Overexpression of circ PTK2 suppresses the progression of nonalcoholic fatty liver disease via the miR-200c/SIK2/PI3K/Akt axis. Kaohsiung J Med Sci 2022. [PMID: 35791807 DOI: 10.1002/kjm2.12568] [Reference Citation Analysis]
39 Hammerschmidt P, Brüning JC. Contribution of specific ceramides to obesity-associated metabolic diseases. Cell Mol Life Sci 2022;79:395. [PMID: 35789435 DOI: 10.1007/s00018-022-04401-3] [Reference Citation Analysis]
40 Chu Y, Yu F, Wu Y, Yang J, Shi J, Ye T, Han D, Wang X. Identification of genes and key pathways underlying the pathophysiological association between nonalcoholic fatty liver disease and atrial fibrillation. BMC Med Genomics 2022;15. [DOI: 10.1186/s12920-022-01300-1] [Reference Citation Analysis]
41 Zhu Y, Ke Y, Hu Y, Wu K, Liu S, Hu J. Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis 2022;21:57. [PMID: 35780150 DOI: 10.1186/s12944-022-01658-2] [Reference Citation Analysis]
42 Guo J, Xu Y, Chen LJ, Zhang SX, Liou YL, Chen XP, Tan ZR, Zhou HH, Zhang W, Chen Y. Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug. J Adv Res 2022;39:319-32. [PMID: 35777915 DOI: 10.1016/j.jare.2021.10.004] [Reference Citation Analysis]
43 Byrne CD, Targher G. How should endocrinologists diagnose and treat non-alcoholic fatty liver disease? The Lancet Diabetes & Endocrinology 2022;10:478-80. [DOI: 10.1016/s2213-8587(22)00167-x] [Reference Citation Analysis]
44 Zhao M, Wang L, Wang M, Zhou S, Lu Y, Cui H, Racanelli AC, Zhang L, Ye T, Ding B, Zhang B, Yang J, Yao Y. Targeting fibrosis, mechanisms and cilinical trials. Signal Transduct Target Ther 2022;7:206. [PMID: 35773269 DOI: 10.1038/s41392-022-01070-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ramanathan R, Ali AH, Ibdah JA. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. IJMS 2022;23:7280. [DOI: 10.3390/ijms23137280] [Reference Citation Analysis]
46 Li H, Luo H, Zhang Y, Liu L, Lin R. Association of Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Stiffness With Bone Mineral Density in American Adults. Front Endocrinol 2022;13:891382. [DOI: 10.3389/fendo.2022.891382] [Reference Citation Analysis]
47 Abeysekera KWM, Orr JG, Gordon FH, Howe LD, Hamilton-Shield J, Heron J, Hickman M. Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis. BMC Gastroenterol 2022;22:323. [PMID: 35773644 DOI: 10.1186/s12876-022-02401-y] [Reference Citation Analysis]
48 Xu R, Pan J, Zhou W, Ji G, Dang Y. Recent advances in lean NAFLD. Biomed Pharmacother 2022;153:113331. [PMID: 35779422 DOI: 10.1016/j.biopha.2022.113331] [Reference Citation Analysis]
49 Jing W, Jiang M, Fu X, Yang J, Chen L, Leng F, Xu P, Huang W, Yu C, Yang Z. Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment. Int J Biol Macromol 2022:S0141-8130(22)01380-0. [PMID: 35777511 DOI: 10.1016/j.ijbiomac.2022.06.167] [Reference Citation Analysis]
50 Carteri RB, Grellert M, Borba DL, Marroni CA, Fernandes SA. Machine learning approaches using blood biomarkers in non-alcoholic fatty liver diseases. Artif Intell Gastroenterol 2022; 3(3): 80-87 [DOI: 10.35712/aig.v3.i3.80] [Reference Citation Analysis]
51 Gravina AG, Romeo M, Pellegrino R, Tuccillo C, Federico A, Loguercio C. Just Drink a Glass of Water? Effects of Bicarbonate–Sulfate–Calcium–Magnesium Water on the Gut–Liver Axis. Front Pharmacol 2022;13:869446. [DOI: 10.3389/fphar.2022.869446] [Reference Citation Analysis]
52 Tang X, Shi Y, Du J, Hu K, Zhou T, Chen L, Zhang Y, Li F, Zhang H, Liebe R, Meyer C, Dooley S, Zhu Z, Weng HL, Jia J, Huang T. Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study. BMJ Open 2022;12:e054891. [PMID: 35760549 DOI: 10.1136/bmjopen-2021-054891] [Reference Citation Analysis]
53 Wang J, Zheng D, Huang F, Zhao A, Kuang J, Ren Z, Chen T, Lei J, Lin J, Wang X, Jia W, Xie G, Zheng X. Theabrownin and Poria cocos Polysaccharide Improve Lipid Metabolism via Modulation of Bile Acid and Fatty Acid Metabolism. Front Pharmacol 2022;13:875549. [DOI: 10.3389/fphar.2022.875549] [Reference Citation Analysis]
54 Bai N, Lu X, Jin L, Alimujiang M, Ma J, Hu F, Xu Y, Sun J, Xu J, Zhang R, Han J, Hu C, Yang Y. CLSTN3 gene variant associates with obesity risk and contributes to dysfunction in white adipose tissue. Mol Metab 2022;:101531. [PMID: 35753632 DOI: 10.1016/j.molmet.2022.101531] [Reference Citation Analysis]
55 Zhang M, Tang L, Cui X, Yu T, Li Z, Li X, Li G. Shear wave elastography in evaluation of carotid elasticity in the type 2 diabetes mellitus patients with nonalcoholic fatty liver disease. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-022-01097-w] [Reference Citation Analysis]
56 Park JH, Hong JY, Han K, Kang W, Park JK. Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. Sci Rep 2022;12:10681. [PMID: 35739172 DOI: 10.1038/s41598-022-14856-w] [Reference Citation Analysis]
57 Mantovani A, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A. MAFLD and CKD: An Updated Narrative Review. IJMS 2022;23:7007. [DOI: 10.3390/ijms23137007] [Reference Citation Analysis]
58 Tao G, Zhang G, Chen W, Yang C, Xue Y, Song G, Qin S. A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease. J Cell Mol Med 2022. [PMID: 35734974 DOI: 10.1111/jcmm.17456] [Reference Citation Analysis]
59 Zhu JY, Chen M, Mu WJ, Luo HY, Guo L. Higd1a facilitates exercise-mediated alleviation of fatty liver in diet-induced obese mice. Metabolism 2022;:155241. [PMID: 35750235 DOI: 10.1016/j.metabol.2022.155241] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol 2022:S0168-8278(22)00375-0. [PMID: 35750137 DOI: 10.1016/j.jhep.2022.06.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Xia J, Li J, Jin G, Yao D, Hua Q. Development of a Nomogram for Estimating the Risk of Left Ventricular Diastolic Dysfunction in Patients with Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2022;15:1749-59. [PMID: 35706476 DOI: 10.2147/DMSO.S371208] [Reference Citation Analysis]
62 Xiang J, Deng Y, Liu H, Pu Y. LncRNA MALAT1 Promotes PPARα/CD36-Mediated Hepatic Lipogenesis in Nonalcoholic Fatty Liver Disease by Modulating miR-206/ARNT Axis. Front Bioeng Biotechnol 2022;10:858558. [DOI: 10.3389/fbioe.2022.858558] [Reference Citation Analysis]
63 Dua P, Mishra A, Reeta KH. Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection. Biomark Med 2022. [PMID: 35694871 DOI: 10.2217/bmm-2021-1129] [Reference Citation Analysis]
64 Theel W, Boxma-de Klerk BM, Dirksmeier-Harinck F, van Rossum EFC, Kanhai DA, Apers J, van Dalen BM, de Knegt RJ, Holleboom AG, Tushuizen ME, Grobbee DE, Wiebolt J, Castro Cabezas M. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. Obes Rev 2022. [PMID: 35692179 DOI: 10.1111/obr.13481] [Reference Citation Analysis]
65 Auth PA, da Silva GR, Amaral EC, Bortoli VF, Manzano MI, de Souza LM, Lovato ECW, Ribeiro-Paes JT, Gasparotto Junior A, Lívero FADR. Croton urucurana Baill. Ameliorates Metabolic Associated Fatty Liver Disease in Rats. Front Pharmacol 2022;13:886122. [PMID: 35668935 DOI: 10.3389/fphar.2022.886122] [Reference Citation Analysis]
66 George ES, Georgousopoulou EN, Mellor DD, Chrysohoou C, Pitsavos C, Panagiotakos DB. Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002-2012). Nutrients 2022;14:2367. [PMID: 35745097 DOI: 10.3390/nu14122367] [Reference Citation Analysis]
67 Ciardullo S, Oltolini A, Cannistraci R, Muraca E, Perseghin G. Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population. Am J Clin Nutr 2022;115:1528-34. [PMID: 35244676 DOI: 10.1093/ajcn/nqac059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Matsubayashi Y, Fujihara K, Yamada-harada M, Mitsuma Y, Sato T, Yaguchi Y, Osawa T, Yamamoto M, Kitazawa M, Yamada T, Kodama S, Sone H. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc Diabetol 2022;21. [DOI: 10.1186/s12933-022-01518-4] [Reference Citation Analysis]
69 Yang M, Xu Y, Hu C, Zhang S, Kuang M, Zou Y. Association between hypertriglyceridemic-waist phenotype and non-alcoholic fatty liver disease: a general population-based study. Lipids Health Dis 2022;21:50. [PMID: 35655216 DOI: 10.1186/s12944-022-01660-8] [Reference Citation Analysis]
70 Sakisaka M, Yoshii D, Sakisaka M, Inomata Y. Modulation of tube feeding protocol to prevent aspiration pneumonia in gastroesophageal reflux. Clinical Nutrition Open Science 2022;43:67-77. [DOI: 10.1016/j.nutos.2022.05.004] [Reference Citation Analysis]
71 Chen X, Wen H, Li Q, Shen L, Luo X, Zhou B, Guo R. Quantification of liver fat deposition in obese and diabetic patients: A pilot study on the correlation with myocardium and periapical fat content☆. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.005] [Reference Citation Analysis]
72 Zhang Y, Li J, Liu H. Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-01050-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Aghemo A, Alekseeva OP, Angelico F, Bakulin IG, Bakulina NV, Bordin D, Bueverov AO, Drapkina OM, Gillessen A, Kagarmanova EM, Korochanskaya NV, Kucheryavii UA, Lazebnik LB, Livzan MA, Maev IV, Martynov AI, Osipenko MF, Sas EI, Starodubova A, Uspensky YP, Vinnitskaya EV, Yakovenko EP, Yakovlev AA. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Annals of Medicine 2022;54:1548-60. [DOI: 10.1080/07853890.2022.2069854] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Zhang X, Mou Y, Aribas E, Amiri M, Nano J, Bramer WM, Kavousi M, de Knegt RJ, Asllanaj E, Ghanbari M. Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis. Genes 2022;13:966. [DOI: 10.3390/genes13060966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Papic N, Samadan L, Vrsaljko N, Radmanic L, Jelicic K, Simicic P, Svoboda P, Lepej SZ, Vince A. Distinct Cytokine Profiles in Severe COVID-19 and Non-Alcoholic Fatty Liver Disease. Life 2022;12:795. [DOI: 10.3390/life12060795] [Reference Citation Analysis]
76 Ding Y, Xu X, Tian T, Yu C, Ge X, Gao J, Lu J, Ge Z, Jiang T, Jiang Y, Ma H, Song C, Hu Z. Weight Change across Adulthood in Relation to Non-Alcoholic Fatty Liver Disease among Non-Obese Individuals. Nutrients 2022;14:2140. [DOI: 10.3390/nu14102140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Tsujita Y, Sofue K, Ueshima E, Ueno Y, Hori M, Murakami T. Clinical Application of Quantitative MR Imaging in Nonalcoholic Fatty Liver Disease. Magn Reson Med Sci 2022. [PMID: 35584952 DOI: 10.2463/mrms.rev.2021-0152] [Reference Citation Analysis]
78 Sun P, Huang L, Shuai P, Wan Z, Liu Y, Xue J, Liu Y. Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial. Front Nutr 2022;9:863834. [PMID: 35571881 DOI: 10.3389/fnut.2022.863834] [Reference Citation Analysis]
79 Mahmoudi A, Jamialahmadi T, Johnston TP, Sahebkar A. Impact of fenofibrate on NAFLD/NASH: A genetic perspective. Drug Discov Today 2022:S1359-6446(22)00194-5. [PMID: 35569762 DOI: 10.1016/j.drudis.2022.05.007] [Reference Citation Analysis]
80 Dong G, Huang X, Chen R, Wu L, Jiang S, Chen S, Kosuru R. Increased PD-L1 Restricts Liver Injury in Nonalcoholic Fatty Liver Disease. Oxidative Medicine and Cellular Longevity 2022;2022:1-18. [DOI: 10.1155/2022/5954437] [Reference Citation Analysis]
81 Guagnano MT, D'ardes D, Ilaria R, Santilli F, Schiavone C, Bucci M, Cipollone F. Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications. JCM 2022;11:2759. [DOI: 10.3390/jcm11102759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Jarmakiewicz-czaja S, Sokal A, Pardak P, Filip R, Granito A. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-13. [DOI: 10.1155/2022/4344905] [Reference Citation Analysis]
83 Yadav AK, Sata TN, Verma D, Mishra AK, Sah AK, Hossain MM, Pant K, Venugopal SK. Free fatty acid-induced miR-181a-5p stimulates apoptosis by targeting XIAP and Bcl2 in hepatic cells. Life Sci 2022;:120625. [PMID: 35551953 DOI: 10.1016/j.lfs.2022.120625] [Reference Citation Analysis]
84 Chen S, Cai X, Liu Y, Shen Y, Guillot A, Tacke F, Tang L, Liu H. The macrophage-associated microRNA-4715-3p / Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data. Bioengineered 2022;13:11740-51. [PMID: 35521691 DOI: 10.1080/21655979.2022.2072602] [Reference Citation Analysis]
85 Petrescu M, Vlaicu SI, Ciumărnean L, Milaciu MV, Mărginean C, Florea M, Vesa ȘC, Popa M. Chronic Inflammation—A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue. Medicina 2022;58:641. [DOI: 10.3390/medicina58050641] [Reference Citation Analysis]
86 Yan S. Role of TFEB in Autophagy and the Pathogenesis of Liver Diseases. Biomolecules 2022;12:672. [DOI: 10.3390/biom12050672] [Reference Citation Analysis]
87 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
88 Cho Y, Chang Y, Ryu S, Jung HS, Kim CW, Oh H, Kim MK, Sohn W, Shin H, Wild SH, Byrne CD. Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. Hepatol Commun 2022. [PMID: 35503803 DOI: 10.1002/hep4.1975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Avignon A. Protecting the Liver: Should We Substitute Fruit Juices for Sugar-Sweetened Beverages? Diabetes Care 2022;45:1032-4. [PMID: 35561135 DOI: 10.2337/dci22-0005] [Reference Citation Analysis]
90 Saunders SL, Clark JM, Rudser K, Chauhan A, Ryder JR, Bolan PJ. Comparison of automatic liver volumetry performance using different types of magnetic resonance images. Magnetic Resonance Imaging 2022. [DOI: 10.1016/j.mri.2022.05.002] [Reference Citation Analysis]
91 Flessa C, Kyrou I, Nasiri‐ansari N, Kaltsas G, Kassi E, Randeva HS. Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD). J of Cellular Biochemistry. [DOI: 10.1002/jcb.30247] [Reference Citation Analysis]
92 D'silva M, Cho JY, Han H, Yoon Y, Lee HW, Lee JS, Lee B, Kim M. Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma. Surgical Oncology 2022;41:101730. [DOI: 10.1016/j.suronc.2022.101730] [Reference Citation Analysis]
93 Haonon O, Liu Z, Dangtakot R, Pinlaor P, Puapairoj A, Cha'on U, Intuyod K, Pongking T, Chantawong C, Sengthong C, Chaidee A, Onsurathum S, Li JV, Pinlaor S. Opisthorchis viverrini infection induces metabolic disturbances in hamsters fed with high fat/high fructose diets: implications for liver and kidney pathologies. The Journal of Nutritional Biochemistry 2022. [DOI: 10.1016/j.jnutbio.2022.109053] [Reference Citation Analysis]
94 Adnan M, Wajid A, Noor W, Batool A, Aasim M, Abbas K, Ain Q. Sociodemographic and genetic determinants of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients. J Genet Eng Biotechnol 2022;20:68. [PMID: 35486295 DOI: 10.1186/s43141-022-00349-w] [Reference Citation Analysis]
95 Tsukahara Y, Ferran B, Minetti ET, Chong BSH, Gower AC, Bachschmid MM, Matsui R. Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis. Antioxidants (Basel) 2022;11:867. [PMID: 35624731 DOI: 10.3390/antiox11050867] [Reference Citation Analysis]
96 Duan T, Jiang HY, Ling WW, Song B. Noninvasive imaging of hepatic dysfunction: A state-of-the-art review. World J Gastroenterol 2022; 28(16): 1625-1640 [DOI: 10.3748/wjg.v28.i16.1625] [Reference Citation Analysis]
97 Torres S, Segalés P, García-Ruiz C, Fernández-Checa JC. Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. Cells 2022;11:1475. [PMID: 35563780 DOI: 10.3390/cells11091475] [Reference Citation Analysis]
98 Vecera R, Poruba M, Hüttl M, Malinska H, Oliyarnyk O, Markova I, Racova Z, Soukop J, Kazdova L. Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats. CIMB 2022;44:1889-900. [DOI: 10.3390/cimb44050129] [Reference Citation Analysis]
99 Kim Y, Chang Y, Ryu S, Cho IY, Kwon MJ, Sohn W, Kim MK, Wild SH, Byrne CD. Resolution of, and risk of incident non-alcoholic fatty liver disease with changes in serum 25-hydroxy vitamin D status. J Clin Endocrinol Metab 2022:dgac255. [PMID: 35460237 DOI: 10.1210/clinem/dgac255] [Reference Citation Analysis]
100 Babu AF, Csader S, Männistö V, Tauriainen MM, Pentikäinen H, Savonen K, Klåvus A, Koistinen V, Hanhineva K, Schwab U. Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool. Sci Rep 2022;12:6485. [PMID: 35444259 DOI: 10.1038/s41598-022-10481-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Yuan Y, Li K, Teng F, Wang W, Zhou B, Zhou X, Lin J, Ye X, Deng Y, Liu W, Luo S, Zhang P, Liu D, Zheng M, Li J, Lu Y, Zhang H. Leukemia inhibitory factor protects against liver steatosis in non-alcoholic fatty liver disease patients and obese mice. J Biol Chem 2022;:101946. [PMID: 35447114 DOI: 10.1016/j.jbc.2022.101946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Gao Z, Dai L, Zhang H, Cheng L. Screening Potential Drugs for the Development of NAFLD Based on Drug Perturbation Gene Set. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/7606716] [Reference Citation Analysis]
103 Sigala DM, Hieronimus B, Medici V, Lee V, Nunez MV, Bremer AA, Cox CL, Price CA, Benyam Y, Abdelhafez Y, McGahan JP, Keim NL, Goran MI, Pacini G, Tura A, Sirlin CB, Chaudhari AJ, Havel PJ, Stanhope KL. The Dose-Response Effects of Consuming High Fructose Corn Syrup-Sweetened Beverages on Hepatic Lipid Content and Insulin Sensitivity in Young Adults. Nutrients 2022;14:1648. [PMID: 35458210 DOI: 10.3390/nu14081648] [Reference Citation Analysis]
104 Hong Q, Shen J, Feng Q, Zheng Q, Qiao Y. Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn's disease. BMC Gastroenterol 2022;22:183. [PMID: 35413806 DOI: 10.1186/s12876-022-02238-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Yoshida R, Yano Y, Hoshi N, Okamoto N, Sui Y, Yamamoto A, Asaji N, Shiomi Y, Yasutomi E, Hatazawa Y, Hayashi H, Ueda Y, Kodama Y. Acid-treated high-amylose corn starch suppresses high-fat diet-induced steatosis. J Food Sci 2022. [PMID: 35411589 DOI: 10.1111/1750-3841.16146] [Reference Citation Analysis]
106 Peng HL, Liu LN, Liu DL, Tan YY. Depression and non-alcoholic fatty liver disease: Association and potential mechanisms. Shijie Huaren Xiaohua Zazhi 2022; 30(7): 295-302 [DOI: 10.11569/wcjd.v30.i7.295] [Reference Citation Analysis]
107 Rojas YAO, Cuellar CLV, Barrón KMA, Verdugo JPA, Miranda AL. Non-alcoholic Fatty Liver Disease prevalence in Latin America: A systematic review and meta-analysis. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100706] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Meyhöfer S, Eckert AJ, Hummel M, Laimer M, Roden M, Kress S, Seufert J, Meyhöfer SM, Holl RW. Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database. Diabetes Obes Metab 2022;24:727-32. [PMID: 34882949 DOI: 10.1111/dom.14616] [Reference Citation Analysis]
109 Minhas AMK, Bhopalwala HM, Dewaswala N, Salah HM, Khan MS, Shahid I, Biegus J, Lopes RD, Pandey A, Fudim M. Association of Non-Alcoholic Fatty Liver Disease with In-Hospital Outcomes in Primary Heart Failure Hospitalizations with Reduced or Preserved Ejection Fraction. Current Problems in Cardiology 2022. [DOI: 10.1016/j.cpcardiol.2022.101199] [Reference Citation Analysis]
110 Latif MU, Schmidt GE, Mercan S, Rahman R, Gibhardt CS, Stejerean-Todoran I, Reutlinger K, Hessmann E, Singh SK, Moeed A, Rehman A, Butt UJ, Bohnenberger H, Stroebel P, Bremer SC, Neesse A, Bogeski I, Ellenrieder V. NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. Gut 2022:gutjnl-2021-325013. [PMID: 35365570 DOI: 10.1136/gutjnl-2021-325013] [Reference Citation Analysis]
111 Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022;71:778-88. [PMID: 33685968 DOI: 10.1136/gutjnl-2021-324191] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
112 Ramadori P, Kam S, Heikenwalder M. T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis. Hepatology 2022;75:1038-49. [PMID: 35023202 DOI: 10.1002/hep.32336] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Xiong G, Huang C, Zou Y, Tao Z, Zou J, Huang J, M.a B. Associations of Urinary Phytoestrogen Concentrations with Nonalcoholic Fatty Liver Disease among Adults. Journal of Healthcare Engineering 2022;2022:1-13. [DOI: 10.1155/2022/4912961] [Reference Citation Analysis]
114 Sun Q, Tang L, Wang M, Zhu P, Li Y, Ma H, Huang O, Hong L, Li G, Byrne CD, Targher G, Liu W, Lu Y, Ding J, Zheng M. Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. Front Med 2022;9:864570. [DOI: 10.3389/fmed.2022.864570] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Weinstein AA, De Avila L, Kannan S, Paik JM, Golabi P, Gerber LH, Younossi ZM. Interrelationship between physical activity and depression in nonalcoholic fatty liver disease. World J Hepatol 2022; 14(3): 612-622 [DOI: 10.4254/wjh.v14.i3.612] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Noda T, Kamiya K, Hamazaki N, Nozaki K, Ichikawa T, Yamashita M, Uchida S, Maekawa E, Terada T, Reed JL, Yamaoka-tojo M, Matsunaga A, Ako J. The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome. JCM 2022;11:1847. [DOI: 10.3390/jcm11071847] [Reference Citation Analysis]
117 Li Z, Tian J, Cheng Z, Teng W, Zhang W, Bao Y, Wang Y, Song B, Chen Y, Li B. Hypoglycemic bioactivity of anthocyanins: A review on proposed targets and potential signaling pathways. Crit Rev Food Sci Nutr 2022;:1-18. [PMID: 35333674 DOI: 10.1080/10408398.2022.2055526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Sun S, Yang Q, Zhou Q, Cao W, Yu S, Zhan S, Sun F. Long-term exposure to air pollution, habitual physical activity and risk of non-alcoholic fatty liver disease: A prospective cohort study. Ecotoxicol Environ Saf 2022;235:113440. [PMID: 35344898 DOI: 10.1016/j.ecoenv.2022.113440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Zou Y, Hu C, Kuang M, Chai Y. Remnant cholesterol/high-density lipoprotein cholesterol ratio is a new powerful tool for identifying non-alcoholic fatty liver disease. BMC Gastroenterol 2022;22:134. [PMID: 35331166 DOI: 10.1186/s12876-022-02216-x] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Policarpo S, Carvalhana S, Craciun A, Crespo RR, Cortez-Pinto H. Do MAFLD Patients with Harmful Alcohol Consumption Have a Different Dietary Intake? Nutrients 2022;14:1335. [PMID: 35405948 DOI: 10.3390/nu14071335] [Reference Citation Analysis]
121 Rebollo-hernanz M, Aguilera Y, Martín-cabrejas MA, Gonzalez de Mejia E. Activating Effects of the Bioactive Compounds From Coffee By-Products on FGF21 Signaling Modulate Hepatic Mitochondrial Bioenergetics and Energy Metabolism in vitro. Front Nutr 2022;9:866233. [DOI: 10.3389/fnut.2022.866233] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
122 Mahmoudi A, Butler AE, Majeed M, Banach M, Sahebkar A. Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis. Nutrients 2022;14:1331. [PMID: 35405942 DOI: 10.3390/nu14071331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
123 Wang X, Shen L, Shen Y, Han F, Ji Z. Association between Non-alcoholic Fatty Liver Disease and the Severity of Coronary Artery Stenosis in Eastern Chinese Population. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.122772] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Zhao CZ, Jiang L, Li WY, Wu G, Chen J, Dong LH, Li M, Jiang W, Zhu JX, Gao YP, Ma QG, Zhong GY, Wei RR. Establishment and metabonomics analysis of nonalcoholic fatty liver disease model in golden hamster. Z Naturforsch C J Biosci 2022. [PMID: 35286786 DOI: 10.1515/znc-2021-0201] [Reference Citation Analysis]
125 Gad AI, Abdel-ghani HA, Barakat AAA. Effect of Ramadan fasting on hepatic steatosis as quantified by controlled attenuation parameter (CAP): a prospective observational study. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00187-y] [Reference Citation Analysis]
126 Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 2022;22:63. [PMID: 35287643 DOI: 10.1186/s12902-022-00980-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
127 Li L, Huang Q, Yang L, Zhang R, Gao L, Han X, Ji L, Zou X. The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004. Nutrients 2022;14:1224. [PMID: 35334881 DOI: 10.3390/nu14061224] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Rinott E, Meir AY, Tsaban G, Zelicha H, Kaplan A, Knights D, Tuohy K, Scholz MU, Koren O, Stampfer MJ, Wang DD, Shai I, Youngster I. The effects of the Green-Mediterranean diet on cardiometabolic health are linked to gut microbiome modifications: a randomized controlled trial. Genome Med 2022;14:29. [PMID: 35264213 DOI: 10.1186/s13073-022-01015-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
129 Baars T, Gieseler RK, Patsalis PC, Canbay A. Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease. Metabolism 2022;:155179. [PMID: 35283187 DOI: 10.1016/j.metabol.2022.155179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Osipova D, Kokoreva K, Lazebnik L, Golovanova E, Pavlov C, Dukhanin A, Orlova S, Starostin K. Regression of Liver Steatosis Following Phosphatidylcholine Administration: A Review of Molecular and Metabolic Pathways Involved. Front Pharmacol 2022;13:797923. [DOI: 10.3389/fphar.2022.797923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Peng A, Liu S, Fang L, Zhu Z, Zhou Y, Yue S, Ma Z, Liu X, Xue S, Qiu Y, Qi R. Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis. Eur J Pharmacol 2022;:174841. [PMID: 35278405 DOI: 10.1016/j.ejphar.2022.174841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Zou D, Liu L, Zeng Y, Wang H, Dai D, Xu M. LncRNA MEG3 up-regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease. Cell Death Discov 2022;8:103. [PMID: 35256601 DOI: 10.1038/s41420-022-00889-7] [Reference Citation Analysis]
133 Yuan L, Hanlon CL, Terrault N, Alqahtani S, Tamim H, Lai M, Saberi B. Portrait of Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. Am J Gastroenterol 2022;117:433-44. [PMID: 35083985 DOI: 10.14309/ajg.0000000000001591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
134 Görigk S, Ouwens DM, Kuhn T, Altenhofen D, Binsch C, Damen M, Khuong JM, Kaiser K, Knebel B, Vogel H, Schürmann A, Chadt A, Al-hasani H. Nudix hydrolase NUDT19 regulates mitochondrial function and ATP production in murine hepatocytes. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2022. [DOI: 10.1016/j.bbalip.2022.159153] [Reference Citation Analysis]
135 Mcglinchey AJ, Govaere O, Geng D, Ratziu V, Allison M, Bousier J, Petta S, de Oliviera C, Bugianesi E, Schattenberg JM, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. Metabolic signatures across the full spectrum of nonalcoholic fatty liver disease. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Gupta H, Min B, Ganesan R, Gebru YA, Sharma SP, Park E, Won S, Jeong J, Lee S, Cha M, Kwon G, Jeong M, Hyun J, Eom J, Park H, Yoon S, Choi M, Kim D, Suk K. Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines 2022;10:550. [DOI: 10.3390/biomedicines10030550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
137 Boulouta A, Aggeletopoulou I, Kanaloupitis S, Tsounis EP, Issaris V, Papantoniou K, Apostolos A, Tsaplaris P, Pastras P, Sotiropoulos C, Tsintoni A, Diamantopoulou G, Thomopoulos K, Michalaki M, Triantos C. The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience. Clin Res Hepatol Gastroenterol 2022;:101896. [PMID: 35227957 DOI: 10.1016/j.clinre.2022.101896] [Reference Citation Analysis]
138 Cervo A, Sebastiani G, Milic J, Krahn T, Mazzola S, Petta S, Cascio A, Guaraldi G, Mazzola G. "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV". HIV Med 2022. [PMID: 35199429 DOI: 10.1111/hiv.13274] [Reference Citation Analysis]
139 Zhang Y, Liu X, Zhang H, Wang X. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol 2022;13:836455. [DOI: 10.3389/fendo.2022.836455] [Reference Citation Analysis]
140 Gao H, Zhou L, Zhong Y, Ding Z, Lin S, Hou X, Zhou X, Shao J, Yang F, Zou X, Cao H, Xiao G. Kindlin-2 haploinsufficiency protects against fatty liver by targeting Foxo1 in mice. Nat Commun 2022;13:1025. [PMID: 35197460 DOI: 10.1038/s41467-022-28692-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
141 Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin Exp Med 2022. [PMID: 35192111 DOI: 10.1007/s10238-022-00799-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Guo M, Xiang L, Yao J, Zhang J, Zhu S, Wang D, Liu C, Li G, Wang J, Gao Y, Xie C, Ma X, Xu L, Zhou J. Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction. Front Endocrinol 2022;13:851520. [DOI: 10.3389/fendo.2022.851520] [Reference Citation Analysis]
143 Maevskaya M, Kotovskaya Y, Ivashkin V, Tkacheva O, Troshina E, Shestakova M, Breder V, Geyvandova N, Doschitsin V, Dudinskaya E, Ershova E, Kodzoeva K, Komshilova K, Korochanskaya N, Mayorov A, Mishina E, Nadinskaya M, Nikitin I, Pogosova N, Tarzimanova A, Shamkhalova M. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv. [DOI: 10.26442/00403660.2022.02.201363] [Reference Citation Analysis]
144 Huang WC, Xu JW, Li S, Ng XE, Tung YT. Effects of exercise on high-fat diet-induced non-alcoholic fatty liver disease and lipid metabolism in ApoE knockout mice. Nutr Metab (Lond) 2022;19:10. [PMID: 35172845 DOI: 10.1186/s12986-022-00644-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
145 Han JE, Shin HB, Ahn YH, Cho HJ, Cheong JY, Park B, Kim SS. Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus. Sci Rep 2022;12:2538. [PMID: 35169195 DOI: 10.1038/s41598-022-06205-8] [Reference Citation Analysis]
146 Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-peralta F. Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. JCM 2022;11:968. [DOI: 10.3390/jcm11040968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
147 Wang K, Li B, Fu R, Jiang Z, Wen X, Ni Y. Bentong ginger oleoresin mitigates liver injury and modulates gut microbiota in mouse with nonalcoholic fatty liver disease induced by high‐fat diet. Journal of Food Science. [DOI: 10.1111/1750-3841.16076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Chou Y, Sun Z, Shen W, Yang Y, Lu F, Chang C, Li C, Wu J. Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. Front Nutr 2022;9:765206. [DOI: 10.3389/fnut.2022.765206] [Reference Citation Analysis]
149 Sun Z, Tang Z, Yang X, Liu QS, Zhang J, Zhou Q, Jiang G. 3-tert-Butyl-4-hydroxyanisole Impairs Hepatic Lipid Metabolism in Male Mice Fed with a High-Fat Diet. Environ Sci Technol 2022. [PMID: 35133139 DOI: 10.1021/acs.est.1c07182] [Reference Citation Analysis]
150 Patel HK, Kovacic R, Chandrasekar VT, Patel SC, Singh M, Le Cam E, Burton JH, Ray A, Shah JN. Correlation of Gastrointestinal Symptoms at Initial Presentation with Clinical Outcomes in Hospitalized COVID-19 Patients: Results from a Large Health System in the Southern USA. Dig Dis Sci. [DOI: 10.1007/s10620-022-07384-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Arora M, Kutinová Canová N, Farghali H. mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174857] [Reference Citation Analysis]
152 Khanna S, Parikh NS, VanWagner LB. Fatty liver and cerebrovascular disease: plausible association and possible mechanisms. Curr Opin Lipidol 2022;33:31-8. [PMID: 34799486 DOI: 10.1097/MOL.0000000000000799] [Reference Citation Analysis]
153 Ehsani S, Zolfaghari H, Kazemi S, Shidfar F. Effects of sumac (Rhus coriaria) on lipid profile, leptin and steatosis in patients with non-alcoholic fatty liver disease: A randomized double-blind placebo-controlled trial. Journal of Herbal Medicine 2022;31:100525. [DOI: 10.1016/j.hermed.2021.100525] [Reference Citation Analysis]
154 Marti-aguado D, Clemente-sanchez A, Bataller R. Cigarette Smoking and Liver Diseases. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.016] [Reference Citation Analysis]
155 Vanessa Fiorentino T, De Vito F, Suraci E, Marasco R, Catalano F, Andreozzi F, Letizia Hribal M, Luzza F, Sesti G. Augmented duodenal levels of sodium/glucose co-transporter 1 are associated with higher risk of nonalcoholic fatty liver disease and noninvasive index of liver fibrosis. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109789] [Reference Citation Analysis]
156 Atefi M, Entezari MH, Vahedi H, Hassanzadeh A, Laranjo M. Sesame Oil Ameliorates Alanine Aminotransferase, Aspartate Aminotransferase, and Fatty Liver Grade in Women with Nonalcoholic Fatty Liver Disease Undergoing Low-Calorie Diet: A Randomized Double-Blind Controlled Trial. International Journal of Clinical Practice 2022;2022:1-11. [DOI: 10.1155/2022/4982080] [Reference Citation Analysis]
157 Zhang L, Wang Y, Wu F, Wang X, Feng Y, Wang Y. MDG, an Ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila. Int J Biol Macromol 2022;196:23-34. [PMID: 34920070 DOI: 10.1016/j.ijbiomac.2021.12.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
158 Huang Z, Ng K, Chen H, Deng W, Li Y. Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement. Front Endocrinol 2022;12:739875. [DOI: 10.3389/fendo.2021.739875] [Reference Citation Analysis]
159 Alshawsh MA, Alsalahi A, Alshehade SA, Saghir SAM, Ahmeda AF, Al Zarzour RH, Mahmoud AM. A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet. Molecules 2022;27:858. [PMID: 35164140 DOI: 10.3390/molecules27030858] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
160 Zhang S, Meng G, Zhang Q, Liu L, Wu H, Gu Y, Wang Y, Zhang T, Wang X, Zhang J, Sun S, Wang X, Zhou M, Jia Q, Song K, Wang Y, Qi L, Niu K. Inflammatory potential of diet and risk of nonalcoholic fatty liver disease: a prospective cohort study. Eur J Clin Nutr 2022. [PMID: 35079162 DOI: 10.1038/s41430-022-01069-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Choi IY, Chang Y, Kang G, Jung HS, Shin H, Wild SH, Byrne CD, Ryu S. Low heart rate variability from 10-s electrocardiograms is associated with development of non-alcoholic fatty liver disease. Sci Rep 2022;12:1062. [PMID: 35058515 DOI: 10.1038/s41598-022-05037-w] [Reference Citation Analysis]
162 Zhai T, Chen Q, Xu J, Jia X, Xia P. Prevalence and Trends in Low Bone Density, Osteopenia and Osteoporosis in U.S. Adults With Non-Alcoholic Fatty Liver Disease, 2005–2014. Front Endocrinol 2022;12:825448. [DOI: 10.3389/fendo.2021.825448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Kim K, Kang K, Sheol H, Shin J, Sim Y, Yang T, Hwang J, Lee JM. The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients. Int J Environ Res Public Health 2022;19:1042. [PMID: 35162067 DOI: 10.3390/ijerph19031042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
164 Firat SN, Durhan A, Erel S, Çulha C. The relationship between non-alcoholic fatty liver disease and breast cancer: a retrospective case-control study. Journal of Health Sciences and Medicine 2022;5:109-13. [DOI: 10.32322/jhsm.993960] [Reference Citation Analysis]
165 Amanatidou AI, Kaliora AC, Amerikanou C, Stojanoski S, Milosevic N, Vezou C, Beribaka M, Banerjee R, Kalafati IP, Smyrnioudis I, Kurth MJ, Kannt A, Francino MP, Visvikis-Siest S, Deloukas P, Llorens C, Marascio F, Milic N, Medic-Stojanoska M, Gastaldelli A, Trivella MG, Dedoussis GV. Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study. Int J Environ Res Public Health 2022;19:971. [PMID: 35055797 DOI: 10.3390/ijerph19020971] [Reference Citation Analysis]
166 Nicolucci A, Maffeis C. The adolescent with obesity: what perspectives for treatment? Ital J Pediatr 2022;48:9. [PMID: 35033162 DOI: 10.1186/s13052-022-01205-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
167 Zou J, Xiong H, Zhang H, Hu C, Lu S, Zou Y. Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02099-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Nelidova AV, Livzan MA, Nikolaev NA, Krolevets TS. Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy. Racionalʹnaâ farmakoterapiâ v kardiologii 2022;17:880-8. [DOI: 10.20996/1819-6446-2021-12-14] [Reference Citation Analysis]
169 Um YJ, Chang Y, Jung H, Cho IY, Shin JH, Shin H, Wild SH, Byrne CD, Ryu S. Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. JPM 2022;12:92. [DOI: 10.3390/jpm12010092] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Zhao J, Hu L, Gui W, Xiao L, Wang W, Xia J, Fan H, Li Z, Zhu Q, Hou X, Chu H, Seki E, Yang L. Hepatocyte TGF-β Signaling Inhibiting WAT Browning to Promote NAFLD and Obesity Is Associated With Let-7b-5p. Hepatol Commun 2022. [PMID: 35018737 DOI: 10.1002/hep4.1892] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
171 Milic J, Barbieri S, Gozzi L, Brigo A, Beghé B, Verduri A, Bacca E, Iadisernia V, Cuomo G, Dolci G, Yaacoub D, Aprile E, Belli M, Venuta M, Meschiari M, Sebastiani G, Clini E, Mussini C, Lonardo A, Guaraldi G, Raggi P. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis 2022;9:ofac003. [PMID: 35146047 DOI: 10.1093/ofid/ofac003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Wu W, Xiang J, Chen X. Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:773342. [PMID: 34992579 DOI: 10.3389/fendo.2021.773342] [Reference Citation Analysis]
173 Chi ZC. Research status and progress of metabolic associated fatty liver disease. Shijie Huaren Xiaohua Zazhi 2022; 30(1): 1-16 [DOI: 10.11569/wcjd.v30.i1.1] [Reference Citation Analysis]
174 Unsal İO, Calapkulu M, Sencar ME, Cakal B, Ozbek M. Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease. Sci Rep 2022;12:283. [PMID: 34997159 DOI: 10.1038/s41598-021-04361-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
175 Xu Z, Shi L, Li D, Wu Q, Zhang Y, Gao M, Ji A, Jiang Q, Chen R, Zhang R, Chen W, Zheng Y, Cui L. Real ambient particulate matter-induced lipid metabolism disorder: Roles of peroxisome proliferators-activated receptor alpha. Ecotoxicol Environ Saf 2022;231:113173. [PMID: 35007830 DOI: 10.1016/j.ecoenv.2022.113173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Sun Y, Chen S, Zhao X, Wang Y, Lan Y, Jiang X, Gao X, Wu S, Wang L. Adherence to the dietary approaches to stop hypertension diet and non-alcoholic fatty liver disease. Liver Int 2022. [PMID: 34990079 DOI: 10.1111/liv.15156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
177 Zhou J, Long Y, Ding N, Su Y. Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109195] [Reference Citation Analysis]
178 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 49.0] [Reference Citation Analysis]
179 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut 2022;71:156-62. [PMID: 33303564 DOI: 10.1136/gutjnl-2020-323082] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 43.0] [Reference Citation Analysis]
180 Yan X, Li L, Liu P, Xu J, Wang Z, Ding L, Yang L. Targeted metabolomics profiles serum fatty acids by HFD induced non-alcoholic fatty liver in mice based on GC-MS. Journal of Pharmaceutical and Biomedical Analysis 2022. [DOI: 10.1016/j.jpba.2022.114620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
181 Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022;19:60-78. [PMID: 34707258 DOI: 10.1038/s41575-021-00523-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 39.0] [Reference Citation Analysis]
182 Wu JT, He BW, Cao JL, Yan JB, Chen ZY. Involvement of STING signaling pathway in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(24): 1396-1401 [DOI: 10.11569/wcjd.v29.i24.1396] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Skat-rørdam J, Pedersen K, Skovsted GF, Gregersen I, Vangsgaard S, Ipsen DH, Latta M, Lykkesfeldt J, Tveden-nyborg P. Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig. Antioxidants 2022;11:69. [DOI: 10.3390/antiox11010069] [Reference Citation Analysis]
184 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Reference Citation Analysis]
185 Yabiku K. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front Endocrinol (Lausanne) 2021;12:768850. [PMID: 34950104 DOI: 10.3389/fendo.2021.768850] [Reference Citation Analysis]
186 He D, Su Y, Meng D, Wang X, Wang J, Ye H. A pilot study optimizing metabolomic and lipidomic acquisition in serum for biomarker discovery in nonalcoholic fatty liver disease. J Mass Spectrom Adv Clin Lab 2021;22:17-25. [PMID: 34939051 DOI: 10.1016/j.jmsacl.2021.10.001] [Reference Citation Analysis]
187 Cai Z, Deng X, Jia J, Wang D, Yuan G. Ectodysplasin A/Ectodysplasin A Receptor System and Their Roles in Multiple Diseases. Front Physiol 2021;12:788411. [PMID: 34938205 DOI: 10.3389/fphys.2021.788411] [Reference Citation Analysis]
188 Song S, Duo Y, Zhang Y, Qiao X, Xu J, Zhang J, Peng Z, Chen Y, Nie X, Sun Q, Yang X, Wang A, Sun W, Fu Y, Dong Y, Lu Z, Yuan T, Zhao W. The Predictive Ability of Hepatic Steatosis Index for Gestational Diabetes Mellitus and Large for Gestational Age Infant Compared with Other Noninvasive Indices Among Chinese Pregnancies: A Preliminary Double-center Cohort Study. Diabetes Metab Syndr Obes 2021;14:4791-800. [PMID: 34938090 DOI: 10.2147/DMSO.S335364] [Reference Citation Analysis]
189 Jung CY, Ryu GW, Kim HW, Ahn SH, Kim SU, Kim BS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia 2021. [PMID: 34932136 DOI: 10.1007/s00125-021-05627-9] [Reference Citation Analysis]
190 Wang R, Wang Z, Sun R, Fu R, Sun Y, Zhu M, Geng Y, Gao D, Tian X, Zhao Y, Yao J. Activation of TAF9 via Danshensu-Induced Upregulation of HDAC1 Expression Alleviates Non-alcoholic Fatty Liver Disease. Front Pharmacol 2021;12:775528. [PMID: 34925033 DOI: 10.3389/fphar.2021.775528] [Reference Citation Analysis]
191 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Mostafa TM, El-Azab GA, Badra GA, Abdelwahed AS, Elsayed AA. Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study. Curr Ther Res Clin Exp 2021;95:100654. [PMID: 34925649 DOI: 10.1016/j.curtheres.2021.100654] [Reference Citation Analysis]
193 Karimi M, Abiri B, Guest PC, Vafa M. Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications. Methods Mol Biol 2022;2343:19-35. [PMID: 34473313 DOI: 10.1007/978-1-0716-1558-4_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 . Cardiovascular computed tomography and HIV: The evolving role of imaging biomarkers in enhanced risk prediction. Imaging 2021;13:106-18. [DOI: 10.1556/1647.2021.00025] [Reference Citation Analysis]
195 Sharma D, Gotlieb N, Farkouh ME, Patel K, Xu W, Bhat M. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort. J Am Heart Assoc 2021;:e022576. [PMID: 34927450 DOI: 10.1161/JAHA.121.022576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Byrne CD, Newsome PN, Noureddin M. Why are there no Strategies for NAFLD? J Hepatol 2021:S0168-8278(21)02251-0. [PMID: 34933023 DOI: 10.1016/j.jhep.2021.12.009] [Reference Citation Analysis]
197 Jendle J, Hyötyläinen T, Orešič M, Nyström T. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovasc Diabetol 2021;20:237. [PMID: 34920733 DOI: 10.1186/s12933-021-01431-2] [Reference Citation Analysis]
198 Park J, Jeong W, Yun C, Kim H, Oh CM. Serotonergic Regulation of Hepatic Energy Metabolism. Endocrinol Metab (Seoul) 2021. [PMID: 34911172 DOI: 10.3803/EnM.2021.1331] [Reference Citation Analysis]
199 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2021. [PMID: 34914079 DOI: 10.1007/s40519-021-01287-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 2021;:1-11. [PMID: 34904923 DOI: 10.1080/14728222.2021.2018418] [Reference Citation Analysis]
201 Liu Z, Lin C, Suo C, Zhao R, Jin L, Zhang T, Chen X. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism 2021;127:154955. [PMID: 34915036 DOI: 10.1016/j.metabol.2021.154955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
202 Bellinato F, Goio I, Malara G, Rosato A, Targher G, Girolomoni G, Gisondi P. Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. J Cutan Med Surg 2021;:12034754211066906. [PMID: 34894782 DOI: 10.1177/12034754211066906] [Reference Citation Analysis]
203 Gao Y, Lu J, Liu X, Liu J, Ma Q, Shi Y, Su H. Effect of Long-Term Exercise on Liver Lipid Metabolism in Chinese Patients With NAFLD: A Systematic Review and Meta-Analysis. Front Physiol 2021;12:748517. [PMID: 34880774 DOI: 10.3389/fphys.2021.748517] [Reference Citation Analysis]
204 Al-Harbi LN, Alshammari GM, Al-Dossari AM, Subash-Babu P, Binobead MA, Alhussain MH, AlSedairy SA, Al-Nouri DM, Shamlan G. Beta vulgaris L. (Beetroot) Methanolic Extract Prevents Hepatic Steatosis and Liver Damage in T2DM Rats by Hypoglycemic, Insulin-Sensitizing, Antioxidant Effects, and Upregulation of PPARα. Biology (Basel) 2021;10:1306. [PMID: 34943221 DOI: 10.3390/biology10121306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
205 Obayemi MJ, Akintayo CO, Oniyide AA, Aturamu A, Badejogbin OC, Atuma CL, Saidi AO, Mahmud H, Olaniyi KS. Protective role of melatonin against adipose-hepatic metabolic comorbidities in experimentally induced obese rat model. PLoS One 2021;16:e0260546. [PMID: 34879109 DOI: 10.1371/journal.pone.0260546] [Reference Citation Analysis]
206 Tanaka M, Takahashi S, Higashiura Y, Sakai A, Koyama M, Saitoh S, Shimamoto K, Ohnishi H, Furuhashi M. Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. J Diabetes Investig 2021. [PMID: 34889064 DOI: 10.1111/jdi.13735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
207 Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, Esmat G, George J, Marchesini G, Novak K, Ocama P, Ratziu V, Razavi H, Romero-Gómez M, Silva M, Spearman CW, Tacke F, Tsochatzis EA, Yilmaz Y, Younossi ZM, Wong VW, Zelber-Sagi S, Cortez-Pinto H, Anstee QM; NAFLD policy review collaborators. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol 2021:S0168-8278(21)02168-1. [PMID: 34895743 DOI: 10.1016/j.jhep.2021.10.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 15.0] [Reference Citation Analysis]
208 Villavicencio EA, Crocker RM, Garcia DO. A Qualitative Analysis of Mexican-Origin Men's Knowledge and Cultural Attitudes Toward Non-Alcoholic Fatty Liver Disease and Interest in Risk Reduction. Am J Mens Health 2021;15:15579883211063335. [PMID: 34872379 DOI: 10.1177/15579883211063335] [Reference Citation Analysis]
209 Ma Y, Tan Z, Li Q, Fan W, Chen G, Bin Y, Zhou Y, Yi J, Luo X, Tan J, Si Z, Li J. Combined Analysis of Expression Profiles in a Mouse Model and Patients Identified BHMT2 as a New Regulator of Lipid Metabolism in Metabolic-Associated Fatty Liver Disease. Front Cell Dev Biol 2021;9:741710. [PMID: 34869329 DOI: 10.3389/fcell.2021.741710] [Reference Citation Analysis]
210 Vernuccio F, Cannella R, Bartolotta TV, Galia M, Tang A, Brancatelli G. Advances in liver US, CT, and MRI: moving toward the future. Eur Radiol Exp 2021;5:52. [PMID: 34873633 DOI: 10.1186/s41747-021-00250-0] [Reference Citation Analysis]
211 Wang M, Li B, Qin F, Ye J, Jin L. Obesity induced Ext1 reduction mediates the occurrence of NAFLD. Biochem Biophys Res Commun 2021;589:123-30. [PMID: 34906902 DOI: 10.1016/j.bbrc.2021.12.017] [Reference Citation Analysis]
212 Loeffelholz CV, Roth J, Coldewey SM, Birkenfeld AL. The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease. Biomedicines 2021;9:1853. [PMID: 34944668 DOI: 10.3390/biomedicines9121853] [Reference Citation Analysis]
213 Heredia NI, Zhang X, Balakrishnan M, Daniel CR, Hwang JP, McNeill LH, Thrift AP. Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of U.S. adults using NHANES 2017-2018. Prev Med 2022;154:106903. [PMID: 34861339 DOI: 10.1016/j.ypmed.2021.106903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
214 Kumar S, Wong R, Newberry C, Yeung M, Peña JM, Sharaiha RZ. Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD. Hepatology 2021;74:3472-8. [PMID: 34324727 DOI: 10.1002/hep.32081] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
215 Xie Y, Tian H, Xiang B, Li D, Liu J, Cai Z, Liu Y, Xiang H. Total polyunsaturated fatty acid intake and the risk of non-alcoholic fatty liver disease in Chinese Han adults: a secondary analysis based on a case-control study. BMC Gastroenterol 2021;21:451. [PMID: 34847883 DOI: 10.1186/s12876-021-02039-2] [Reference Citation Analysis]
216 Targher G, Mantovani A, Grander C, Foco L, Motta B, Byrne CD, Pramstaller PP, Tilg H. Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. Nutr Metab Cardiovasc Dis 2021;31:3464-73. [PMID: 34627696 DOI: 10.1016/j.numecd.2021.08.037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Cheung A, Ahmed A. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. Clin Exp Gastroenterol 2021;14:457-65. [PMID: 34819740 DOI: 10.2147/CEG.S226130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
218 Nah EH, Cho S, Park H, Noh D, Kwon E, Cho HI. Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study. PLoS One 2021;16:e0260477. [PMID: 34818372 DOI: 10.1371/journal.pone.0260477] [Reference Citation Analysis]
219 Pahk K, Lee SG, Joung C, Kim EO, Kwon HW, Kim DH, Hwang JI, Kim S, Kim WK. SP-1154, a novel synthetic TGF-β inhibitor, alleviates obesity and hepatic steatosis in high-fat diet-induced mice. Biomed Pharmacother 2022;145:112441. [PMID: 34813997 DOI: 10.1016/j.biopha.2021.112441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Li S, Han S, Jin K, Yu T, Chen H, Zhou X, Tan Z, Zhang G. SOCS2 Suppresses Inflammation and Apoptosis during NASH Progression through Limiting NF-κB Activation in Macrophages. Int J Biol Sci 2021;17:4165-75. [PMID: 34803490 DOI: 10.7150/ijbs.63889] [Reference Citation Analysis]
221 Han Q, Chen H, Wang L, An Y, Hu X, Zhao Y, Zhang H, Zhang R. Systemic Deficiency of GHR in Pigs leads to Hepatic Steatosis via Negative Regulation of AHR Signaling. Int J Biol Sci 2021;17:4108-21. [PMID: 34803486 DOI: 10.7150/ijbs.64894] [Reference Citation Analysis]
222 Xie L, Wen K, Li Q, Huang CC, Zhao JL, Zhao QH, Xiao YF, Guan XH, Qian YS, Gan L, Wang LF, Deng KY, Xin HB. CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD+/Sirtuins Signaling Pathways-Mediated Inhibition of Lipid Accumulation and Oxidative Stress in Hepatocytes. Int J Biol Sci 2021;17:4305-15. [PMID: 34803499 DOI: 10.7150/ijbs.65588] [Reference Citation Analysis]
223 Longo M, Meroni M, Paolini E, Erconi V, Carli F, Fortunato F, Ronchi D, Piciotti R, Sabatini S, Macchi C, Alisi A, Miele L, Soardo G, Comi GP, Valenti L, Ruscica M, Fracanzani AL, Gastaldelli A, Dongiovanni P. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00241-1. [PMID: 34823063 DOI: 10.1016/j.jcmgh.2021.11.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
224 De Roza MA, Lamba M, Goh GBB, Lum JHM, Cheah MCC, Ngu JHJ. Immunoglobulin G in non-alcoholic steatohepatitis predicts clinical outcome: A prospective multi-centre cohort study. World J Gastroenterol 2021; 27(43): 7563-7571 [PMID: 34887649 DOI: 10.3748/wjg.v27.i43.7563] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
225 Guo H, Jiang W, Zhao B, Xiong Y, Lu Z. A Predictive Model of Metabolic Syndrome by Medical Examination: Evidence from an 8-Year Chinese Cohort. Diabetes Metab Syndr Obes 2021;14:4459-67. [PMID: 34795493 DOI: 10.2147/DMSO.S314550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Darbandi M, Hamzeh B, Ayenepour A, Rezaeian S, Najafi F, Shakiba E, Pasdar Y. Anti-inflammatory diet consumption reduced fatty liver indices. Sci Rep 2021;11:22601. [PMID: 34799655 DOI: 10.1038/s41598-021-98685-3] [Reference Citation Analysis]
227 Roeb E. Nichtalkoholische Steatohepatitis (NASH) und alkoholische Steatohepatitis (ASH). Drug Res (Stuttg) 2021;71:S16-8. [PMID: 34788881 DOI: 10.1055/a-1606-5858] [Reference Citation Analysis]
228 Swift O, Sharma S, Ramanarayanan S, Umar H, Laws KR, Vilar E, Farrington K. Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis. Clinical Kidney Journal 2021. [DOI: 10.1093/ckj/sfab230] [Reference Citation Analysis]
229 Bima A, Eldakhakhny B, Nuwaylati D, Alnami A, Ajabnoor M, Elsamanoudy A. The Interplay of Vitamin D Deficiency and Cellular Senescence in The Pathogenesis of Obesity-Related Co-Morbidities. Nutrients 2021;13:4127. [PMID: 34836382 DOI: 10.3390/nu13114127] [Reference Citation Analysis]
230 Kim J, Lee SK, Jeong SY, Cho HJ, Park J, Kim TM, Kim S. Cargo proteins in extracellular vesicles: potential for novel therapeutics in non-alcoholic steatohepatitis. J Nanobiotechnology 2021;19:372. [PMID: 34789265 DOI: 10.1186/s12951-021-01120-y] [Reference Citation Analysis]
231 Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2021:S0168-8278(21)02180-2. [PMID: 34800610 DOI: 10.1016/j.jhep.2021.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
232 Scorletti E, Carr RM. A new perspective on NAFLD: focusing on lipid droplets. J Hepatol 2021:S0168-8278(21)02181-4. [PMID: 34793866 DOI: 10.1016/j.jhep.2021.11.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
233 Ismaiel A, Spinu M, Budisan L, Leucuta DC, Popa SL, Chis BA, Berindan-Neagoe I, Olinic DM, Dumitrascu DL. Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease. J Clin Med 2021;10:5194. [PMID: 34768714 DOI: 10.3390/jcm10215194] [Reference Citation Analysis]
234 Shafiha R, Bahcivanci B, Gkoutos GV, Acharjee A. Machine Learning-Based Identification of Potentially Novel Non-Alcoholic Fatty Liver Disease Biomarkers. Biomedicines 2021;9:1636. [PMID: 34829865 DOI: 10.3390/biomedicines9111636] [Reference Citation Analysis]
235 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 35.0] [Reference Citation Analysis]
236 Yaskolka Meir A, Rinott E, Tsaban G, Zelicha H, Kaplan A, Rosen P, Shelef I, Youngster I, Shalev A, Blüher M, Ceglarek U, Stumvoll M, Tuohy K, Diotallevi C, Vrhovsek U, Hu F, Stampfer M, Shai I. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut 2021;70:2085-95. [PMID: 33461965 DOI: 10.1136/gutjnl-2020-323106] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 30.0] [Reference Citation Analysis]
237 Liu Y, Croft KD, Caparros-Martin J, O'Gara F, Mori TA, Ward NC. Beneficial effects of inorganic nitrate in non-alcoholic fatty liver disease. Arch Biochem Biophys 2021;711:109032. [PMID: 34520731 DOI: 10.1016/j.abb.2021.109032] [Reference Citation Analysis]
238 Bracic Tomazic S, Schatz C, Haybaeck J. Translational Regulation in Hepatocellular Carcinogenesis. Drug Des Devel Ther 2021;15:4359-69. [PMID: 34703211 DOI: 10.2147/DDDT.S255582] [Reference Citation Analysis]
239 Sozen E, Demirel-Yalciner T, Sari D, Avcilar C, Samanci TF, Ozer NK. Deficiency of SREBP1c modulates autophagy mediated lipid droplet catabolism during oleic acid induced steatosis. Metabol Open 2021;12:100138. [PMID: 34704008 DOI: 10.1016/j.metop.2021.100138] [Reference Citation Analysis]
240 Nikeghbalian S, Rahimi R, Nikoupour H, Soleimani N, Vakili S, Zal F, Kaveh Baghbahadorani F. Correlation between HDL2, HDL3 and serum ferritin levels with fatty liver and NAFLD activity score (NAS) in liver histology of organ donors. BMC Gastroenterol 2021;21:405. [PMID: 34706656 DOI: 10.1186/s12876-021-01958-4] [Reference Citation Analysis]
241 Vural H, Armutcu F, Akyol O, Weiskirchen R. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases. Clin Chim Acta 2021;523:374-9. [PMID: 34678296 DOI: 10.1016/j.cca.2021.10.018] [Reference Citation Analysis]
242 Siskind D, Russell AW, Suetani S, Flaws D, Kisely S, Moudgil V, Northwood K, Robinson G, Scott JG, Stedman T, Warren N, Winckel K, Cosgrove P, Baker A. CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine. Ther Adv Psychopharmacol 2021;11:20451253211045248. [PMID: 34671454 DOI: 10.1177/20451253211045248] [Reference Citation Analysis]
243 Osei TB, van Dijk AM, Dingerink S, Chilunga FP, Beune E, Meeks KAC, Bahendeka S, Schulze MB, Agyemang C, Nicolaou M, Holleboom AG, Danquah I. Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study. Nutrients 2021;13:3679. [PMID: 34835937 DOI: 10.3390/nu13113679] [Reference Citation Analysis]
244 Um YJ, Chang Y, Jung HS, Cho IY, Shin JH, Shin H, Wild SH, Byrne CD, Ryu S. Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. Clin Transl Gastroenterol 2021;12:e00417. [PMID: 34665792 DOI: 10.14309/ctg.0000000000000417] [Reference Citation Analysis]
245 Pădureanu V, Dop D, Drăgoescu AN, Pădureanu R, Mușetescu AE, Nedelcu L. Non-alcoholic fatty liver disease and hematologic manifestations (Review). Exp Ther Med 2021;22:1355. [PMID: 34659501 DOI: 10.3892/etm.2021.10790] [Reference Citation Analysis]
246 Ali Z, Saeed IM, Bybee KA, Thompson R, O'Keefe JH, Shafiq M, Saeed L, Zafar Y, Kennedy KF, Al-Sayyed L. Correlation of Hepatic Steatosis Among Cohabitants Using Hounsfield Unit From Coronary Computed Tomography. Cureus 2021;13:e17834. [PMID: 34660042 DOI: 10.7759/cureus.17834] [Reference Citation Analysis]
247 Bilson J, Scorletti E, Bindels LB, Afolabi PR, Targher G, Calder PC, Sethi JK, Byrne CD. Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. Nutr Diabetes 2021;11:32. [PMID: 34663793 DOI: 10.1038/s41387-021-00170-3] [Reference Citation Analysis]
248 Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis 2021;20:139. [PMID: 34657611 DOI: 10.1186/s12944-021-01573-y] [Reference Citation Analysis]
249 Wang X, Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Front Med (Lausanne) 2021;8:651658. [PMID: 34646834 DOI: 10.3389/fmed.2021.651658] [Reference Citation Analysis]
250 Hu MJ, Long M, Dai RJ. Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3. Mol Cell Biochem 2021. [PMID: 34652536 DOI: 10.1007/s11010-021-04269-0] [Reference Citation Analysis]
251 Wang X, Li G, Guo C, Zhang J, Kong J, He J, Li F, Liu Y, Yang Y, Lu Z, Liu J. Ethyl 2-[2,3,4-Trimethoxy-6-(1-Octanoyl)Phenyl] Acetate (TMPA) Ameliorates Lipid Accumulation by Disturbing the Combination of LKB1 with Nur77 and Activating the AMPK Pathway in HepG2 Cells and Mice Primary Hepatocytes. Diabetes Metab Syndr Obes 2021;14:4165-77. [PMID: 34629883 DOI: 10.2147/DMSO.S321246] [Reference Citation Analysis]
252 Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease. Lipids Health Dis 2021;20:134. [PMID: 34629059 DOI: 10.1186/s12944-021-01561-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Wang FX, Zhu N, Zhou F, Lin DX. Natural Aporphine Alkaloids with Potential to Impact Metabolic Syndrome. Molecules 2021;26:6117. [PMID: 34684698 DOI: 10.3390/molecules26206117] [Reference Citation Analysis]
254 Xu P, Wang S, Pang D. A Novel Identified Peptide Hormone "Metabolitin" Attenuates Lipid Absorption in the Small Intestine of Diabetic Mice with Nonalcoholic Fatty Liver Disease by Regulating Neurotensin and AMPK Signaling Pathway. Evid Based Complement Alternat Med 2021;2021:8386848. [PMID: 34621326 DOI: 10.1155/2021/8386848] [Reference Citation Analysis]
255 Li F, Liu G, Xue P, Ren Z, Dai P, Niu W, Xin M. YiQi YangYin Decoction Attenuates Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Rats. Evid Based Complement Alternat Med 2021;2021:5511019. [PMID: 34621322 DOI: 10.1155/2021/5511019] [Reference Citation Analysis]
256 Quesada-Vázquez S, Colom-Pellicer M, Navarro-Masip È, Aragonès G, Del Bas JM, Caimari A, Escoté X. Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice. Nutrients 2021;13:3532. [PMID: 34684533 DOI: 10.3390/nu13103532] [Reference Citation Analysis]
257 Yang M, Geng CA, Liu X, Guan M. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines 2021;9:1405. [PMID: 34680522 DOI: 10.3390/biomedicines9101405] [Reference Citation Analysis]
258 Moraes KCM, Montagne J. Drosophila melanogaster: A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases. Front Physiol 2021;12:728407. [PMID: 34603083 DOI: 10.3389/fphys.2021.728407] [Reference Citation Analysis]
259 Vranić L, Radovan A, Poropat G, Mikolašević I, Milić S. Non-Alcoholic Fatty Liver Disease and COVID-19-Two Pandemics Hitting at the Same Time. Medicina (Kaunas) 2021;57:1057. [PMID: 34684094 DOI: 10.3390/medicina57101057] [Reference Citation Analysis]
260 He Z, Li X, Yang H, Wu P, Wang S, Cao D, Guo X, Xu Z, Gao J, Zhang W, Luo X. Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front Nutr 2021;8:745609. [PMID: 34595203 DOI: 10.3389/fnut.2021.745609] [Reference Citation Analysis]
261 Gong H, Liu X, Cheng F. Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. J Int Med Res 2021;49:3000605211047074. [PMID: 34590877 DOI: 10.1177/03000605211047074] [Reference Citation Analysis]
262 Zhang D, Wu S, Lan Y, Chen S, Wang Y, Sun Y, Liao W, Wang L. Blood manganese and nonalcoholic fatty liver disease: A cohort-based case-control study. Chemosphere 2022;287:132316. [PMID: 34592210 DOI: 10.1016/j.chemosphere.2021.132316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Huang R, Guo F, Li Y, Liang Y, Li G, Fu P, Ma L. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis. Phytomedicine 2021;92:153739. [PMID: 34592488 DOI: 10.1016/j.phymed.2021.153739] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Liu Y, Dou X, Zhou WY, Ding M, Liu L, Du RQ, Guo L, Qian SW, Tang Y, Yang QQ, Pan DN, Li XY, Lu Y, Cheng JK, Tang QQ. Hepatic Small Ubiquitin-Related Modifier (SUMO)-Specific Protease 2 Controls Systemic Metabolism Through SUMOylation-Dependent Regulation of Liver-Adipose Tissue Crosstalk. Hepatology 2021;74:1864-83. [PMID: 33934381 DOI: 10.1002/hep.31881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
265 Meroni M, Longo M, Tria G, Dongiovanni P. Genetics Is of the Essence to Face NAFLD. Biomedicines 2021;9:1359. [PMID: 34680476 DOI: 10.3390/biomedicines9101359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Han J, Guo X, Koyama T, Kawai D, Zhang J, Yamaguchi R, Zhou X, Motoo Y, Satoh T, Yamada S. Zonarol Protected Liver from Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease in a Mouse Model. Nutrients 2021;13:3455. [PMID: 34684455 DOI: 10.3390/nu13103455] [Reference Citation Analysis]
267 Reinson T, Byrne CD, Patel J, El-Gohary M, Moore M. Transient elastography in patients at risk of liver fibrosis in primary care: a follow-up study over 54 months. BJGP Open 2021;5:BJGPO. [PMID: 34580065 DOI: 10.3399/BJGPO.2021.0145] [Reference Citation Analysis]
268 Park J, Kim G, Kim H, Lee J, Lee YB, Jin SM, Hur KY, Kim JH. The association of hepatic steatosis and fibrosis with heart failure and mortality. Cardiovasc Diabetol 2021;20:197. [PMID: 34583706 DOI: 10.1186/s12933-021-01374-8] [Reference Citation Analysis]
269 Gao F, He Q, Li G, Huang OY, Tang LJ, Wang XD, Targher G, Byrne CD, Luo JW, Zheng MH. A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. Liver Int 2021. [PMID: 34564946 DOI: 10.1111/liv.15064] [Reference Citation Analysis]
270 Kaur J, Kumar V, Kumar V, Shafi S, Khare P, Mahajan N, Bhadada SK, Kondepudi KK, Bhunia RK, Kuhad A, Bishnoi M. Combination of TRP channel dietary agonists induces energy expending and glucose utilizing phenotype in HFD-fed mice. Int J Obes (Lond) 2021. [PMID: 34564707 DOI: 10.1038/s41366-021-00967-3] [Reference Citation Analysis]
271 Ayaz T, Polat HB, Kilictas B. Evaluation of the reciprocal interaction between hepatic steatosis and type 2 diabetes: a comparative analysis with respect to anti-diabetic treatment, glycemic control, renal and hepatic function. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-021-01009-4] [Reference Citation Analysis]
272 Reiter FP, Ye L, Ofner A, Schiergens TS, Ziesch A, Brandl L, Ben Khaled N, Hohenester S, Wimmer R, Artmann R, He Y, Lee SML, Mayr D, Zhang C, Gerbes AL, Mayerle J, Denk G, De Toni EN. p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice. Cell Mol Gastroenterol Hepatol 2021;13:95-112. [PMID: 34537439 DOI: 10.1016/j.jcmgh.2021.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
273 Majnooni MB, Ataee M, Bahrami G, Heydarpour F, Aneva IY, Farzaei MH, Ahmadi-Juoibari T. The effects of co-administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: A randomized clinical trial. Phytother Res 2021. [PMID: 34533249 DOI: 10.1002/ptr.7279] [Reference Citation Analysis]
274 Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z, Zhou L, Xie H, Zheng S. Metabolic Changes of Hepatocytes in NAFLD. Front Physiol 2021;12:710420. [PMID: 34526911 DOI: 10.3389/fphys.2021.710420] [Reference Citation Analysis]
275 Wu MJ, Fang QL, Zou SY, Zhu Y, Lu W, Du X, Shi BM. Influencing factors for hepatic fat accumulation in patients with type 2 diabetes mellitus. World J Clin Cases 2021; 9(26): 7717-7728 [PMID: 34621822 DOI: 10.12998/wjcc.v9.i26.7717] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 Hadjihambi A. Cerebrovascular alterations in NAFLD: Is it increasing our risk of Alzheimer's disease? Anal Biochem 2021;:114387. [PMID: 34537182 DOI: 10.1016/j.ab.2021.114387] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
277 Lu X, Huang L, Huang Z, Feng D, Clark RJ, Chen C. LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity. Front Endocrinol (Lausanne) 2021;12:717544. [PMID: 34512549 DOI: 10.3389/fendo.2021.717544] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Byrne CD, Targher G. Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed. Gut 2021:gutjnl-2021-325965. [PMID: 34509980 DOI: 10.1136/gutjnl-2021-325965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
279 Chen X, Xiao J, Pang J, Chen S, Wang Q, Ling W. Pancreatic β-Cell Dysfunction Is Associated with Nonalcoholic Fatty Liver Disease. Nutrients 2021;13:3139. [PMID: 34579016 DOI: 10.3390/nu13093139] [Reference Citation Analysis]
280 Kawachi Y, Fujishima Y, Nishizawa H, Nakamura T, Akari S, Murase T, Saito T, Miyazaki Y, Nagao H, Fukuda S, Kita S, Katakami N, Doki Y, Maeda N, Shimomura I. Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation. JCI Insight 2021;6:144762. [PMID: 34494551 DOI: 10.1172/jci.insight.144762] [Reference Citation Analysis]
281 Holzner ML, Florman S, Schwartz ME, Tabrizian P. Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma. HPB (Oxford) 2021:S1365-182X(21)01587-2. [PMID: 34544629 DOI: 10.1016/j.hpb.2021.08.943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
282 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2021:S1590-8658(21)00214-0. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Pan Z, Fan JG, Eslam M. An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. Curr Opin Pharmacol 2021;60:170-6. [PMID: 34455284 DOI: 10.1016/j.coph.2021.07.007] [Reference Citation Analysis]
284 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2021. [PMID: 34459096 DOI: 10.1111/liv.15046] [Reference Citation Analysis]
285 van Dijk AM, Dingerink S, Chilunga FP, Meeks KAC, Bahendeka S, Schulze MB, Danquah I, Osei TB, Serné E, Agyemang C, Holleboom AG. Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations. J Clin Transl Hepatol 2021;9:494-502. [PMID: 34447678 DOI: 10.14218/JCTH.2021.00066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
286 Zhu M, Hua T, Ouyang T, Qian H, Yu B. Applications of Mesenchymal Stem Cells in Liver Fibrosis: Novel Strategies, Mechanisms, and Clinical Practice. Stem Cells Int 2021;2021:6546780. [PMID: 34434239 DOI: 10.1155/2021/6546780] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
287 Trindade AJ, Thaniyavarn T, Hashemi N, Coppolino A 3rd, Kennedy JC, Mallidi HR, El-Chemaly S, Goldberg HJ. 1-year outcomes for lung transplantation recipients with non-alcoholic fatty liver disease. ERJ Open Res 2021;7:00103-2021. [PMID: 34435032 DOI: 10.1183/23120541.00103-2021] [Reference Citation Analysis]
288 Pan MX, Zheng CY, Deng YJ, Tang KR, Nie H, Xie JQ, Liu DD, Tu GF, Yang QH, Zhang YP. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease. J Integr Med 2021;19:428-38. [PMID: 34426178 DOI: 10.1016/j.joim.2021.07.004] [Reference Citation Analysis]
289 Zhang R, Wang M, Wang M, Zhang L, Ding Y, Tang Z, Fu Z, Fan H, Zhang W, Wang J. Vitamin D Level and Vitamin D Receptor Genetic Variation Were Involved in the Risk of Non-Alcoholic Fatty Liver Disease: A Case-Control Study. Front Endocrinol (Lausanne) 2021;12:648844. [PMID: 34421816 DOI: 10.3389/fendo.2021.648844] [Reference Citation Analysis]
290 Gianmoena K, Gasparoni N, Jashari A, Gabrys P, Grgas K, Ghallab A, Nordström K, Gasparoni G, Reinders J, Edlund K, Godoy P, Schriewer A, Hayen H, Hudert CA, Damm G, Seehofer D, Weiss TS, Boor P, Anders HJ, Motrapu M, Jansen P, Schiergens TS, Falk-Paulsen M, Rosenstiel P, Lisowski C, Salido E, Marchan R, Walter J, Hengstler JG, Cadenas C. Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria. Cell Rep 2021;36:109526. [PMID: 34433051 DOI: 10.1016/j.celrep.2021.109526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Yu H, Zhao L, Liu L, Li Y, Sun J, Liu Y. Relationship between serum uric acid level and nonalcoholic fatty liver disease in type 2 diabetes patients. Medicine (Baltimore) 2021;100:e26946. [PMID: 34414956 DOI: 10.1097/MD.0000000000026946] [Reference Citation Analysis]
292 Xiong Y, Huang J. Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment. Chin Med 2021;16:80. [PMID: 34407830 DOI: 10.1186/s13020-021-00489-0] [Reference Citation Analysis]
293 Schafberg M, Loest K, Müller-Belecke A, Rohn S. Pike-Perch (Sander lucioperca) and Rainbow Trout (Oncorhynchus mykiss) Fed with an Alternative Microorganism Mix for Reducing Fish Meal and Oil-Fishes' Growth Performances and Quality Traits. Foods 2021;10:1799. [PMID: 34441576 DOI: 10.3390/foods10081799] [Reference Citation Analysis]
294 Niu Y, Zhang W, Zhang H, Li X, Lin N, Su W, Gu H, Zhu L, Fan J, Qin L, Yang Z, Su Q. Serum creatinine levels and risk of nonalcohol fatty liver disease in a middle-aged and older Chinese population: A cross-sectional analysis. Diabetes Metab Res Rev 2021;:e3489. [PMID: 34344058 DOI: 10.1002/dmrr.3489] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Sun Q, Niu Q, Guo Y, Zhuang Y, Li X, Liu J, Li N, Li Z, Huang F, Qiu Z. Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD. J Agric Food Chem 2021;69:8714-25. [PMID: 34323067 DOI: 10.1021/acs.jafc.1c03105] [Reference Citation Analysis]
296 Liu T, Xu L, Chen FH, Zhou YB. Association of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol 2020;32:140-7. [PMID: 31895886 DOI: 10.1097/MEG.0000000000001486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
297 Wang R, Dai L, Zhong Y, Xie G. Usefulness of the triglyceride glucose-body mass index in evaluating nonalcoholic fatty liver disease: insights from a general population. Lipids Health Dis 2021;20:77. [PMID: 34321005 DOI: 10.1186/s12944-021-01506-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
298 Ye FZ, Liu WY, Zheng KI, Pan XY, Ma HL, Wang XD, Chen YP, Zheng MH. Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2020;32:80-6. [PMID: 31625959 DOI: 10.1097/MEG.0000000000001483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
299 Wang Z, Chen N, Li Z, Xu G, Zhan X, Tang J, Xiao X, Bai Z. The Cytosolic DNA-Sensing cGAS-STING Pathway in Liver Diseases. Front Cell Dev Biol 2021;9:717610. [PMID: 34386500 DOI: 10.3389/fcell.2021.717610] [Reference Citation Analysis]
300 de Freitas Júnior JR, Ribeiro IB, de Moura DTH, Sagae VMT, de Souza GMV, de Oliveira GHP, Sánchez-Luna SA, de Souza TF, de Moura ETH, de Oliveira CPMS, Bernardo WM, de Moura EGH. Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis. World J Hepatol 2021; 13(7): 815-829 [PMID: 34367502 DOI: 10.4254/wjh.v13.i7.815] [Reference Citation Analysis]
301 Castillo V, Figueroa F, González-Pizarro K, Jopia P, Ibacache-Quiroga C. Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. Foods 2021;10:1719. [PMID: 34441497 DOI: 10.3390/foods10081719] [Reference Citation Analysis]
302 Skat-Rørdam J, Ipsen DH, Hardam PD, Latta M, Lykkesfeldt J, Tveden-Nyborg P. Differential Effects of Dietary Components on Glucose Intolerance and Non-Alcoholic Steatohepatitis. Nutrients 2021;13:2523. [PMID: 34444683 DOI: 10.3390/nu13082523] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Mitrovic M, Sistilli G, Horakova O, Rossmeisl M. Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives. Eur J Clin Invest 2021;:e13650. [PMID: 34291454 DOI: 10.1111/eci.13650] [Reference Citation Analysis]
304 Senesi P, Ferrulli A, Luzi L, Terruzzi I. Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction. Int J Mol Sci 2021;22:7772. [PMID: 34360538 DOI: 10.3390/ijms22157772] [Reference Citation Analysis]
305 Dong M, Liu S, Wang M, Wang Y, Xin Y, Xuan S. Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han population. J Int Med Res 2021;49:3000605211019263. [PMID: 34275374 DOI: 10.1177/03000605211019263] [Reference Citation Analysis]
306 Yokomori H, Ando W. Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis. BMJ Open Gastroenterol 2020;7:e000370. [PMID: 32414752 DOI: 10.1136/bmjgast-2019-000370] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
307 von Loeffelholz C, Coldewey SM, Birkenfeld AL. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells 2021;10:1822. [PMID: 34359991 DOI: 10.3390/cells10071822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
308 Rodriguez LA, Kanaya AM, Shiboski SC, Fernandez A, Herrington D, Ding J, Bradshaw PT. Does NAFLD mediate the relationship between obesity and type 2 diabetes risk? evidence from the multi-ethnic study of atherosclerosis (MESA). Ann Epidemiol 2021;63:15-21. [PMID: 34293421 DOI: 10.1016/j.annepidem.2021.07.005] [Reference Citation Analysis]
309 Formichi C, Nigi L, Grieco GE, Maccora C, Fignani D, Brusco N, Licata G, Sebastiani G, Dotta F. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. Int J Mol Sci 2021;22:7716. [PMID: 34299336 DOI: 10.3390/ijms22147716] [Reference Citation Analysis]
310 Yan S, Zhang S, Du A, Miao H, Lu B, Huang Z, Ji L. Network pharmacology-based identification of significant pathway for protection of Yinhuang granule in a mice model of metabolic-associated fatty liver disease. Phytomedicine 2021;91:153666. [PMID: 34339944 DOI: 10.1016/j.phymed.2021.153666] [Reference Citation Analysis]
311 Wang H, Pai S, Ishiyama S, Guo X, Gao WD, Santhanam L, Gabrielson K, Njoku DB. Mitochondrial-triggered immune responses mechanistically connect drug-induced steatohepatitis and cardiomyopathy associated with nonalcoholic steatohepatitis. Cell Mol Immunol 2021;18:2078-80. [PMID: 34253858 DOI: 10.1038/s41423-021-00724-6] [Reference Citation Analysis]
312 Eslam M, Ahmed A, Després JP, Jha V, Halford JCG, Wei Chieh JT, Harris DCH, Nangaku M, Colagiuri S, Targher G, Joshi S, Byrne CD, Khunti K, Nguyen MH, Gish RG, George J. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol 2021;6:743-53. [PMID: 34265276 DOI: 10.1016/S2468-1253(21)00132-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
313 Zhao R, Hernando D, Harris DT, Hinshaw LA, Li K, Ananthakrishnan L, Bashir MR, Duan X, Ghasabeh MA, Kamel IR, Lowry C, Mahesh M, Marin D, Miller J, Pickhardt PJ, Shaffer J, Yokoo T, Brittain JH, Reeder SB. Multisite multivendor validation of a quantitative MRI and CT compatible fat phantom. Med Phys 2021;48:4375-86. [PMID: 34105167 DOI: 10.1002/mp.15038] [Reference Citation Analysis]
314 Fan Y, Yan LT, Yao Z, Xiong GY. Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:3161-72. [PMID: 34276221 DOI: 10.2147/DMSO.S315471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
315 Ismaiel A, Leucuta DC, Popa SL, Dumitrascu DL. Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis. J Clin Med 2021;10:3029. [PMID: 34300193 DOI: 10.3390/jcm10143029] [Reference Citation Analysis]
316 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
317 Roohani S, Tacke F. Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. Int J Mol Sci 2021;22:7249. [PMID: 34298870 DOI: 10.3390/ijms22147249] [Reference Citation Analysis]
318 Sohn W, Kwon HJ, Chang Y, Ryu S, Cho YK. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00706-0. [PMID: 34224877 DOI: 10.1016/j.cgh.2021.06.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
319 Ren F, Chen Q, Meng C, Chen H, Zhou Y, Zhang H, Chen W. Serum metabonomics revealed the mechanism of Ganoderma amboinense polysaccharides in preventing non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet. Journal of Functional Foods 2021;82:104496. [DOI: 10.1016/j.jff.2021.104496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
320 Lin J, Liu G, Duan Z. The mechanism of esophagus dysmotility in diabetes and research progress of relating treatments. Expert Rev Gastroenterol Hepatol 2021;15:919-27. [PMID: 34156876 DOI: 10.1080/17474124.2021.1945921] [Reference Citation Analysis]
321 Han Q, Li H, Jia M, Wang L, Zhao Y, Zhang M, Zhang Q, Meng Z, Shao J, Yang Y, Zhu L. Age-related changes in metabolites in young donor livers and old recipient sera after liver transplantation from young to old rats. Aging Cell 2021;20:e13425. [PMID: 34157207 DOI: 10.1111/acel.13425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
322 Surlin P, Didilescu AC, Lazar L, Arsenie CC, Camen A, Popescu DM, Gheorghe DN, Osiac E, Rogoveanu I. Evaluation Through the Optical Coherence Tomography Analysis of the Influence of Non-Alcoholic Fatty Liver Disease on the Gingival Inflammation in Periodontal Patients. Diabetes Metab Syndr Obes 2021;14:2935-42. [PMID: 34234491 DOI: 10.2147/DMSO.S310314] [Reference Citation Analysis]
323 Kozaczek M, Bottje W, Albataineh D, Hakkak R. Effects of Short- and Long-Term Soy Protein Feeding on Hepatic Cytochrome P450 Expression in Obese Nonalcoholic Fatty Liver Disease Rat Model. Front Nutr 2021;8:699620. [PMID: 34262928 DOI: 10.3389/fnut.2021.699620] [Reference Citation Analysis]
324 Ji L, Cai X, Bai Y, Li T. Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China. Int J Gen Med 2021;14:2909-22. [PMID: 34234521 DOI: 10.2147/IJGM.S319759] [Reference Citation Analysis]
325 Wijarnpreecha K, Lou S, Watthanasuntorn K, Kroner PT, Cheungpasitporn W, Lukens FJ, Pungpapong S, Keaveny AP, Ungprasert P. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:601-8. [PMID: 31567712 DOI: 10.1097/MEG.0000000000001541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
326 Fan GH, Wei RL, Wei XY, Zhang CZ, Qi ZT, Xie HY, Zheng SS, Xu X. Key factors and potential drug combinations of nonalcoholic steatohepatitis: Bioinformatic analysis and experimental validation-based study. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00111-9. [PMID: 34233850 DOI: 10.1016/j.hbpd.2021.06.001] [Reference Citation Analysis]
327 Johnston MP, Patel J, Byrne CD. Update on cardiovascular risk in nonalcoholic fatty liver disease. Curr Opin Cardiol 2021;36:478-86. [PMID: 34059612 DOI: 10.1097/HCO.0000000000000861] [Reference Citation Analysis]
328 Saleh Al-Maamari JN, Rahmadi M, Panggono SM, Prameswari DA, Pratiwi ED, Ardianto C, Balan SS, Suprapti B. The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice. J Basic Clin Physiol Pharmacol 2021;32:637-44. [PMID: 34214346 DOI: 10.1515/jbcpp-2020-0423] [Reference Citation Analysis]
329 Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34172937 DOI: 10.1038/s41575-021-00477-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 25.0] [Reference Citation Analysis]
330 Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front Nutr 2021;8:700058. [PMID: 34250000 DOI: 10.3389/fnut.2021.700058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
331 Balakrishnan M, Loomba R. The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD. J Clin Gastroenterol 2020;54:107-13. [PMID: 31789757 DOI: 10.1097/MCG.0000000000001284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
332 Chen R, Du J, Zhu H, Ling Q. The role of cGAS-STING signalling in liver diseases. JHEP Rep 2021;3:100324. [PMID: 34381984 DOI: 10.1016/j.jhepr.2021.100324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
333 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
334 Shen C, Pan Z, Wu S, Zheng M, Zhong C, Xin X, Lan S, Zhu Z, Liu M, Wu H, Huang Q, Zhang J, Liu Z, Si Y, Tu H, Deng Z, Yu Y, Liu H, Zhong Y, Guo J, Cai J, Xian S. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway. J Ethnopharmacol 2021;279:114340. [PMID: 34171397 DOI: 10.1016/j.jep.2021.114340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
335 Tan Y, Tang X, Mu P, Yang Y, Li M, Nie Y, Li H, Zhu Y, Chen Y. High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes. Diabetes Metab Syndr Obes 2021;14:2841-9. [PMID: 34188507 DOI: 10.2147/DMSO.S313224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
336 Dogru T, Kirik A, Gurel H, Rizvi AA, Rizzo M, Sonmez A. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int J Mol Sci 2021;22:6627. [PMID: 34205674 DOI: 10.3390/ijms22126627] [Reference Citation Analysis]
337 Siddiqui B, Kamran M, Tikmani SS, Azmat R, Mushtaq Z, Zafar SB, Khan MT, Yakoob J, Abbas Z. Frequency and risk factors of non-alcoholic fatty liver disease in Helicobacter pylori-infected dyspeptic patients: A cross-sectional study. SAGE Open Med 2021;9:20503121211025421. [PMID: 34211711 DOI: 10.1177/20503121211025421] [Reference Citation Analysis]
338 Hong SH, Lee JS, Kim JA, Lee YB, Roh E, Hee Yu J, Kim NH, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi KM. Glycemic variability and the risk of nonalcoholic fatty liver disease : A nationwide population-based cohort study. Diabetes Res Clin Pract 2021;177:108922. [PMID: 34146602 DOI: 10.1016/j.diabres.2021.108922] [Reference Citation Analysis]
339 Lastuvkova H, Faradonbeh FA, Schreiberova J, Hroch M, Mokry J, Faistova H, Nova Z, Hyspler R, Igreja Sa IC, Nachtigal P, Stefela A, Pavek P, Micuda S. Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis. Int J Mol Sci 2021;22:6468. [PMID: 34208774 DOI: 10.3390/ijms22126468] [Reference Citation Analysis]
340 Zheng X, Cao C, He Y, Wang X, Wu J, Hu H. Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching. Lipids Health Dis 2021;20:59. [PMID: 34130693 DOI: 10.1186/s12944-021-01485-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
341 Koo BK, Denenberg JO, Wright CM, Criqui MH, Allison MA. Associations of Perirenal Fat Thickness with Renal and Systemic Calcified Atherosclerosis. Endocrinol Metab (Seoul) 2020;35:122-31. [PMID: 32207272 DOI: 10.3803/EnM.2020.35.1.122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
342 Zuo G, Xuan L, Xin Z, Xu Y, Lu J, Chen Y, Dai M, Zhang D, Wang W, Li M, Bi Y, Ning G, Xu M. New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease. J Clin Endocrinol Metab 2021:dgab425. [PMID: 34125886 DOI: 10.1210/clinem/dgab425] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
343 Stevanović-Silva J, Beleza J, Coxito P, Costa RC, Ascensão A, Magalhães J. Fit mothers for a healthy future: Breaking the intergenerational cycle of non-alcoholic fatty liver disease with maternal exercise. Eur J Clin Invest 2021;:e13596. [PMID: 34120338 DOI: 10.1111/eci.13596] [Reference Citation Analysis]
344 Popa SL, Ismaiel A, Cristina P, Cristina M, Chiarioni G, David L, Dumitrascu DL. Non-Alcoholic Fatty Liver Disease: Implementing Complete Automated Diagnosis and Staging. A Systematic Review. Diagnostics (Basel) 2021;11:1078. [PMID: 34204822 DOI: 10.3390/diagnostics11061078] [Reference Citation Analysis]
345 Kim Y, Chang Y, Kwon MJ, Hong YS, Kim MK, Sohn W, Cho YK, Shin H, Wild SH, Byrne CD, Ryu S. Fasting Ketonuria and the Risk of Incident Nonalcoholic Fatty Liver Disease With and Without Liver Fibrosis in Nondiabetic Adults. Am J Gastroenterol 2021. [PMID: 34114568 DOI: 10.14309/ajg.0000000000001344] [Reference Citation Analysis]
346 Ma Y, Li J, Ju Z, Huang W, Wang Z, Yang L, Ding L. Danning tablets alleviate high fat diet-induced obesity and fatty liver in mice via modulating SREBP pathway. J Ethnopharmacol 2021;279:114320. [PMID: 34116189 DOI: 10.1016/j.jep.2021.114320] [Reference Citation Analysis]
347 Zhou Y, Tian S, Qian L, Jiang S, Tang Y, Han T. DHA-enriched phosphatidylserine ameliorates non-alcoholic fatty liver disease and intestinal dysbacteriosis in mice induced by a high-fat diet. Food Funct 2021;12:4021-33. [PMID: 33977946 DOI: 10.1039/d0fo03471a] [Reference Citation Analysis]
348 Yu H, Jiang X, Dong F, Zhang F, Ji X, Xue M, Yang F, Chen J, Hu X, Bao Z. Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway. Exp Cell Res 2021;405:112689. [PMID: 34107274 DOI: 10.1016/j.yexcr.2021.112689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
349 Zhang HJ, Wang YY, Chen C, Lu YL, Wang NJ. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016. Chin Med J (Engl) 2021;134:1593-601. [PMID: 34091530 DOI: 10.1097/CM9.0000000000001513] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
350 Braude MR, Con D, Lubel J, Bidwai A, Nguyen HT, Sharmamiglani S, Clarke D, Dev A, Sievert W. Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools. Hepatol Int 2021;15:812-20. [PMID: 34081288 DOI: 10.1007/s12072-021-10195-6] [Reference Citation Analysis]
351 Mikolasevic I, Rahelic D, Turk-Wensween T, Ruzic A, Domislovic V, Hauser G, Matic T, Radic-Kristo D, Krznaric Z, Radic M, Filipec Kanizaj T, Martinovic M, Jerkic H, Medjimurec M, Targher G. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. Diabetes Res Clin Pract 2021;177:108884. [PMID: 34082054 DOI: 10.1016/j.diabres.2021.108884] [Reference Citation Analysis]
352 Kalra S, Bhattacharya S, Rawal P. Hepatocrinology. Med Sci (Basel) 2021;9:39. [PMID: 34205986 DOI: 10.3390/medsci9020039] [Reference Citation Analysis]
353 Ganjooei NA, Jamialahmadi T, Nematy M, Jangjoo A, Goshayeshi L, Khadem-Rezaiyan M, Reiner Ž, Alidadi M, Markin AM, Sahebkar A. The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients. Front Cardiovasc Med 2021;8:682352. [PMID: 34136549 DOI: 10.3389/fcvm.2021.682352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 Song Y, Dang Y, Wang P, Tian G, Ruan L. CHD is Associated With Higher Grades of NAFLD Predicted by Liver Stiffness. J Clin Gastroenterol 2020;54:271-7. [PMID: 31305280 DOI: 10.1097/MCG.0000000000001238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
355 Sugasawa T, Ono S, Yonamine M, Fujita SI, Matsumoto Y, Aoki K, Nakano T, Tamai S, Yoshida Y, Kawakami Y, Takekoshi K. One Week of CDAHFD Induces Steatohepatitis and Mitochondrial Dysfunction with Oxidative Stress in Liver. Int J Mol Sci 2021;22:5851. [PMID: 34072586 DOI: 10.3390/ijms22115851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
356 Faradonbeh FA, Sa II, Lastuvkova H, Cermanova J, Hroch M, Faistova H, Mokry J, Nova Z, Uher M, Nachtigal P, Pavek P, Micuda S. Metformin impairs bile acid homeostasis in ethinylestradiol-induced cholestasis in mice. Chem Biol Interact 2021;345:109525. [PMID: 34058177 DOI: 10.1016/j.cbi.2021.109525] [Reference Citation Analysis]
357 Yaskolka Meir A, Keller M, Müller L, Bernhart SH, Tsaban G, Zelicha H, Rinott E, Kaplan A, Gepner Y, Shelef I, Schwarzfuchs D, Ceglarek U, Stadler P, Blüher M, Stumvoll M, Kovacs P, Shai I. Effects of lifestyle interventions on epigenetic signatures of liver fat: Central randomized controlled trial. Liver Int 2021;41:2101-11. [PMID: 33938135 DOI: 10.1111/liv.14916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
358 Varghese DS, Ali BR. Pathological Crosstalk Between Oxidized LDL and ER Stress in Human Diseases: A Comprehensive Review. Front Cell Dev Biol 2021;9:674103. [PMID: 34124059 DOI: 10.3389/fcell.2021.674103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
359 Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, Liu X, Li C, Chen S, Ye J, Huang Z, Lu Y. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes 2021;13:1-19. [PMID: 34030573 DOI: 10.1080/19490976.2021.1927633] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
360 Sheng G, Xie Q, Wang R, Hu C, Zhong M, Zou Y. Waist-to-height ratio and non-alcoholic fatty liver disease in adults. BMC Gastroenterol 2021;21:239. [PMID: 34034671 DOI: 10.1186/s12876-021-01824-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
361 Ma N, Wang YK, Xu S, Ni QZ, Zheng QW, Zhu B, Cao HJ, Jiang H, Zhang FK, Yuan YM, Zhang EB, Chen TW, Xia J, Ding XF, Chen ZH, Zhang XP, Wang K, Cheng SQ, Qiu L, Li ZG, Yu YC, Wang XF, Zhou B, Li JJ, Xie D. PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling. Nat Commun 2021;12:3059. [PMID: 34031390 DOI: 10.1038/s41467-021-23285-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
362 Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, Hirshberg B, Ambery P. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care 2021:dc202151. [PMID: 34016612 DOI: 10.2337/dc20-2151] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 34.0] [Reference Citation Analysis]
363 Kasper P, Breuer S, Hoffmann T, Vohlen C, Janoschek R, Schmitz L, Appel S, Fink G, Hünseler C, Quaas A, Demir M, Lang S, Steffen HM, Martin A, Schramm C, Bürger M, Mahabir E, Goeser T, Dötsch J, Hucklenbruch-Rother E, Bae-Gartz I. Maternal Exercise Mediates Hepatic Metabolic Programming via Activation of AMPK-PGC1α Axis in the Offspring of Obese Mothers. Cells 2021;10:1247. [PMID: 34069390 DOI: 10.3390/cells10051247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Mantovani A, Valenti L. A call to action for fatty liver disease. Liver Int 2021;41:1182-5. [DOI: 10.1111/liv.14907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
365 Bonsembiante L, Targher G, Maffeis C. Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition? Eur J Clin Nutr 2021. [PMID: 34006994 DOI: 10.1038/s41430-021-00928-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
366 Sheng G, Peng N, Hu C, Zhong L, Zhong M, Zou Y. The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population. Lipids Health Dis 2021;20:50. [PMID: 33993872 DOI: 10.1186/s12944-021-01479-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
367 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
368 Ivashkin VT, Maevskaya MV, Shirokova EN, Maev IV, Samsonov AA, Sas EI, Palgova LK, Starostin K. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies. Drugs Real World Outcomes 2021;8:369-82. [PMID: 33993460 DOI: 10.1007/s40801-021-00250-x] [Reference Citation Analysis]
369 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
370 Zhang Q, Ma X, Xing J, Shi H, Yang R, Jiao Y, Chen S, Wu S, Zhang S, Sun X. Serum Uric Acid Is a Mediator of the Association Between Obesity and Incident Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study. Front Endocrinol (Lausanne) 2021;12:657856. [PMID: 34054728 DOI: 10.3389/fendo.2021.657856] [Reference Citation Analysis]
371 Kehagias D, Mulita F, Drakos N, Seretis F, Liolis E, Kehagias I. Bariatric surgery: blessing or sometimes curse for the liver? Prz Menopauzalny 2021;20:108-11. [PMID: 34321990 DOI: 10.5114/pm.2021.106062] [Reference Citation Analysis]
372 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 60.0] [Reference Citation Analysis]
373 Skinner RC, Hagaman JA. The interplay of Western diet and binge drinking on the onset, progression, and outlook of liver disease. Nutr Rev 2021:nuab031. [PMID: 33969426 DOI: 10.1093/nutrit/nuab031] [Reference Citation Analysis]
374 Zhang S, Gu Y, Bian S, Lu Z, Zhang Q, Liu L, Meng G, Yao Z, Wu H, Wang Y, Zhang T, Wang X, Sun S, Wang X, Zhou M, Jia Q, Song K, Qi L, Niu K. Soft drink consumption and risk of nonalcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) cohort study. Am J Clin Nutr 2021;113:1265-74. [PMID: 33564868 DOI: 10.1093/ajcn/nqaa380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
375 Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021;32:500-14. [PMID: 33975804 DOI: 10.1016/j.tem.2021.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
376 Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol 2021; 27(17): 1864-1882 [PMID: 34007127 DOI: 10.3748/wjg.v27.i17.1864] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
377 Pasanta D, Htun KT, Pan J, Tungjai M, Kaewjaeng S, Kim H, Kaewkhao J, Kothan S. Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications. Diagnostics (Basel) 2021;11:842. [PMID: 34067193 DOI: 10.3390/diagnostics11050842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
378 Jiang H, Qian Y, Shen Z, Liu Y, He Y, Gao R, Shen M, Chen S, Fu Q, Yang T. Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological marker of non‑alcoholic fatty liver disease. Mol Med Rep 2021;24:498. [PMID: 33955511 DOI: 10.3892/mmr.2021.12137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
379 Barbosa PO, Souza MO, Silva MPS, Santos GT, Silva ME, Bermano G, Freitas RN. Açaí (Euterpe oleracea Martius) supplementation improves oxidative stress biomarkers in liver tissue of dams fed a high-fat diet and increases antioxidant enzymes' gene expression in offspring. Biomed Pharmacother 2021;139:111627. [PMID: 33965728 DOI: 10.1016/j.biopha.2021.111627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
380 Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021;6:578-88. [PMID: 33961787 DOI: 10.1016/S2468-1253(21)00020-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 51.0] [Reference Citation Analysis]
381 Morán-Costoya A, Proenza AM, Gianotti M, Lladó I, Valle A. Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver-Adipose Tissue Crosstalk. Antioxid Redox Signal 2021;35:753-74. [PMID: 33736456 DOI: 10.1089/ars.2021.0044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
382 Liu X, Zhou P, He K, Wen Z, Gao Y. Dioscorea Zingiberensis New Saponin Inhibits the Growth of Hepatocellular Carcinoma by Suppressing the Expression of Long Non-coding RNA TCONS-00026762. Front Pharmacol 2021;12:678620. [PMID: 34012402 DOI: 10.3389/fphar.2021.678620] [Reference Citation Analysis]
383 Tuzer C, Sertbas Y, Duman E, Komoglu S, Kan O, Ay S, Yigit A, Sertbas M, Okuroglu N, Ozen B, Dalbeler A, Ozdemir A. The role of mean platelet volume in nonalcoholic fatty liver disease without cardiovascular comorbidities, obesity and diabetes mellitus. Eur J Gastroenterol Hepatol 2021;33:1222-8. [PMID: 34397640 DOI: 10.1097/MEG.0000000000002189] [Reference Citation Analysis]
384 Han S, Zhu F, Huang X, Yan P, Xu K, Shen F, Sun J, Yang Z, Jin G, Teng Y. Maternal obesity accelerated non-alcoholic fatty liver disease in offspring mice by reducing autophagy. Exp Ther Med 2021;22:716. [PMID: 34007325 DOI: 10.3892/etm.2021.10148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Syväri J, Junker D, Patzelt L, Kappo K, Al Sadat L, Erfanian S, Makowski MR, Hauner H, Karampinos DC. Longitudinal changes on liver proton density fat fraction differ between liver segments. Quant Imaging Med Surg 2021;11:1701-9. [PMID: 33936958 DOI: 10.21037/qims-20-873] [Reference Citation Analysis]
386 Sbeit W, Greener T, Kadah A, Mari A, Goldin E, Khoury T, Mahamid M. Pancreatobiliary manifestations of nonalcoholic fatty liver disease: a retrospective case-control multicenter study. Eur J Gastroenterol Hepatol 2021;33:722-6. [PMID: 32483086 DOI: 10.1097/MEG.0000000000001780] [Reference Citation Analysis]
387 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 24.0] [Reference Citation Analysis]
388 Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 2021;70:962-9. [PMID: 32938692 DOI: 10.1136/gutjnl-2020-322572] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 84.0] [Reference Citation Analysis]
389 Liang XY, Hong FF, Yang SL. Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:1871-83. [PMID: 33953586 DOI: 10.2147/DMSO.S304817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
390 Lian J, Fu J. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:615409. [PMID: 33995271 DOI: 10.3389/fendo.2021.615409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Kim MN, Han K, Yoo J, Ha Y, Chon YE, Lee JH, Simon TG, Chan AT, Hwang SG. Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Sci Rep 2021;11:9154. [PMID: 33911167 DOI: 10.1038/s41598-021-88733-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
392 Lin T, Li L, Liang C, Peng L. Network Pharmacology-Based Investigation of the Therapeutic Mechanisms of Action of Danning Tablets in Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2021;2021:3495360. [PMID: 33995543 DOI: 10.1155/2021/3495360] [Reference Citation Analysis]
393 Chen Y, Chen X, Chen Q, Yu C. Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population. Front Endocrinol (Lausanne) 2021;12:565714. [PMID: 33967948 DOI: 10.3389/fendo.2021.565714] [Reference Citation Analysis]
394 Policarpo S, Machado MV, Cortez-Pinto H. Telemedicine as a tool for dietary intervention in NAFLD-HIV patients during the COVID-19 lockdown: A randomized controlled trial. Clin Nutr ESPEN 2021;43:329-34. [PMID: 34024536 DOI: 10.1016/j.clnesp.2021.03.031] [Reference Citation Analysis]
395 Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A. Nicht-alkoholische Fettlebererkrankung und Psoriasis - besteht ein gemeinsames proinflammatorisches Netzwerk? J Dtsch Dermatol Ges 2021;19:517-29. [PMID: 33861000 DOI: 10.1111/ddg.14425_g] [Reference Citation Analysis]
396 Federico A, Rosato V, Masarone M, Torre P, Dallio M, Romeo M, Persico M. The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. Nutrients 2021;13:1314. [PMID: 33923525 DOI: 10.3390/nu13041314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
397 Hokkanen A, Hämäläinen H, Laitinen TM, Laitinen TP. Test-Retest Reliability of the Assessment of Fatty Liver Disease Using Low-Dose Computed Tomography in Cardiac Patients. Front Med (Lausanne) 2021;8:656658. [PMID: 33937292 DOI: 10.3389/fmed.2021.656658] [Reference Citation Analysis]
398 Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med (Lausanne) 2021;8:615978. [PMID: 33937277 DOI: 10.3389/fmed.2021.615978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
399 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
400 Yu CS, Chang SS, Lin CH, Lin YJ, Wu JL, Chen RJ. Identify the Characteristics of Metabolic Syndrome and Non-obese Phenotype: Data Visualization and a Machine Learning Approach. Front Med (Lausanne) 2021;8:626580. [PMID: 33898478 DOI: 10.3389/fmed.2021.626580] [Reference Citation Analysis]
401 Scapaticci S, D'Adamo E, Mohn A, Chiarelli F, Giannini C. Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.Front Endocrinol (Lausanne). 2021;12:639548. [PMID: 33889132 DOI: 10.3389/fendo.2021.639548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
402 Younossi ZM, Pham H, Felix S, Stepanova M, Jeffers T, Younossi E, Allawi H, Lam B, Cable R, Afendy M, Younoszai Z, Afendy A, Rafiq N, Alzubaidi N, Ousman Y, Bailey M, Chris Z, Castillo-Catoni M, Fozdar P, Ramirez M, Husain M, Hudson E, Schneider I, Golabi P, Nader F. Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. Clin Transl Gastroenterol 2021;12:e00340. [PMID: 33825721 DOI: 10.14309/ctg.0000000000000340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
403 Semmler G, Wernly S, Bachmayer S, Wernly B, Schwenoha L, Huber-Schönauer U, Stickel F, Niederseer D, Aigner E, Datz C. Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study. Clin Transl Gastroenterol 2021;12:e00326. [PMID: 33821832 DOI: 10.14309/ctg.0000000000000326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
404 Darlyuk-Saadon I, Bai C, Heng CKM, Gilad N, Yu WP, Lim PY, Cazenave-Gassiot A, Zhang Y, Wong WSF, Engelberg D. Active p38α causes macrovesicular fatty liver in mice. Proc Natl Acad Sci U S A 2021;118:e2018069118. [PMID: 33811139 DOI: 10.1073/pnas.2018069118] [Reference Citation Analysis]
405 Amzolini AM, Forţofoiu MC, Barău Abu-Alhija A, Vladu IM, Clenciu D, Mitrea A, Forţofoiu M, Matei D, Enăchescu V, Predescu OI, Micu ES. Triglyceride and glucose index: a useful tool for non-alcoholic liver disease assessed by liver biopsy in patients with metabolic syndrome? Rom J Morphol Embryol 2021;62:475-80. [PMID: 35024735 DOI: 10.47162/RJME.62.2.13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Liu L, Zhao J, Zhang R, Wang X, Wang Y, Chen Y, Feng R. Serum untargeted metabolomics delineates the metabolic status in different subtypes of non-alcoholic fatty liver disease. J Pharm Biomed Anal 2021;200:114058. [PMID: 33865049 DOI: 10.1016/j.jpba.2021.114058] [Reference Citation Analysis]
407 Wang H, Li F, Feng J, Wang J, Liu X. The effects of S-nitrosylation-induced PPARγ/SFRP5 pathway inhibition on the conversion of non-alcoholic fatty liver to non-alcoholic steatohepatitis. Ann Transl Med 2021;9:684. [PMID: 33987382 DOI: 10.21037/atm-21-1070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Xu Y, Ke H, Li Y, Xie L, Su H, Xie J, Mo J, Chen W. Malvidin-3-O-Glucoside from Blueberry Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Transcription Factor EB-Mediated Lysosomal Function and Activating the Nrf2/ARE Signaling Pathway. J Agric Food Chem 2021;69:4663-73. [PMID: 33787249 DOI: 10.1021/acs.jafc.0c06695] [Reference Citation Analysis]
409 Yan J, Nie Y, Cao J, Luo M, Yan M, Chen Z, He B. The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases. Front Cardiovasc Med 2021;8:655575. [PMID: 33869312 DOI: 10.3389/fcvm.2021.655575] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
410 Moise CG, Donoiu I, Târtea GC, Mirea O, Rogoveanu I. Assessment of Left Ventricular Diastolic Function in Young Adults with Nonalcoholic Fatty Liver Disease. Curr Health Sci J 2021;47:23-7. [PMID: 34211743 DOI: 10.12865/CHSJ.47.01.04] [Reference Citation Analysis]
411 Di Stasi V, Maseroli E, Rastrelli G, Scavello I, Cipriani S, Todisco T, Marchiani S, Sorbi F, Fambrini M, Petraglia F, Maggi M, Vignozzi L. SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirsutism and in Women With Sexual Dysfunction. Front Endocrinol (Lausanne). 2021;12:641446. [PMID: 33854482 DOI: 10.3389/fendo.2021.641446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
412 Alswat K, Sanai FM, Al-Hamoudi W, Ismail M, Dahlan Y, AlGhamdi HS, Altraif I, Alalwan A, Babatin MMA, Alqahtani SA. Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. Diabetes Metab Syndr Obes 2021;14:1167-75. [PMID: 33762835 DOI: 10.2147/DMSO.S300051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
413 Yamazaki F. Psoriasis: Comorbidities. J Dermatol 2021;48:732-40. [PMID: 33763899 DOI: 10.1111/1346-8138.15840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
414 Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network?J Dtsch Dermatol Ges. 2021;19:517-528. [PMID: 33768700 DOI: 10.1111/ddg.14425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
415 Gao WY, Chen PY, Hsu HJ, Lin CY, Wu MJ, Yen JH. Tanshinone IIA Downregulates Lipogenic Gene Expression and Attenuates Lipid Accumulation through the Modulation of LXRα/SREBP1 Pathway in HepG2 Cells. Biomedicines 2021;9:326. [PMID: 33806955 DOI: 10.3390/biomedicines9030326] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
416 Liu PJ, Lou HP, Zhu YN. Identification of Hepatic Steatosis in Premenopausal and Postmenopausal Women Based on Phenotypes Combining Triglyceride Levels and Anthropometric Indices: A Cross-Sectional Study. Diabetes Metab Syndr Obes 2021;14:1339-47. [PMID: 33790601 DOI: 10.2147/DMSO.S302297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
417 Flessa CM, Kyrou I, Nasiri-Ansari N, Kaltsas G, Papavassiliou AG, Kassi E, Randeva HS. Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives. Curr Obes Rep 2021;10:134-61. [PMID: 33751456 DOI: 10.1007/s13679-021-00431-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
418 Kichloo A, Solanki S, Haq KF, Dahiya D, Bailey B, Solanki D, Singh J, Albosta M, Wani F, Aljadah M, Shah H, Khan H, Jafri SM. Association of non-alcoholic fatty liver disease with gallstone disease in the United States hospitalized patient population. World J Gastrointest Pathophysiol 2021; 12(2): 14-24 [PMID: 33815863 DOI: 10.4291/wjgp.v12.i2.14] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
419 Guo T, Dai Z, You K, Battaglia-Hsu SF, Feng J, Wang F, Li B, Yang J, Li Z. S-adenosylmethionine upregulates the angiotensin receptor-binding protein ATRAP via the methylation of HuR in NAFLD. Cell Death Dis 2021;12:306. [PMID: 33753727 DOI: 10.1038/s41419-021-03591-1] [Reference Citation Analysis]
420 Zhang J, Li K, Pan L, Teng F, Zhang P, Lin B, Yuan Y, Wei X, Li W, Zhang H. Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study. BMC Gastroenterol 2021;21:131. [PMID: 33743586 DOI: 10.1186/s12876-021-01721-9] [Reference Citation Analysis]
421 Whitson RH Jr, Li SL, Zhang G, Larson GP, Itakura K. Mice with Fabp4-Cre ablation of Arid5b are resistant to diet-induced obesity and hepatic steatosis. Mol Cell Endocrinol 2021;528:111246. [PMID: 33757861 DOI: 10.1016/j.mce.2021.111246] [Reference Citation Analysis]
422 An YA, Chen S, Deng Y, Wang ZV, Funcke JB, Shah M, Shan B, Gordillo R, Yoshino J, Klein S, Kusminski CM, Scherer PE. The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. J Hepatol 2021;75:387-99. [PMID: 33746082 DOI: 10.1016/j.jhep.2021.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
423 Shi J, Wang Z, Zhang W, Niu Y, Lin N, Li X, Zhang H, Ning G, Fan J, Qin L, Su Q, Yang Z. Neck circumference as an independent predictor for NAFLD among postmenopausal women with normal body mass index. Nutr Metab (Lond) 2021;18:30. [PMID: 33731171 DOI: 10.1186/s12986-021-00562-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 Sánchez V, Brandt A, Jin CJ, Rajcic D, Engstler AJ, Jung F, Nier A, Baumann A, Bergheim I. Fortifying Butterfat with Soybean Oil Attenuates the Onset of Diet-Induced Non-Alcoholic Steatohepatitis and Glucose Intolerance. Nutrients 2021;13:959. [PMID: 33809593 DOI: 10.3390/nu13030959] [Reference Citation Analysis]
425 Qiu S, Cao P, Guo Y, Lu H, Hu Y. Exploring the Causality Between Hypothyroidism and Non-alcoholic Fatty Liver: A Mendelian Randomization Study. Front Cell Dev Biol 2021;9:643582. [PMID: 33791302 DOI: 10.3389/fcell.2021.643582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
426 Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 2021;15:206-16. [PMID: 32921636 DOI: 10.5009/gnl20127] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
427 Liu Q, Li L, Gao L, Li C, Huan Y, Lei L, Cao H, Li L, Gao A, Liu S, Shen Z. Combination of bis (α-furancarboxylato) oxovanadium (IV) and metformin improves hepatic steatosis through down-regulating inflammatory pathways in high-fat diet-induced obese C57BL/6J mice. Basic Clin Pharmacol Toxicol 2021;128:747-57. [PMID: 33599105 DOI: 10.1111/bcpt.13573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
428 Han Y, Zhang Y, Liu S, Chen G, Cao L, Xin Y. Association of LDLR rs1433099 with the Risk of NAFLD and CVD in Chinese Han Population. J Clin Transl Hepatol 2021;9:203-9. [PMID: 34007802 DOI: 10.14218/JCTH.2020.00163] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
429 Chou YT, Li CH, Sun ZJ, Shen WC, Yang YC, Lu FH, Chang CJ, Wu JS. A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones. Nutrients 2021;13:914. [PMID: 33799865 DOI: 10.3390/nu13030914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
430 Trujillo MJ, Chen J, Rubin JM, Gao J. Non-invasive imaging biomarkers to assess nonalcoholic fatty liver disease: A review. Clin Imaging 2021;78:22-34. [PMID: 33721575 DOI: 10.1016/j.clinimag.2021.02.039] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
431 Veracruz N, Hameed B, Saab S, Wong RJ. The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers. J Clin Exp Hepatol 2021;11:45-81. [PMID: 33679048 DOI: 10.1016/j.jceh.2020.04.018] [Reference Citation Analysis]
432 Yaskolka Meir A, Keller M, Bernhart SH, Rinott E, Tsaban G, Zelicha H, Kaplan A, Schwarzfuchs D, Shelef I, Gepner Y, Li J, Lin Y, Blüher M, Ceglarek U, Stumvoll M, Stadler PF, Stampfer MJ, Kovacs P, Liang L, Shai I. Lifestyle weight-loss intervention may attenuate methylation aging: the CENTRAL MRI randomized controlled trial. Clin Epigenetics 2021;13:48. [PMID: 33663610 DOI: 10.1186/s13148-021-01038-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
433 Kao WY, Lin YF, Chang IW, Chen CL, Tang JH, Chang CC, Chang YJ, Wang W. Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis. J Chin Med Assoc 2021;84:261-6. [PMID: 33306598 DOI: 10.1097/JCMA.0000000000000469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
434 Fotschki B, Juśkiewicz J, Jurgoński A, Sójka M. Fructo-Oligosaccharides and Pectins Enhance Beneficial Effects of Raspberry Polyphenols in Rats with Nonalcoholic Fatty Liver. Nutrients 2021;13:833. [PMID: 33802455 DOI: 10.3390/nu13030833] [Reference Citation Analysis]
435 Al Attar A, Antaramian A, Noureddin M. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Rev Clin Pharmacol 2021;14:457-64. [PMID: 33612037 DOI: 10.1080/17512433.2021.1894127] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Khiatah B, Nasrollah L, Covington S, Carlson D. Nonalcoholic fatty liver disease as a risk factor for cytomegalovirus hepatitis in an immunocompetent patient: A case report. World J Clin Cases 2021; 9(6): 1455-1460 [PMID: 33644215 DOI: 10.12998/wjcc.v9.i6.1455] [Reference Citation Analysis]
437 Zhang D, Dai J, Zhang M, Xie Y, Cao Y, He G, Xu W, Wang L, Qiao Z, Qiao Z. Paternal nicotine exposure promotes hepatic fibrosis in offspring. Toxicol Lett 2021;343:44-55. [PMID: 33640489 DOI: 10.1016/j.toxlet.2021.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Zhao M, Chen S, Ji X, Shen X, You J, Liang X, Yin H, Zhao L. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacol Res 2021;166:105517. [PMID: 33636349 DOI: 10.1016/j.phrs.2021.105517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Ni L, Yu D, Wu T, Jin F. Gender-specific association between non-alcoholic fatty liver disease and type 2 diabetes mellitus among a middle-aged and elderly Chinese population: An observational study. Medicine (Baltimore) 2021;100:e24743. [PMID: 33578624 DOI: 10.1097/MD.0000000000024743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
440 Du F, Huang R, Lin D, Wang Y, Yang X, Huang X, Zheng B, Chen Z, Huang Y, Wang X, Chen F. Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota. Front Microbiol 2021;12:611323. [PMID: 33708180 DOI: 10.3389/fmicb.2021.611323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
441 Al-Mrabeh A. β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies. Biomedicines 2021;9:226. [PMID: 33672162 DOI: 10.3390/biomedicines9020226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
442 Alqahtani SA, Golabi P, Paik JM, Lam B, Moazez AH, Elariny HA, Goodman Z, Younossi ZM. Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obes Surg 2021;31:2002-10. [PMID: 33616848 DOI: 10.1007/s11695-020-04996-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
443 Kwon HC, Song JJ, Park YB, Lee SW. Fibrosis-5 predicts end-stage renal disease in patients with microscopic polyangiitis and granulomatosis with polyangiitis without substantial liver diseases. Clin Exp Med 2021;21:399-406. [PMID: 33611672 DOI: 10.1007/s10238-021-00691-2] [Reference Citation Analysis]
444 Liang Y, Lin C, Deng Y, Zhang Y, Yang Q. Effects of traditional Chinese medicine Chaihu-Shugan-San aqueous extract on high-fat diet-induced liver steatosis in rats via intestinal microbiota metabolite SCFAs and its receptor Gpr43/109a. ADV TRADIT MED (ADTM) 2022;22:395-400. [DOI: 10.1007/s13596-021-00552-z] [Reference Citation Analysis]
445 Guirguis E, Grace Y, Bolson A, DellaVecchia MJ, Ruble M. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. Pharmacotherapy 2021;41:315-28. [PMID: 33278029 DOI: 10.1002/phar.2489] [Reference Citation Analysis]
446 Cui Y, Liu J, Shi H, Hu W, Song L, Zhao Q. Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. J Diabetes Complications 2021;35:107874. [PMID: 33640265 DOI: 10.1016/j.jdiacomp.2021.107874] [Reference Citation Analysis]
447 Cho J, Lee I, Park DH, Kwak HB, Min K. Relationships between Socioeconomic Status, Handgrip Strength, and Non-Alcoholic Fatty Liver Disease in Middle-Aged Adults. Int J Environ Res Public Health 2021;18:1892. [PMID: 33669288 DOI: 10.3390/ijerph18041892] [Reference Citation Analysis]
448 Mikolasevic I, Delija B, Mijic A, Stevanovic T, Skenderevic N, Sosa I, Krznaric-Zrnic I, Abram M, Krznaric Z, Domislovic V, Filipec Kanizaj T, Radic-Kristo D, Cubranic A, Grubesic A, Nakov R, Skrobonja I, Stimac D, Hauser G. Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. Int J Clin Pract 2021;75:e13947. [PMID: 33406286 DOI: 10.1111/ijcp.13947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
449 Makker J, Tariq H, Kumar K, Ravi M, Shaikh DH, Leung V, Hayat U, Hassan MT, Patel H, Nayudu S, Chilimuri S. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. World J Gastroenterol 2021; 27(6): 523-533 [PMID: 33642826 DOI: 10.3748/wjg.v27.i6.523] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
450 Bhowmick S, Singh V, Jash S, Lal M, Sinha Roy S. Mitochondrial metabolism and calcium homeostasis in the development of NAFLD leading to hepatocellular carcinoma. Mitochondrion 2021;58:24-37. [PMID: 33581332 DOI: 10.1016/j.mito.2021.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
451 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 41.0] [Reference Citation Analysis]
453 Thiagarajan P, Bawden SJ, Aithal GP. Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy. J Clin Med 2021;10:632. [PMID: 33562284 DOI: 10.3390/jcm10040632] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
454 Wang K, Tan W, Liu X, Deng L, Huang L, Wang X, Gao X. New insight and potential therapy for NAFLD: CYP2E1 and flavonoids. Biomed Pharmacother 2021;137:111326. [PMID: 33556870 DOI: 10.1016/j.biopha.2021.111326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
455 Gawlik-Kotelnicka O, Strzelecki D. Adiposity in Depression or Depression in Adiposity? The Role of Immune-Inflammatory-Microbial Overlap. Life (Basel) 2021;11:117. [PMID: 33557031 DOI: 10.3390/life11020117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
456 Itier R, Guillaume M, Ricci JE, Roubille F, Delarche N, Picard F, Galinier M, Roncalli J. Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. ESC Heart Fail 2021;8:789-98. [PMID: 33534958 DOI: 10.1002/ehf2.13222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
457 Kim KM, Roh JH, Lee S, Yoon JH. Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci Rep 2021;11:2884. [PMID: 33536442 DOI: 10.1038/s41598-021-81959-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
458 Srinivas AN, Suresh D, Santhekadur PK, Suvarna D, Kumar DP. Extracellular Vesicles as Inflammatory Drivers in NAFLD. Front Immunol 2020;11:627424. [PMID: 33603757 DOI: 10.3389/fimmu.2020.627424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
459 Tao S, Yang Y, Li J, Wang H, Ma Y. Bixin Attenuates High-Fat Diet-Caused Liver Steatosis and Inflammatory Injury through Nrf2/PPARα Signals. Oxid Med Cell Longev 2021;2021:6610124. [PMID: 33603948 DOI: 10.1155/2021/6610124] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
460 El Khoury D, Pauley RJ, Berseth CL. Dietary approaches to managing nonalcoholic fatty liver disease. Nurse Pract 2021;46:19-26. [PMID: 33399334 DOI: 10.1097/01.NPR.0000731560.23509.ff] [Reference Citation Analysis]
461 Amanatidou AI, Dedoussis GV. Construction and analysis of protein-protein interaction network of non-alcoholic fatty liver disease. Comput Biol Med 2021;131:104243. [PMID: 33550014 DOI: 10.1016/j.compbiomed.2021.104243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
462 Cui P, Hu W, Ma T, Hu M, Tong X, Zhang F, Shi J, Xu X, Li X, Shao LR, Billig H, Feng Y. Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats. J Steroid Biochem Mol Biol 2021;208:105829. [PMID: 33513383 DOI: 10.1016/j.jsbmb.2021.105829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
463 You N, Xu J, Wang L, Zhuo L, Zhou J, Song Y, Ali A, Luo Y, Yang J, Yang W, Zheng M, Xu J, Shao L, Shi J. Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. Obesity (Silver Spring) 2021;29:350-8. [PMID: 33491316 DOI: 10.1002/oby.23073] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 El Amrousy D, El Ashry H, Maher S, Ganna S, Hasan S. Pulmonary function test abnormalities in children and adolescents with non-alcoholic fatty liver disease. Eur J Pediatr 2021;180:1693-9. [DOI: 10.1007/s00431-021-03941-3] [Reference Citation Analysis]
465 El Amrousy D, El Ashry H, Maher S, Ganna S, Hasan S. Pulmonary function test abnormalities in children and adolescents with non-alcoholic fatty liver disease. Eur J Pediatr 2021;180:1693-9. [PMID: 33479799 DOI: 10.1007/s00431-021-03941-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
466 Wang Y, Tai YL, Zhao D, Zhang Y, Yan J, Kakiyama G, Wang X, Gurley EC, Liu J, Liu J, Liu J, Lai G, Hylemon PB, Pandak WM, Chen W, Zhou H. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways. Cells 2021;10:210. [PMID: 33494295 DOI: 10.3390/cells10020210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
467 Shi R, Lin C, Hong Y, Xia X, Chen Y, Li S, Xiu L. Free Triiodothyronine Is Independently Associated with Nonalcoholic Fatty Liver Disease in Hospitalized Type 2 Diabetes Mellitus Patients. Biomed Res Int 2021;2021:8868339. [PMID: 33532498 DOI: 10.1155/2021/8868339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
468 Oh J, Park HJ, Lee ES, Park SB, Choi BI, Ahn S. Severity of hyperechoic pancreas on ultrasonography as a risk factor for glycemic progression. Ultrasonography 2021;40:499-511. [PMID: 33730774 DOI: 10.14366/usg.20122] [Reference Citation Analysis]
469 Jiang X, Li Y, Wang W, Han X, Han J, Chen M, Zhang J, Wang C, Li S, Luo J, Wang X, Xu Y, Xu Y, Cheng J, Si S. Nuclear Factor Erythroid 2 Related Factor 2 Activator JC-5411 Inhibits Atherosclerosis Through Suppression of Inflammation and Regulation of Lipid Metabolism. Front Pharmacol 2020;11:532568. [PMID: 33442380 DOI: 10.3389/fphar.2020.532568] [Reference Citation Analysis]
470 Li N, Liu Y, Yu S, Hu B, Zhao H. Composite BMI and Waist-to-Height Ratio Index for Risk Assessment of Non-alcoholic Fatty Liver Disease in Adult Populations. Hepat Mon 2021;20. [DOI: 10.5812/hepatmon.103607] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
471 Hong SH, Hwang SY, Kim JA, Lee YB, Roh E, Kim NH, Seo JA, Kim SG, Kim NH, Choi KM, Baik SH, Yoo HJ. Comparison of anthropometric indices for the screening of nonalcoholic fatty liver disease in pre- and postmenopausal women. Menopause 2020;27:88-94. [PMID: 31613826 DOI: 10.1097/GME.0000000000001419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
472 Guan J, Wang G, Yang Q, Chen C, Deng J, Gu X, Zhu H. Natural Killer T Cells in Various Mouse Models of Hepatitis. Biomed Res Int 2021;2021:1782765. [PMID: 33506011 DOI: 10.1155/2021/1782765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
473 Barsouk A, Thandra KC, Saginala K, Rawla P, Barsouk A. Chemical Risk Factors of Primary Liver Cancer: An Update. Hepat Med 2020;12:179-88. [PMID: 33447099 DOI: 10.2147/HMER.S278070] [Reference Citation Analysis]
474 Masroor M, Haque Z. HbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters. J Clin Transl Hepatol 2021;9:15-21. [PMID: 33604251 DOI: 10.14218/JCTH.2019.00046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
475 Ge J, Lai JC, Boike JR, German M, Jest N, Morelli G, Spengler E, Said A, Lee A, Hristov A, Desai AP, Junna S, Pokhrel B, Couri T, Paul S, Frenette C, Christian-Miller N, Laurito M, Verna EC, Rahim U, Goel A, Das A, Pine S, Gregory D, VanWagner LB, Kolli KP; Advancing Liver Therapeutic Approaches (ALTA) Study Group. Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post-Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study. Liver Transpl 2021;27:329-40. [PMID: 33217178 DOI: 10.1002/lt.25949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
476 Sun Z, Cao H, Liu QS, Liang Y, Fiedler H, Zhang J, Zhou Q, Jiang G. 4-Hexylphenol influences adipogenic differentiation and hepatic lipid accumulation in vitro. Environ Pollut 2021;268:115635. [PMID: 33045592 DOI: 10.1016/j.envpol.2020.115635] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Ezhilarasan D. Advantages and challenges in nanomedicines for chronic liver diseases: A hepatologist's perspectives. Eur J Pharmacol 2021;893:173832. [PMID: 33359144 DOI: 10.1016/j.ejphar.2020.173832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
478 Silva MBDBE, Tustumi F, Dantas ACB, Miranda BCJ, Pajecki D, De-cleva R, Santo MA, Nahas SC. OBESIDADE E ESTEATOSE GRAVE: A IMPORTÂNCIA DA AVALIAÇÃO BIOQUÍMICA E ESCORES. ABCD, arq bras cir dig 2021;34:e1626. [DOI: 10.1590/0102-672020210002e1626] [Reference Citation Analysis]
479 Thandra KC, Barsouk A, Saginala K, Aluru JS, Rawla P, Barsouk A. Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. Clin Exp Hepatol 2020;6:289-94. [PMID: 33511275 DOI: 10.5114/ceh.2020.102153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
480 Gu D, Yi H, Jiang K, Fakhar SH, Shi J, He Y, Liu B, Guo Y, Fan X, Li S. Transcriptome analysis reveals the efficacy of ginsenoside-Rg1 in the treatment of nonalcoholic fatty liver disease. Life Sci 2021;267:118986. [PMID: 33385408 DOI: 10.1016/j.lfs.2020.118986] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
481 Sandhu S, Orsi C, Francis GL, Wang Z, Fernandez R, Alkhouri N. Shear wave elastography reveals a high prevalence of liver fibrosis in overweight or obese Hispanic youth. J Ultrason 2020;20:e162-8. [PMID: 33365151 DOI: 10.15557/JoU.2020.0027] [Reference Citation Analysis]
482 Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa R, Huiban L, Cojocariu C, Singeap AM, Girleanu I, Chiriac S, Stanciu C. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Can J Gastroenterol Hepatol 2020;2020:6638306. [PMID: 33425804 DOI: 10.1155/2020/6638306] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
483 Finan B, Parlee SD, Yang B. Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. Mol Metab 2021;46:101153. [PMID: 33359400 DOI: 10.1016/j.molmet.2020.101153] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
484 Gong X, Li T, Wan R, Sha L. Cordycepin attenuates high-fat diet-induced non-alcoholic fatty liver disease via down-regulation of lipid metabolism and inflammatory responses. Int Immunopharmacol 2021;91:107173. [PMID: 33352441 DOI: 10.1016/j.intimp.2020.107173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
485 Lee H, Lee YH, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2021;19:2138-2147.e10. [PMID: 33348045 DOI: 10.1016/j.cgh.2020.12.022] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 35.5] [Reference Citation Analysis]
486 Kawachi Y, Fujishima Y, Nishizawa H, Nagao H, Nakamura T, Akari S, Murase T, Taya N, Omori K, Miyake A, Fukuda S, Takahara M, Kita S, Katakami N, Maeda N, Shimomura I. Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment. J Diabetes Investig 2021;12:1512-20. [PMID: 33211396 DOI: 10.1111/jdi.13467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
487 Di Costanzo A, Ronca A, D'Erasmo L, Manfredini M, Baratta F, Pastori D, Di Martino M, Ceci F, Angelico F, Del Ben M, Pavanello C, Turri M, Calabresi L, Favari E, Arca M. HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines 2020;8:E625. [PMID: 33352841 DOI: 10.3390/biomedicines8120625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
488 Ismaiel A, Popa SL, Dumitrascu DL. Acute Coronary Syndromes and Nonalcoholic Fatty Liver Disease: "Un Affaire de Coeur". Can J Gastroenterol Hepatol 2020;2020:8825615. [PMID: 33313020 DOI: 10.1155/2020/8825615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
489 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
490 Li J, Li X, Liu D, Zhang S, Tan N, Yokota H, Zhang P. Phosphorylation of eIF2α signaling pathway attenuates obesity-induced non-alcoholic fatty liver disease in an ER stress and autophagy-dependent manner. Cell Death Dis 2020;11:1069. [PMID: 33318479 DOI: 10.1038/s41419-020-03264-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
491 Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020;134:8-19. [PMID: 33323806 DOI: 10.1097/cm9.0000000000001263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
492 Imierska M, Kurianiuk A, Błachnio-Zabielska A. The Influence of Physical Activity on the Bioactive Lipids Metabolism in Obesity-Induced Muscle Insulin Resistance. Biomolecules 2020;10:E1665. [PMID: 33322719 DOI: 10.3390/biom10121665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
493 Bayoumi A, Shatat M, Eslam M. Metabolic associated fatty liver disease and cancer risk: causal role or epiphenomenon? Hepatobiliary Surg Nutr 2020;9:774-6. [PMID: 33299832 DOI: 10.21037/hbsn.2020.03.05] [Reference Citation Analysis]
494 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
495 Pavlov VA. The evolving obesity challenge: targeting the vagus nerve and the inflammatory reflex in the response. Pharmacol Ther. 2021;222:107794. [PMID: 33310156 DOI: 10.1016/j.pharmthera.2020.107794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
496 Lu P, Yang G, Jiang L, He W, Wu W, Qi L, Shen S, Rao J, Zhang P, Xue Z, Jiang C, Fan G, Zhu X. Characterizing disease progression of nonalcoholic steatohepatitis in Leptin-deficient rats by integrated transcriptome analysis. Exp Biol Med (Maywood) 2021;246:678-87. [PMID: 33302736 DOI: 10.1177/1535370220976530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
497 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
498 Martínez-Uña M, López-Mancheño Y, Diéguez C, Fernández-Rojo MA, Novelle MG. Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases. Int J Mol Sci 2020;21:E9368. [PMID: 33316927 DOI: 10.3390/ijms21249368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
499 Hendrikx T, Binder CJ. Oxidation-Specific Epitopes in Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2020;11:607011. [PMID: 33362721 DOI: 10.3389/fendo.2020.607011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
500 Pyun DH, Kim TJ, Kim MJ, Hong SA, Abd El-Aty AM, Jeong JH, Jung TW. Endogenous metabolite, kynurenic acid, attenuates nonalcoholic fatty liver disease via AMPK/autophagy- and AMPK/ORP150-mediated signaling. J Cell Physiol 2021;236:4902-12. [PMID: 33283879 DOI: 10.1002/jcp.30199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
501 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
502 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
503 Ren TY, Li XY, Fan JG. Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try. Clin Mol Hepatol 2021;27:83-6. [PMID: 33317240 DOI: 10.3350/cmh.2020.0298] [Reference Citation Analysis]
504 De Munck TJI, Xu P, Vanderfeesten BLJ, Elizalde M, Masclee AAM, Nevens F, Cassiman D, Schaap FG, Jonkers DMAE, Verbeek J. The Role of Brown Adipose Tissue in the Development and Treatment of Nonalcoholic Steatohepatitis: An Exploratory Gene Expression Study in Mice. Horm Metab Res 2020;52:869-76. [PMID: 33260239 DOI: 10.1055/a-1301-2378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
505 Colletta C, Colletta A, Placentino G. Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease. J Diabetes Metab Disord 2020;19:883-94. [PMID: 33520810 DOI: 10.1007/s40200-020-00576-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
506 Tu C, Xiong H, Hu Y, Wang W, Mei G, Wang H, Li Y, Zhou Z, Meng F, Zhang P, Mei Z. Cardiolipin Synthase 1 Ameliorates NASH Through Activating Transcription Factor 3 Transcriptional Inactivation. Hepatology 2020;72:1949-67. [PMID: 32096565 DOI: 10.1002/hep.31202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
507 Freag MS, Namgung B, Reyna Fernandez ME, Gherardi E, Sengupta S, Jang HL. Human Nonalcoholic Steatohepatitis on a Chip. Hepatol Commun 2021;5:217-33. [PMID: 33553970 DOI: 10.1002/hep4.1647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
508 Sasson A, Kristoferson E, Batista R, McClung JA, Abraham NG, Peterson SJ. The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Arch Biochem Biophys 2021;697:108679. [PMID: 33248947 DOI: 10.1016/j.abb.2020.108679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
509 Xu QY, Li H, Cao HX, Pan Q, Fan JG. APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2020;2020:8869674. [PMID: 33294458 DOI: 10.1155/2020/8869674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
510 Wang T, Chen K, Yao W, Zheng R, He Q, Xia J, Li J, Shao Y, Zhang L, Huang L, Qin L, Xu M, Zhang Z, Pan D, Li Z, Huang F. Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance. J Hepatol 2021;74:1038-52. [PMID: 33248168 DOI: 10.1016/j.jhep.2020.11.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
511 Wang G, Zou H, Lai C, Huang X, Yao Y, Xiang G. Repression of MicroRNA-124-3p Alleviates High-Fat Diet-Induced Hepatosteatosis by Targeting Pref-1. Front Endocrinol (Lausanne) 2020;11:589994. [PMID: 33324345 DOI: 10.3389/fendo.2020.589994] [Reference Citation Analysis]
512 Zhao B, Li S, Guo Z, Chen Z, Zhang X, Xu C, Chen J, Wei C. Dopamine receptor D2 inhibition alleviates diabetic hepatic stellate cells fibrosis by regulating the TGF-β1/Smads and NFκB pathways. Clin Exp Pharmacol Physiol 2021;48:370-80. [PMID: 33179312 DOI: 10.1111/1440-1681.13437] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
513 Zou Y, Zhong L, Hu C, Sheng G. Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids Health Dis 2020;19:245. [PMID: 33239040 DOI: 10.1186/s12944-020-01419-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
514 Zhao H, Yang A, Mao L, Quan Y, Cui J, Sun Y. Association Between Dietary Fiber Intake and Non-alcoholic Fatty Liver Disease in Adults. Front Nutr 2020;7:593735. [PMID: 33330594 DOI: 10.3389/fnut.2020.593735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
515 Lombardi R, Iuculano F, Pallini G, Fargion S, Fracanzani AL. Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. Int J Mol Sci 2020;21:E8761. [PMID: 33228237 DOI: 10.3390/ijms21228761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
516 Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. MAFLD and risk of CKD. Metabolism 2021;115:154433. [PMID: 33212070 DOI: 10.1016/j.metabol.2020.154433] [Cited by in Crossref: 73] [Cited by in F6Publishing: 51] [Article Influence: 36.5] [Reference Citation Analysis]
517 Park HS, Song JW, Park JH, Lim BK, Moon OS, Son HY, Lee JH, Gao B, Won YS, Kwon HJ. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. Autophagy 2020;:1-16. [PMID: 33190588 DOI: 10.1080/15548627.2020.1834711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
518 An L, Shi Q, Zhu Y, Wang H, Peng Q, Wu J, Cheng Y, Zhang W, Yi Y, Bao Z, Zhang H, Luo Y, Fan J. Bone morphogenetic protein 4 (BMP4) promotes hepatic glycogen accumulation and reduces glucose level in hepatocytes through mTORC2 signaling pathway. Genes Dis 2021;8:531-44. [PMID: 34179315 DOI: 10.1016/j.gendis.2020.11.004] [Reference Citation Analysis]
519 Yang J, Tao D, Ma W, Liu S, Liao Y, Shu L, Zhang S, Li C, Du N, Shi Z. Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway. Evid Based Complement Alternat Med 2020;2020:6363748. [PMID: 33178320 DOI: 10.1155/2020/6363748] [Reference Citation Analysis]
520 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
521 Wijarnpreecha K, Panjawatanan P, Kroner PT, Cheungpasitporn W, Ungprasert P. Association between cardiac conduction defect and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Gastroenterol 2020;33:661-6. [PMID: 33162743 DOI: 10.20524/aog.2020.0535] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
522 Mikolasevic I, Domislovic V, Filipec Kanizaj T, Radic-Kristo D, Krznaric Z, Milovanovic T, Juric T, Klapan M, Skenderevic N, Delija B, Stevanovic T, Mijic A, Lukic A, Stimac D. Relationship between coffee consumption, sleep duration and smoking status with elastographic parameters of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. Int J Clin Pract 2021;75:e13770. [PMID: 33070425 DOI: 10.1111/ijcp.13770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
523 Galarregui C, Marin-Alejandre BA, Perez-Diaz-Del-Campo N, Cantero I, Monreal JI, Elorz M, Benito-Boillos A, Herrero JI, Tur JA, Martínez JA, Zulet MA, Abete I. Predictive Value of Serum Ferritin in Combination with Alanine Aminotransferase and Glucose Levels for Noninvasive Assessment of NAFLD: Fatty Liver in Obesity (FLiO) Study. Diagnostics (Basel) 2020;10:E917. [PMID: 33171699 DOI: 10.3390/diagnostics10110917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
524 Huh JY, Reilly SM, Abu-Odeh M, Murphy AN, Mahata SK, Zhang J, Cho Y, Seo JB, Hung CW, Green CR, Metallo CM, Saltiel AR. TANK-Binding Kinase 1 Regulates the Localization of Acyl-CoA Synthetase ACSL1 to Control Hepatic Fatty Acid Oxidation. Cell Metab 2020;32:1012-1027.e7. [PMID: 33152322 DOI: 10.1016/j.cmet.2020.10.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
525 Cai X, Aierken X, Ahmat A, Cao Y, Zhu Q, Wu T, Li N. A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study. Biomed Res Int 2020;2020:8852198. [PMID: 33204721 DOI: 10.1155/2020/8852198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
526 Milic J, Menozzi V, Schepis F, Malagoli A, Besutti G, Franconi I, Raimondi A, Carli F, Mussini C, Sebastiani G, Guaraldi G. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. AIDS 2020;34:1915-21. [PMID: 33009010 DOI: 10.1097/QAD.0000000000002650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
527 Starekova J, Reeder SB. Liver fat quantification: where do we stand? Abdom Radiol (NY) 2020;45:3386-99. [PMID: 33025153 DOI: 10.1007/s00261-020-02783-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
528 Maev IV, Samsonov AA, Lazebnik LB, Golovanova EV, Pavlov CS, Vovk EI, Ratziu V, Starostin KM. A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Adv Ther 2020;37:4627-40. [PMID: 32939691 DOI: 10.1007/s12325-020-01493-w] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
529 Zhang M, Wang Z, Hao S, Hao L, Zhang X, Yu P, Sun H. Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome. Eur J Med Chem 2020;205:112649. [PMID: 32791402 DOI: 10.1016/j.ejmech.2020.112649] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
530 Musaogullari A, Chai YC. Redox Regulation by Protein S-Glutathionylation: From Molecular Mechanisms to Implications in Health and Disease. Int J Mol Sci 2020;21:E8113. [PMID: 33143095 DOI: 10.3390/ijms21218113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
531 Minamikawa T, Ichimura-Shimizu M, Takanari H, Morimoto Y, Shiomi R, Tanioka H, Hase E, Yasui T, Tsuneyama K. Molecular imaging analysis of microvesicular and macrovesicular lipid droplets in non-alcoholic fatty liver disease by Raman microscopy. Sci Rep 2020;10:18548. [PMID: 33122711 DOI: 10.1038/s41598-020-75604-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
532 Ziogas IA, Zapsalis K, Giannis D, Tsoulfas G. Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!. World J Hepatol 2020; 12(10): 709-721 [PMID: 33200011 DOI: 10.4254/wjh.v12.i10.709] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
533 Lee J, Kim HS, Cho YK, Kim EH, Lee MJ, Bae IY, Jung CH, Park JY, Kim HK, Lee WJ. Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease. Sci Rep 2020;10:18323. [PMID: 33110139 DOI: 10.1038/s41598-020-75266-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
534 Asghar MS, Hassan M, Rasheed U, Haider Kazmi SJ, Khan NA, Khalid F, Anum A, Anwar S. Impact of Fasting Lipid Profile on Chronic Kidney Disease Patients Having Fatty Liver Disease. Cureus 2020;12:e11146. [PMID: 33251056 DOI: 10.7759/cureus.11146] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
535 Sae-Wong J, Chaopathomkul B, Phewplung T, Chaijitraruch N, Sahakitrungruang T. The Prevalence of Nonalcoholic Fatty Liver Disease and Its Risk Factors in Children and Young Adults with Type 1 Diabetes Mellitus. J Pediatr 2021;230:32-37.e1. [PMID: 33250172 DOI: 10.1016/j.jpeds.2020.10.043] [Reference Citation Analysis]
536 Hwangbo H, Kim MY, Ji SY, Kim SY, Lee H, Kim GY, Park C, Keum YS, Hong SH, Cheong J, Choi YH. Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. Antioxidants (Basel) 2020;9:E1040. [PMID: 33114221 DOI: 10.3390/antiox9111040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
537 Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour J, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 2021;18:24-39. [DOI: 10.1038/s41575-020-00366-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 34.0] [Reference Citation Analysis]
538 Fondevila MF, Mercado-Gómez M, Rodríguez A, Gonzalez-Rellan MJ, Iruzubieta P, Valentí V, Escalada J, Schwaninger M, Prevot V, Dieguez C, Crespo J, Frühbeck G, Martinez-Chantar ML, Nogueiras R. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. J Hepatol 2021;74:469-71. [PMID: 33096086 DOI: 10.1016/j.jhep.2020.09.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
539 Gonzalez A, Huerta-Salgado C, Orozco-Aguilar J, Aguirre F, Tacchi F, Simon F, Cabello-Verrugio C. Role of Oxidative Stress in Hepatic and Extrahepatic Dysfunctions during Nonalcoholic Fatty Liver Disease (NAFLD). Oxid Med Cell Longev 2020;2020:1617805. [PMID: 33149804 DOI: 10.1155/2020/1617805] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
540 Dobrindt EM, Allex L, Saipbaev A, Öllinger R, Schöning W, Pratschke J, Eurich D. Association between obesity after liver transplantation and steatosis, inflammation, and fibrosis of the graft. Clin Transplant 2020;34:e14093. [PMID: 32970896 DOI: 10.1111/ctr.14093] [Reference Citation Analysis]
541 Tsuru H, Osaka M, Hiraoka Y, Yoshida M. HFD-induced hepatic lipid accumulation and inflammation are decreased in Factor D deficient mouse. Sci Rep 2020;10:17593. [PMID: 33067533 DOI: 10.1038/s41598-020-74617-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
542 Hunter H, de Gracia Hahn D, Duret A, Im YR, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, McKeown L, Mitrofan CG, Rao R, Utukuri M, Rowe IA, Mann JP. Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. Elife 2020;9:e56573. [PMID: 33063664 DOI: 10.7554/eLife.56573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
543 Asif S, Morrow NM, Mulvihill EE, Kim KH. Understanding Dietary Intervention-Mediated Epigenetic Modifications in Metabolic Diseases. Front Genet 2020;11:590369. [PMID: 33193730 DOI: 10.3389/fgene.2020.590369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
544 Cao Y, Shu XB, Yao Z, Ji G, Zhang L. Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis? World J Gastroenterol 2020; 26(38): 5812-5821 [PMID: 33132636 DOI: 10.3748/wjg.v26.i38.5812] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
545 Orrù C, Giordano S, Columbano A. Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases. Cancers (Basel) 2020;12:E2932. [PMID: 33053665 DOI: 10.3390/cancers12102932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
546 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, Carvalho D, Leite-Moreira A. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413. [PMID: 33010191 DOI: 10.1002/dmrr.3413] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
547 Jamali R, Pourhassan S, Maghbouli N, Ashraf H, Sohrabpour AA. Liver fat content might be an appropriate measure for estimation of cardiovascular disease risk in non-alcoholic steatohepatitis patients. Med J Islam Repub Iran. 2020;34:135. [PMID: 33437731 DOI: 10.34171/mjiri.34.135] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
548 Sun J, Wang HJ, Yu J, Li T, Han Y. Protective effect of celastrol on type 2 diabetes mellitus with nonalcoholic fatty liver disease in mice. Food Sci Nutr 2020;8:6207-16. [PMID: 33282271 DOI: 10.1002/fsn3.1917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
549 Haghbin H, Gangwani MK, Ravi SJK, Perisetti A, Aziz M, Goyal H, Nawras A, Sodeman T. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Ann Gastroenterol 2020;33:603-14. [PMID: 33162737 DOI: 10.20524/aog.2020.0550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
550 Shao SY, Wang YL, Feng LM, Zhao Y. Serum non-high-density lipoprotein cholesterol level is increased in Chinese patients with nonalcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2020;19:602-4. [PMID: 33077366 DOI: 10.1016/j.hbpd.2020.09.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
551 Wijarnpreecha K, Kim D, Raymond P, Scribani M, Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur J Gastroenterol Hepatol 2019;31:1121-8. [PMID: 30888971 DOI: 10.1097/MEG.0000000000001397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
552 Targher G. What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. Metabolites. 2020;10. [PMID: 33049948 DOI: 10.3390/metabo10100397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
553 Geiger MA, Guillaumon AT, Paneni F, Matter CM, Stein S. Role of the Nuclear Receptor Corepressor 1 (NCOR1) in Atherosclerosis and Associated Immunometabolic Diseases. Front Immunol 2020;11:569358. [PMID: 33117357 DOI: 10.3389/fimmu.2020.569358] [Reference Citation Analysis]
554 Hu Y, Yin F, Liu Z, Xie H, Xu Y, Zhou D, Zhu B. Acerola polysaccharides ameliorate high-fat diet-induced non-alcoholic fatty liver disease through reduction of lipogenesis and improvement of mitochondrial functions in mice. Food Funct 2020;11:1037-48. [PMID: 31819934 DOI: 10.1039/c9fo01611b] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
555 Atri A, Jiwanmall SA, Nandyal MB, Kattula D, Paravathareddy S, Paul TV, Thomas N, Kapoor N. The Prevalence and Predictors of Non-alcoholic Fatty Liver Disease in Morbidly Obese Women - A Cross-sectional Study from Southern India.Eur Endocrinol. 2020;16:152-155. [PMID: 33117448 DOI: 10.17925/EE.2020.16.2.152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
556 Vincent RK, Williams DM, Evans M. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer? Diabetes Obes Metab 2020;22:2227-40. [DOI: 10.1111/dom.14196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
557 Zhao Y, Ma DX, Wang HG, Li MZ, Talukder M, Wang HR, Li JL. Lycopene Prevents DEHP-Induced Liver Lipid Metabolism Disorder by Inhibiting the HIF-1α-Induced PPARα/PPARγ/FXR/LXR System. J Agric Food Chem 2020;68:11468-79. [PMID: 32962341 DOI: 10.1021/acs.jafc.0c05077] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
558 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.Ann Hepatol. 2020;19:674-690. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
559 Ikejima K, Kon K, Yamashina S. Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights. Clin Mol Hepatol 2020;26:728-35. [PMID: 33053942 DOI: 10.3350/cmh.2020.0202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
560 Collin de l'Hortet A, Takeishi K, Guzman-Lepe J, Morita K, Achreja A, Popovic B, Wang Y, Handa K, Mittal A, Meurs N, Zhu Z, Weinberg F, Salomon M, Fox IJ, Deng CX, Nagrath D, Soto-Gutierrez A. Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. Cell Metab 2019;30:385-401.e9. [PMID: 31390551 DOI: 10.1016/j.cmet.2019.06.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
561 Wang Y, Zhu Y, Niu J, Deng Q, Guo S, Jiang H, Peng Z, Xue Y, Peng H, Xuan L, Pan G. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicol Appl Pharmacol 2020;404:115169. [PMID: 32738331 DOI: 10.1016/j.taap.2020.115169] [Reference Citation Analysis]
562 Kizivat T, Maric I, Mudri D, Curcic IB, Primorac D, Smolic M. Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications. J Clin Transl Hepatol 2020;8:347-53. [PMID: 33083258 DOI: 10.14218/JCTH.2020.00027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
563 Guo F, Xu S, Zhu Y, Zheng X, Lu Y, Tu J, He Y, Jin L, Li Y. PPARγ Transcription Deficiency Exacerbates High-Fat Diet-Induced Adipocyte Hypertrophy and Insulin Resistance in Mice. Front Pharmacol 2020;11:1285. [PMID: 32973516 DOI: 10.3389/fphar.2020.01285] [Reference Citation Analysis]
564 Fujita T, Daimon M, Mizushiri S, Nishiya Y, Murakami H, Tanabe J, Matsuhashi Y, Yanagimachi M, Tokuda I, Sawada K, Ihara K. FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population. Sci Rep 2020;10:15814. [PMID: 32978491 DOI: 10.1038/s41598-020-72894-8] [Reference Citation Analysis]
565 Rosato V, Masarone M, Aglitti A, Persico M. The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00018] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
566 López-Pastor AR, Infante-Menéndez J, Escribano Ó, Gómez-Hernández A. miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease. Front Med (Lausanne) 2020;7:527059. [PMID: 33102495 DOI: 10.3389/fmed.2020.527059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
567 Isoura Y, Cho Y, Fujimoto H, Hamazaki T, Tokuhara D. Effects of obesity reduction on transient elastography-based parameters in pediatric non-alcoholic fatty liver disease. Obes Res Clin Pract 2020;14:473-8. [PMID: 32938556 DOI: 10.1016/j.orcp.2020.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
568 Hayat U, Siddiqui AA, Okut H, Afroz S, Tasleem S, Haris A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. Ann Hepatol 2021;20:100254. [PMID: 32920163 DOI: 10.1016/j.aohep.2020.08.071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
569 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
570 Vural Keskinler M, Mutlu HH, Sirin A, Erkalma Senates B, Colak Y, Tuncer I, Oguz A. Visceral Adiposity Index As a Practical Tool in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Metab Syndr Relat Disord 2021;19:26-31. [PMID: 32898457 DOI: 10.1089/met.2020.0054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
571 Wang Z, Miu KK, Zhang X, Wan AT, Lu G, Cheung HH, Lee HM, Kong AP, Chan JC, Chan WY. Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor. JHEP Rep 2020;2:100179. [PMID: 33134908 DOI: 10.1016/j.jhepr.2020.100179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
572 Cherkashchenko NA, Livzan MA, Krolevets TS. [Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease]. Ter Arkh 2020;92:29-36. [PMID: 33346459 DOI: 10.26442/00403660.2020.08.000764] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
573 Anisonyan AV, Sandler YG, Khaimenova TY, Keyan VA, Saliev KG, Sbikina ES, Vinnitskaya EV. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus: issues of the liver fibrosis diagnostics]. Ter Arkh 2020;92:73-8. [PMID: 33346465 DOI: 10.26442/00403660.2020.08.000770] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
574 Remmerie A, Martens L, Thoné T, Castoldi A, Seurinck R, Pavie B, Roels J, Vanneste B, De Prijck S, Vanhockerhout M, Binte Abdul Latib M, Devisscher L, Hoorens A, Bonnardel J, Vandamme N, Kremer A, Borghgraef P, Van Vlierberghe H, Lippens S, Pearce E, Saeys Y, Scott CL. Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver. Immunity 2020;53:641-657.e14. [PMID: 32888418 DOI: 10.1016/j.immuni.2020.08.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 21.0] [Reference Citation Analysis]
575 Li K, Zhang K, Wang H, Wu Y, Chen N, Chen J, Qiu C, Cai P, Li M, Liang X, Su D. Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice. Metabolism 2021;114:154349. [PMID: 32888949 DOI: 10.1016/j.metabol.2020.154349] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
576 Xu F, Guo W. The progress of epigenetics in the development and progression of non-alcoholic fatty liver disease. Liver Research 2020;4:118-23. [DOI: 10.1016/j.livres.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
577 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020;69:1691-705. [PMID: 32321858 DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 130] [Cited by in F6Publishing: 96] [Article Influence: 65.0] [Reference Citation Analysis]
578 Shimizu K, Egusa Y, Nishimuta S, Fukumura Y, Yoshimura M, Inomoto T, Terada T, Tomita K, Nishinaka T. Dietary calamondin supplementation slows the progression of non-alcoholic fatty liver disease in C57BL/6 mice fed a high-fat diet. Int J Food Sci Nutr 2021;72:335-47. [PMID: 32862731 DOI: 10.1080/09637486.2020.1813262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
579 Fathi M, Alavinejad P, Haidari Z, Amani R. The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. J Trace Elem Med Biol 2020;62:126635. [PMID: 32932174 DOI: 10.1016/j.jtemb.2020.126635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
580 Kartsoli S, Kostara CE, Tsimihodimos V, Bairaktari ET, Christodoulou DK. Lipidomics in non-alcoholic fatty liver disease. World J Hepatol 2020; 12(8): 436-450 [PMID: 32952872 DOI: 10.4254/wjh.v12.i8.436] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
581 Lira MMP, de Medeiros Filho JEM, Baccin Martins VJ, da Silva G, de Oliveira Junior FA, de Almeida Filho ÉJB, Silva AS, Henrique da Costa-Silva J, de Brito Alves JL. Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. PLoS One 2020;15:e0237360. [PMID: 32845887 DOI: 10.1371/journal.pone.0237360] [Reference Citation Analysis]
582 Xin Z, Liu S, Niu J, Xu M, Wang T, Lu J, Chen Y, Wang W, Ning G, Bi Y, Xu Y, Li M, Zhao Z. The association of low-grade albuminuria with incident non-alcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycaemia status. Liver Int 2021;41:101-9. [PMID: 32840963 DOI: 10.1111/liv.14649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
583 Liu ST, Su KQ, Zhang LH, Liu MH, Zhao WX. Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus: A protocol for systematic review and network meta-analysis. Medicine (Baltimore) 2020;99:e21568. [PMID: 32769900 DOI: 10.1097/MD.0000000000021568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
584 Chen YS, Chen D, Shen C, Chen M, Jin CH, Xu CF, Yu CH, Li YM. A novel model for predicting fatty liver disease by means of an artificial neural network. Gastroenterol Rep (Oxf) 2021;9:31-7. [PMID: 33747524 DOI: 10.1093/gastro/goaa035] [Reference Citation Analysis]
585 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
586 Si Z, Guan X, Teng X, Peng X, Wan Z, Li Q, Chen G, Tan J, Li J. Identification of CYP46A1 as a new regulator of lipid metabolism through CRISPR-based whole-genome screening. FASEB J 2020;34:13776-91. [PMID: 32816363 DOI: 10.1096/fj.202001067R] [Reference Citation Analysis]
587 Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
588 Sun X, Chen R, Yan G, Chen Z, Yuan H, Huang W, Lu Y. Gender-specific associations between apolipoprotein A1 and arterial stiffness in patients with nonalcoholic fatty liver disease. PeerJ 2020;8:e9757. [PMID: 32874784 DOI: 10.7717/peerj.9757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
589 Ye L, Cao Z, Lai X, Shi Y, Zhou N. Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet. J Nutr 2020;150:672-84. [PMID: 31858105 DOI: 10.1093/jn/nxz303] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
590 Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:430-43. [PMID: 32791578 DOI: 10.3350/cmh.2020.0137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
591 Dorling JL, Ravussin E, Redman LM, Bhapkar M, Huffman KM, Racette SB, Das SK, Apolzan JW, Kraus WE, Höchsmann C, Martin CK; CALERIE Phase 2 Study Group. Effect of 2 years of calorie restriction on liver biomarkers: results from the CALERIE phase 2 randomized controlled trial. Eur J Nutr 2021;60:1633-43. [PMID: 32803412 DOI: 10.1007/s00394-020-02361-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
592 Im HJ, Hwang SJ, Lee JS, Lee SB, Kang JY, Son CG. Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. Nutrients 2020;12:E2433. [PMID: 32823613 DOI: 10.3390/nu12082433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
593 Zhang X, Bai R, Jia Y, Zong J, Wang Y, Dong Y. The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus. Int J Diabetes Dev Ctries 2020;40:491-9. [DOI: 10.1007/s13410-020-00857-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
594 Hodges JK, Sasaki GY, Bruno RS. Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies. J Nutr Biochem 2020;85:108478. [PMID: 32801031 DOI: 10.1016/j.jnutbio.2020.108478] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
595 Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Adv Pharm Bull. 2020;10:542-555. [PMID: 33072533 DOI: 10.34172/apb.2020.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
596 Haas SL, Löfgren P, Stål P, Hoffstedt J. Glucagon and Liver Fat are Downregulated in Response to Very Low-calorie Diet in Patients with Obesity and Type-2 Diabetes. Exp Clin Endocrinol Diabetes 2022;130:55-60. [PMID: 32767285 DOI: 10.1055/a-1220-6160] [Reference Citation Analysis]
597 Maseroli E, Comeglio P, Corno C, Cellai I, Filippi S, Mello T, Galli A, Rapizzi E, Presenti L, Truglia MC, Lotti F, Facchiano E, Beltrame B, Lucchese M, Saad F, Rastrelli G, Maggi M, Vignozzi L. Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men. J Endocrinol Invest 2021;44:819-42. [PMID: 32772323 DOI: 10.1007/s40618-020-01381-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
598 Meroni M, Longo M, Dongiovanni P. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 2020;1:218-43. [DOI: 10.37349/emed.2020.00015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
599 Brandt A, Rajcic D, Jin CJ, Sánchez V, Engstler AJ, Jung F, Nier A, Baumann A, Bergheim I. Fortifying diet with rapeseed oil instead of butterfat attenuates the progression of diet-induced non-alcoholic fatty liver disease (NAFLD) and impairment of glucose tolerance. Metabolism 2020;109:154283. [DOI: 10.1016/j.metabol.2020.154283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
600 Kumar S, Srivastava A, Palaia T, Hall C, Lee J, Stevenson M, Zhao CL, Ragolia L. Lipocalin-type prostaglandin D2 synthase deletion induces dyslipidemia and non-alcoholic fatty liver disease. Prostaglandins & Other Lipid Mediators 2020;149:106429. [DOI: 10.1016/j.prostaglandins.2020.106429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
601 Cao X, Gu Y, Bian S, Zhang Q, Meng G, Liu L, Wu H, Zhang S, Wang Y, Zhang T, Wang X, Sun S, Wang X, Jia Q, Song K, Niu K. Association between eating speed and newly diagnosed nonalcoholic fatty liver disease among the general population. Nutr Res 2020;80:78-88. [PMID: 32736293 DOI: 10.1016/j.nutres.2020.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
602 Mantovani A, Targher G, Zoppini G. Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. Clinics in Geriatric Medicine 2020;36:527-47. [DOI: 10.1016/j.cger.2020.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
603 Frohme J, Tacke F. The socioeconomic aspects of nonalcoholic fatty liver disease: food insecurity as a novel risk factor for steatosis and liver fibrosis. Hepatobiliary Surg Nutr 2020;9:543-5. [PMID: 32832515 DOI: 10.21037/hbsn.2020.03.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
604 Kashiwagi K, Takayama M, Fukuhara K, Shimizu-hirota R, Chu P, Nakamoto N, Inoue N, Iwao Y, Kanai T. A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity. Clinical Nutrition ESPEN 2020;38:86-93. [DOI: 10.1016/j.clnesp.2020.05.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
605 Yan FJ, Wang X, Wang SE, Hong HT, Lu J, Ye Q, Zheng YL, Wang YJ. C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD. Biochem J 2020;477:691-708. [PMID: 31957809 DOI: 10.1042/BCJ20190799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
606 Fiorentino TV, Miceli S, Succurro E, Sciacqua A, Andreozzi F, Sesti G. Nonalcoholic fatty liver disease is associated with a decreased myocardial mechano-energetic efficiency. J Intern Med 2021;289:221-31. [PMID: 32633873 DOI: 10.1111/joim.13155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
607 Zhao Q, Wei M, Zhang S, Huang Z, Lu B, Ji L. The water extract of Sophorae tonkinensis Radix et Rhizoma alleviates non-alcoholic fatty liver disease and its mechanism. Phytomedicine 2020;77:153270. [PMID: 32702591 DOI: 10.1016/j.phymed.2020.153270] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
608 Abhari K, Saadati S, Yari Z, Hosseini H, Hedayati M, Abhari S, Alavian SM, Hekmatdoost A. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN 2020;39:53-60. [PMID: 32859329 DOI: 10.1016/j.clnesp.2020.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
609 Sandeman LY, Kang WX, Wang X, Jensen KB, Wong D, Bo T, Gao L, Zhao J, Byrne CD, Page AJ, Proud CG. Disabling MNK protein kinases promotes oxidative metabolism and protects against diet-induced obesity. Mol Metab 2020;42:101054. [PMID: 32712434 DOI: 10.1016/j.molmet.2020.101054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
610 Alemany-Pagès M, Moura-Ramos M, Araújo S, Macedo MP, Ribeiro RT, do Ó D, Ramalho-Santos J, Azul AM. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance? BMC Public Health 2020;20:1142. [PMID: 32690054 DOI: 10.1186/s12889-020-09249-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
611 Huang S, Mu F, Li F, Wang W, Chen H, Lei L, Ma Y, Ding Y, Wang J. A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease. J Diabetes Res 2020;2020:7867245. [PMID: 32724826 DOI: 10.1155/2020/7867245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
612 Zhu H, Ge K, Lu J, Jia C. Downregulation of GNAI3 Promotes the Pathogenesis of Methionine/Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease. Gut Liver 2020;14:492-9. [PMID: 31694365 DOI: 10.5009/gnl19115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
613 Androutsakos T, Schina M, Pouliakis A, Kontos A, Sipsas N, Hatzis G. Liver Fibrosis Assessment in a Cohort of Greek HIV Mono-Infected Patients by Non-Invasive Biomarkers. Curr HIV Res 2019;17:173-82. [PMID: 31549590 DOI: 10.2174/1570162X17666190809153245] [Reference Citation Analysis]
614 Ogawa Y, Kobayashi T, Honda Y, Kessoku T, Tomeno W, Imajo K, Nakahara T, Oeda S, Nagaoki Y, Amano Y, Ando T, Hirayama M, Isono O, Kamiguchi H, Nagabukuro H, Ogawa S, Satomi Y, Saigusa Y, Takahashi H, Hyogo H, Yoneda M, Saito S, Yamanaka T, Aishima S, Eguchi Y, Kage M, Chayama K, Nakajima A. Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study. Hepatol Res 2020;50:955-65. [PMID: 32455496 DOI: 10.1111/hepr.13528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
615 Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med 2020;37:1793-806. [PMID: 32619031 DOI: 10.1111/dme.14356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
616 Gao Y, Zhang S, Li J, Zhao J, Xiao Q, Zhu Y, Zhang J, Huang W. Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid. Biosci Biotechnol Biochem 2020;84:2228-40. [PMID: 32654591 DOI: 10.1080/09168451.2020.1793293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
617 Kim NH, Jung YS, Park JH, Park DI, Sohn CI. Impact of nonalcoholic fatty liver disease on the risk of metachronous colorectal neoplasia after polypectomy. Korean J Intern Med 2021;36:557-67. [PMID: 32630984 DOI: 10.3904/kjim.2019.360] [Reference Citation Analysis]
618 Lu FB, Zheng KI, Rios RS, Targher G, Byrne CD, Zheng MH. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2020;35:2041-50. [PMID: 32573017 DOI: 10.1111/jgh.15156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
619 Meroni M, Longo M, Fracanzani AL, Dongiovanni P. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine 2020;57:102866. [PMID: 32629394 DOI: 10.1016/j.ebiom.2020.102866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
620 Yu Z, Wang S, Hou H, Ma L, Zhu Y. Lipidomic Profiling Reveals the Effect of Egg Components on Nonalcoholic Steatosis in HepG2 Cells and Its Involved Mechanisms. Eur J Lipid Sci Technol 2020;122:1900451. [DOI: 10.1002/ejlt.201900451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
621 Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202-9. [PMID: 32278004 DOI: 10.1016/j.jhep.2020.03.039] [Cited by in Crossref: 726] [Cited by in F6Publishing: 626] [Article Influence: 363.0] [Reference Citation Analysis]
622 El-derany MO, El-demerdash E. Pyrvinium pamoate attenuates non-alcoholic steatohepatitis: Insight on hedgehog/Gli and Wnt/β-catenin signaling crosstalk. Biochemical Pharmacology 2020;177:113942. [DOI: 10.1016/j.bcp.2020.113942] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
623 Sun L, Ling Y, Jiang J, Wang D, Wang J, Li J, Wang X, Wang H. Differential mechanisms regarding triclosan vs. bisphenol A and fluorene-9-bisphenol induced zebrafish lipid-metabolism disorders by RNA-Seq. Chemosphere 2020;251:126318. [DOI: 10.1016/j.chemosphere.2020.126318] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
624 Reja D, Makar M, Visaria A, Karanfilian B, Rustgi V. Blood lead level is associated with advanced liver fibrosis in patients with non-alcoholic fatty liver disease: A nationwide survey (NHANES 2011–2016). Annals of Hepatology 2020;19:404-10. [DOI: 10.1016/j.aohep.2020.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
625 Deng J, Wang M, Guo Y, Fischer H, Yu X, Kem D, Li H. Activation of α7nAChR via vagus nerve prevents obesity-induced insulin resistance via suppressing endoplasmic reticulum stress-induced inflammation in Kupffer cells. Medical Hypotheses 2020;140:109671. [DOI: 10.1016/j.mehy.2020.109671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
626 Wang C, Hu N, Yu L, Gong L, Dai X, Peng C, Li Y. 2,3,5,4'-tetrahydroxystilbence-2-O-β-D-glucoside attenuates hepatic steatosis via IKKβ/NF-κB and Keap1-Nrf2 pathways in larval zebrafish. Biomedicine & Pharmacotherapy 2020;127:110138. [DOI: 10.1016/j.biopha.2020.110138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
627 Zhang X, Lin Y, Lin S, Li C, Gao J, Feng Z, Wang J, Zhang J, Zhang H, Zhang Y, Chen X, Chen S, Xu C, Li Y, Yu C, Zeng H. Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction. Hepatol Int 2020;14:828-41. [PMID: 32607732 DOI: 10.1007/s12072-020-10068-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
628 Omar N, Koshy M, Hanafiah M, Hatta SFWM, Shah FZM, Johari B, Zamhuri I, Kasim SS, Rahman TA, Ghani RA. Relationships between severity of steatosis with glycemic control and carotid intima-media thickness among diabetic patients with ischemic heart disease. J Res Med Sci 2020;25:64. [PMID: 33088301 DOI: 10.4103/jrms.JRMS_560_17] [Reference Citation Analysis]
629 Fallatah HI, Al-Dabbagh A, Hiejazi MT, Hanbazazah SAA, Hussein AO, Al-Sahafi MA, Akbar HO. Prevalence and Clinical Characteristics of NAFLD in Chronic Liver Disease Patients from King Abdulaziz University Hospital, Jeddah. Saudi J Med Med Sci 2020;8:118-24. [PMID: 32587493 DOI: 10.4103/sjmms.sjmms_272_19] [Reference Citation Analysis]
630 Liu Z, Wei R, Li Y. Coronary heart disease is associated with nonalcoholic fatty liver disease in patients without hypertension and diabetes. Medicine (Baltimore) 2020;99:e20898. [PMID: 32590801 DOI: 10.1097/MD.0000000000020898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
631 Kolb R, Zhang W. Obesity and Breast Cancer: A Case of Inflamed Adipose Tissue. Cancers (Basel) 2020;12:E1686. [PMID: 32630445 DOI: 10.3390/cancers12061686] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
632 Hong Y, Choi SI, Hong E, Kim GH. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice. J Food Sci 2020;85:2216-26. [PMID: 32579753 DOI: 10.1111/1750-3841.15166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
633 Xiao Z, Chu Y, Qin W. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease. Life Sci 2020;256:117997. [PMID: 32585242 DOI: 10.1016/j.lfs.2020.117997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
634 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 21.0] [Reference Citation Analysis]
635 Zou Y, Yu M, Sheng G. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study. Lipids Health Dis 2020;19:145. [PMID: 32563249 DOI: 10.1186/s12944-020-01326-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
636 Bisaccia G, Ricci F, Mantini C, Tana C, Romani GL, Schiavone C, Gallina S. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. SAGE Open Med 2020;8:2050312120933804. [PMID: 32612827 DOI: 10.1177/2050312120933804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
637 Mayer C, Côme M, Blanckaert V, Chini Zittelli G, Faraloni C, Nazih H, Ouguerram K, Mimouni V, Chénais B. Effect of Carotenoids from Phaeodactylum tricornutum on Palmitate-Treated HepG2 Cells. Molecules 2020;25:E2845. [PMID: 32575640 DOI: 10.3390/molecules25122845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
638 Tsuji Y, Kaji K, Kitade M, Kaya D, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Moriya K, Akahane T, Yoshiji H. Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. Microorganisms 2020;8:E925. [PMID: 32575352 DOI: 10.3390/microorganisms8060925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
639 Jin M, Feng H, Wang Y, Yan S, Shen B, Li Z, Qin H, Wang Q, Li J, Liu G. Gentiopicroside Ameliorates Oxidative Stress and Lipid Accumulation through Nuclear Factor Erythroid 2-Related Factor 2 Activation. Oxid Med Cell Longev 2020;2020:2940746. [PMID: 32655764 DOI: 10.1155/2020/2940746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
640 Xu J, Wang R, You S, Zhang L, Zheng P, Ji G, Liu B. Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial. Trials 2020;21:512. [PMID: 32522273 DOI: 10.1186/s13063-020-04362-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
641 Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, Marotta P, Elkhashab M, Bajaj HS, Estes C, Razavi H. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. CMAJ Open 2020;8:E429-36. [PMID: 32518095 DOI: 10.9778/cmajo.20190212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
642 Tang K, Deng Y, Zheng C, Nie H, Pan M, Chen R, Xie J, Yang Q, Zhang Y. Prevention of Nonalcoholic Hepatic Steatosis by Shenling Baizhu Powder: Involvement of Adiponectin-Induced Inhibition of Hepatic SREBP-1c. Oxid Med Cell Longev 2020;2020:9701285. [PMID: 33062150 DOI: 10.1155/2020/9701285] [Reference Citation Analysis]
643 Qiao ZP, Zheng KI, Zhu PW, Gao F, Ma HL, Li G, Li YY, Targher G, Byrne CD, Zheng MH. Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. Nutr Metab Cardiovasc Dis 2020;30:1820-5. [PMID: 32636124 DOI: 10.1016/j.numecd.2020.05.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
644 Zhang X, Xu Y, Bai Q, Li X, Han J, Hou Y, Ji Y, Zhang Z. Inhibition of LXR signaling by SULT2B1b promotes liver regeneration after partial hepatectomy in mouse models of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2020;319:G87-96. [PMID: 32475129 DOI: 10.1152/ajpgi.00380.2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
645 Wang S, Cai B, Han X, Gao Y, Zhang X, Wang R, Zhang Y, Chen Q. Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20148. [PMID: 32384501 DOI: 10.1097/MD.0000000000020148] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
646 Liu SS, Ma XF, Zhao J, Du SX, Zhang J, Dong MZ, Xin YN. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. Lipids Health Dis 2020;19:118. [PMID: 32475354 DOI: 10.1186/s12944-020-01288-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
647 Fiorentino TV, Succurro E, Sciacqua A, Andreozzi F, Perticone F, Sesti G. Non‐alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance. Diabetes Metab Res Rev 2020;36. [DOI: 10.1002/dmrr.3333] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
648 Gadiparthi C, Spatz M, Greenberg S, Iqbal U, Kanna S, Satapathy SK, Broder A, Ahmed A. NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. J Clin Transl Hepatol. 2020;8:215-221. [PMID: 32832402 DOI: 10.14218/jcth.2020.00014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
649 Al-Mrabeh A. Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us? Cardiovasc Endocrinol Metab 2020;9:132-42. [PMID: 33225228 DOI: 10.1097/XCE.0000000000000201] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
650 Olaniyi KS, Amusa OA. Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin-nicotinamide-induced diabetic rats. Biomed Pharmacother 2020;128:110226. [PMID: 32460191 DOI: 10.1016/j.biopha.2020.110226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
651 Pisetta C, Chillè C, Pelizzari G, Pigozzi MG, Salvetti M, Paini A, Muiesan ML, De Ciuceis C, Ricci C, Rizzoni D. Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease. High Blood Press Cardiovasc Prev 2020;27:321-30. [DOI: 10.1007/s40292-020-00389-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
652 Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM. Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. Hepatol Commun 2020;4:1136-48. [PMID: 32766474 DOI: 10.1002/hep4.1534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
653 Shaunak M, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Non-alcoholic fatty liver disease and childhood obesity.Arch Dis Child. 2021;106:3-8. [PMID: 32409495 DOI: 10.1136/archdischild-2019-318063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
654 Rhee EJ. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective. Endocrinol Metab (Seoul) 2019;34:226-33. [PMID: 31565874 DOI: 10.3803/EnM.2019.34.3.226] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
655 Sawazaki H, Kitamura Y, Yagi K, Arai Y. Impact of Androgen Deprivation Therapy on Non-Alcoholic Fatty Liver Disease in Patients with Prostate Cancer: A CT Evaluation. Urol Int 2020;104:425-30. [PMID: 32396918 DOI: 10.1159/000507351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
656 Emamat H, Ghalandari H, Tangestani H, Abdollahi A, Hekmatdoost A. Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism. EXCLI J 2020;19:620-6. [PMID: 32483408 DOI: 10.17179/excli2020-1226] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
657 Badolati N, Masselli R, Sommella E, Sagliocchi S, Di Minno A, Salviati E, Campiglia P, Dentice M, Tenore GC, Stornaiuolo M, Novellino E. The Hepatoprotective Effect of Taurisolo, a Nutraceutical Enriched in Resveratrol and Polyphenols, Involves Activation of Mitochondrial Metabolism in Mice Liver. Antioxidants (Basel) 2020;9:E410. [PMID: 32403305 DOI: 10.3390/antiox9050410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
658 Sun X, Harris EN. New aspects of hepatic endothelial cells in physiology and nonalcoholic fatty liver disease. Am J Physiol Cell Physiol 2020;318:C1200-13. [PMID: 32374676 DOI: 10.1152/ajpcell.00062.2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
659 Worm N. Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD. Nutrients 2020;12:E1316. [PMID: 32384593 DOI: 10.3390/nu12051316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
660 Lutz SZ, Hennige AM, Peter A, Kovarova M, Totsikas C, Machann J, Kröber SM, Sperl B, Schleicher E, Schick F, Heni M, Ullrich A, Häring HU, Stefan N. The Gly385(388)Arg Polymorphism of the FGFR4 Receptor Regulates Hepatic Lipogenesis Under Healthy Diet. J Clin Endocrinol Metab 2019;104:2041-53. [PMID: 30541128 DOI: 10.1210/jc.2018-01573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
661 Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology 2020;71:1851-64. [PMID: 32012320 DOI: 10.1002/hep.31150] [Cited by in Crossref: 113] [Cited by in F6Publishing: 95] [Article Influence: 56.5] [Reference Citation Analysis]
662 Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G; SHIVER Network. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology 2020;71:1831-44. [PMID: 32052857 DOI: 10.1002/hep.31177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
663 Wang Y, Zhou X, Zhao D, Wang X, Gurley EC, Liu R, Li X, Hylemon PB, Chen W, Zhou H. Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes. PLoS One 2020;15:e0232630. [PMID: 32357187 DOI: 10.1371/journal.pone.0232630] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
664 Du J, Ren W, Zhang Q, Fu N, Han F, Cui P, Li W, Kong L, Zhao S, Wang R, Zhang Y, Yang L, Kong L, Nan Y. Heme Oxygenase-1 Suppresses Wnt Signaling Pathway in Nonalcoholic Steatohepatitis-Related Liver Fibrosis. Biomed Res Int 2020;2020:4910601. [PMID: 32461992 DOI: 10.1155/2020/4910601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
665 Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Liver Int. 2020;40:1254-1261. [PMID: 32301554 DOI: 10.1111/liv.14478] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 35.5] [Reference Citation Analysis]
666 Zhao Z, Chen L, Zhao Y, Wang C, Duan C, Yang G, Niu C, Li S. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.Appl Microbiol Biotechnol. 2020;104:5273-5282. [PMID: 32335723 DOI: 10.1007/s00253-020-10633-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
667 Sommerfeld O, von Loeffelholz C, Diab M, Kiessling S, Doenst T, Bauer M, Sponholz C. Association between high dose catecholamine support and liver dysfunction following cardiac surgery. J Card Surg 2020;35:1228-36. [PMID: 32333454 DOI: 10.1111/jocs.14555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
668 Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of Kidney Dysfunction IN Nafld. CPD 2020;26:1045-61. [DOI: 10.2174/1381612825666191026113119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
669 Song DS, Chang UI, Kang SG, Song SW, Yang JM. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2019;13:658-68. [PMID: 30970434 DOI: 10.5009/gnl18439] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
670 Meroni M, Longo M, Rustichelli A, Dongiovanni P. Nutrition and Genetics in NAFLD: The Perfect Binomium. Int J Mol Sci 2020;21:E2986. [PMID: 32340286 DOI: 10.3390/ijms21082986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
671 Shi Z, Li T, Liu Y, Cai T, Yao W, Jiang J, He Y, Shan L. Hepatoprotective and Anti-Oxidative Effects of Total Flavonoids From Qu Zhi Qiao (Fruit of Citrus Paradisi cv.Changshanhuyou) on Nonalcoholic Steatohepatitis In Vivo and In Vitro Through Nrf2-ARE Signaling Pathway. Front Pharmacol 2020;11:483. [PMID: 32390839 DOI: 10.3389/fphar.2020.00483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
672 Wu L, Liu Y, Zhao Y, Li M, Guo L. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1. Free Radic Biol Med 2020;153:140-58. [PMID: 32311490 DOI: 10.1016/j.freeradbiomed.2020.04.009] [Reference Citation Analysis]
673 Lee YJ, Wang CP, Hung WC, Tang WH, Chang YH, Hu DW, Lu YC, Yu TH, Wu CC, Chung FM, Hsu CC. Common and Unique Factors and the Bidirectional Relationship Between Chronic Kidney Disease and Nonalcoholic Fatty Liver in Type 2 Diabetes Patients. Diabetes Metab Syndr Obes 2020;13:1203-14. [PMID: 32368113 DOI: 10.2147/DMSO.S237700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
674 Sayiner M, Arshad T, Golabi P, Paik J, Farhat F, Younossi ZM. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. Hepatol Int 2020;14:556-66. [DOI: 10.1007/s12072-020-10038-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
675 Alemany-Pagès M, Tavares R, Varela Amaral S, Barros-Viegas AT, Oliveira PJ, Ramalho-Santos J, Azul AM. Publicly stressing the role of mitochondria in NAFLD with(in) a sports event. Eur J Clin Invest 2020;50:e13234. [PMID: 32291744 DOI: 10.1111/eci.13234] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
676 Hu C, Zhang Y, Wang S, Lin L, Peng K, Du R, Qi H, Zhang J, Wang T, Zhao Z, Li M, Xu Y, Xu M, Li D, Bi Y, Wang W, Chen Y, Lu J. Association of bedtime with the risk of non‐alcoholic fatty liver disease among middle‐aged and elderly Chinese adults with pre‐diabetes and diabetes. Diabetes Metab Res Rev 2020;36. [DOI: 10.1002/dmrr.3322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
677 Kur P, Kolasa-Wołosiuk A, Misiakiewicz-Has K, Wiszniewska B. Sex Hormone-Dependent Physiology and Diseases of Liver. Int J Environ Res Public Health 2020;17:E2620. [PMID: 32290381 DOI: 10.3390/ijerph17082620] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
678 Wikan N, Tocharus J, Sivasinprasasn S, Kongkaew A, Chaichompoo W, Suksamrarn A, Tocharus C. Capsaicinoid nonivamide improves nonalcoholic fatty liver disease in rats fed a high-fat diet. J Pharmacol Sci 2020;143:188-98. [PMID: 32414691 DOI: 10.1016/j.jphs.2020.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
679 Yang Y, Yang X, Lin Y, Yang G, Li L. LASS2 regulates hepatocyte steatosis by interacting with NDUFS2/OXPHOS related proteins. Biochem Biophys Res Commun 2020;526:871-9. [PMID: 32279995 DOI: 10.1016/j.bbrc.2020.02.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
680 Niederseer D, Wernly S, Bachmayer S, Wernly B, Bakula A, Huber-Schönauer U, Semmler G, Schmied C, Aigner E, Datz C. Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. J Clin Med 2020;9:E1065. [PMID: 32283679 DOI: 10.3390/jcm9041065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
681 Jin K, Liu Y, Shi Y, Zhang H, Sun Y, Zhangyuan G, Wang F, Yu W, Wang J, Tao X, Chen X, Zhang W, Sun B. PTPROt aggravates inflammation by enhancing NF-κB activation in liver macrophages during nonalcoholic steatohepatitis. Theranostics 2020;10:5290-304. [DOI: 10.7150/thno.42658] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
682 Lee SB, Kim MK, Kang S, Park K, Kim JH, Baik SJ, Nam JS, Ahn CW, Park JS. Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults. Endocrinol Metab (Seoul) 2019;34:179-86. [PMID: 31257745 DOI: 10.3803/EnM.2019.34.2.179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
683 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
684 Møller S, Kimer N, Barløse M, Bendtsen F. Pathophysiological-based treatments of complications of cirrhosis. Scand J Gastroenterol 2020;55:383-94. [PMID: 32233873 DOI: 10.1080/00365521.2020.1744709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
685 Collin de l'Hortet A, Gilgenkrantz H. [Emergence of 3D human fatty liver models engineered in the laboratory]. Med Sci (Paris) 2020;36:261-3. [PMID: 32228845 DOI: 10.1051/medsci/2020027] [Reference Citation Analysis]
686 Bayoumi A, Grønbæk H, George J, Eslam M. The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends Genet 2020;36:429-41. [PMID: 32396836 DOI: 10.1016/j.tig.2020.03.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
687 Ghazali R, Mehta KJ, Bligh SA, Tewfik I, Clemens D, Patel VB. High omega arachidonic acid/docosahexaenoic acid ratio induces mitochondrial dysfunction and altered lipid metabolism in human hepatoma cells. World J Hepatol 2020; 12(3): 84-98 [PMID: 32231762 DOI: 10.4254/wjh.v12.i3.84] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
688 Goldner D, Lavine JE. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology. 2020;158:1967-1983.e1. [PMID: 32201176 DOI: 10.1053/j.gastro.2020.01.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
689 Wu H, Ni X, Xu Q, Wang Q, Li X, Hua J. Regulation of lipid‐induced macrophage polarization through modulating peroxisome proliferator‐activated receptor‐gamma activity affects hepatic lipid metabolism via a Toll‐like receptor 4/NF‐κB signaling pathway. Journal of Gastroenterology and Hepatology 2020;35:1998-2008. [DOI: 10.1111/jgh.15025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
690 Zhang N, Tao J, Gao L, Bi Y, Li P, Wang H, Zhu D, Feng W. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet. Biomed Res Int 2020;2020:2947549. [PMID: 32149099 DOI: 10.1155/2020/2947549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
691 Romero-Zerbo SY, García-Fernández M, Espinosa-Jiménez V, Pozo-Morales M, Escamilla-Sánchez A, Sánchez-Salido L, Lara E, Cobo-Vuilleumier N, Rafacho A, Olveira G, Rojo-Martínez G, Gauthier BR, González-Mariscal I, Bermúdez-Silva FJ. The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2020;11:103. [PMID: 32210914 DOI: 10.3389/fendo.2020.00103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
692 Wu L, Sun J, Liu L, Du X, Liu Y, Yan X, Kombo Osoro E, Zhang F, Feng L, Liang D, Li Y, Chen Q, Sun S, Zhang L, Lan X, Li D, Lu S. Anti-toll-like receptor 2 antibody ameliorates hepatic injury, inflammation, fibrosis and steatosis in obesity-related metabolic disorder rats via regulating MAPK and NF-κB pathways. Int Immunopharmacol 2020;82:106368. [PMID: 32151955 DOI: 10.1016/j.intimp.2020.106368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
693 Pirmoazen AM, Khurana A, El Kaffas A, Kamaya A. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics 2020;10:4277-89. [PMID: 32226553 DOI: 10.7150/thno.40249] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 15.5] [Reference Citation Analysis]
694 Latorre J, Ortega FJ, Liñares-Pose L, Moreno-Navarrete JM, Lluch A, Comas F, Oliveras-Cañellas N, Ricart W, Höring M, Zhou Y, Liebisch G, Nidhina Haridas PA, Olkkonen VM, López M, Fernández-Real JM. Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes. EBioMedicine 2020;53:102697. [PMID: 32143184 DOI: 10.1016/j.ebiom.2020.102697] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
695 Chen H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. Liver Research 2020;4:15-22. [DOI: 10.1016/j.livres.2020.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
696 Mantovani A, Zusi C. PNPLA3 gene and kidney disease. Exploration of Medicine 2020;1:42-50. [DOI: 10.37349/emed.2020.00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
697 Thiagarajan P, Chalmers J, Ban L, Grindlay D, Aithal GP. L-carnitine supplementation in non-alcoholic fatty liver disease: A systematic review and meta-analysis. World J Meta-Anal 2020; 8(1): 4-14 [DOI: 10.13105/wjma.v8.i1.4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
698 Lv Y, Zhang HJ. Effect of Non-alcoholic Fatty Liver Disease on the Risk of Synchronous Liver Metastasis: Analysis of 451 Consecutive Patients of Newly Diagnosed Colorectal Cancer. Front Oncol 2020;10:251. [PMID: 32181157 DOI: 10.3389/fonc.2020.00251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
699 Rao A, van de Peppel IP, Gumber S, Karpen SJ, Dawson PA. Attenuation of the Hepatoprotective Effects of Ileal Apical Sodium Dependent Bile Acid Transporter (ASBT) Inhibition in Choline-Deficient L-Amino Acid-Defined (CDAA) Diet-Fed Mice. Front Med (Lausanne) 2020;7:60. [PMID: 32158763 DOI: 10.3389/fmed.2020.00060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
700 Wang N, Wang Y, Chen X, Zhang W, Chen Y, Xia F, Wan H, Li Q, Jiang B, Hu B, Lu Y. Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes. Front Endocrinol (Lausanne) 2019;10:926. [PMID: 32063885 DOI: 10.3389/fendo.2019.00926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
701 Wang Y, Yu Y, Wan H, Chen Y, Xia F, Zhang W, Zhang K, Gu X, Zhang Y, Lin Z, Yu Y, Wang N, Lu Y. Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients. Diabetes Metab Res Rev 2020;36:e3294. [PMID: 32017389 DOI: 10.1002/dmrr.3294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
702 Choe AR, Ryu DR, Kim HY, Lee HA, Lim J, Kim JS, Lee JK, Kim TH, Yoo K. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol 2020;21:50. [PMID: 32066395 DOI: 10.1186/s12882-020-01718-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
703 Nilsson PM, Korduner J, Magnusson M. Metabolically Healthy Obesity (MHO)-New Research Directions for Personalised Medicine in Cardiovascular Prevention. Curr Hypertens Rep 2020;22:18. [PMID: 32067105 DOI: 10.1007/s11906-020-1027-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
704 Tommasi S, Yoon JI, Besaratinia A. Secondhand Smoke Induces Liver Steatosis through Deregulation of Genes Involved in Hepatic Lipid Metabolism. Int J Mol Sci 2020;21:E1296. [PMID: 32075112 DOI: 10.3390/ijms21041296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
705 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
706 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
707 Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785-801. [PMID: 32059982 DOI: 10.1016/j.jhep.2020.01.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 28.0] [Reference Citation Analysis]
708 Wei YT, Lee PY, Lin CY, Chen HJ, Lin CC, Wu JS, Chang YF, Wu CL, Guo HR. Non-alcoholic fatty liver disease among patients with sleep disorders: a Nationwide study of Taiwan. BMC Gastroenterol 2020;20:32. [PMID: 32041532 DOI: 10.1186/s12876-020-1178-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
709 Yano K, Seko Y, Takahashi A, Okishio S, Kataoka S, Takemura M, Okuda K, Mizuno N, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan. Diagnostics (Basel) 2020;10:E86. [PMID: 32041289 DOI: 10.3390/diagnostics10020086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
710 Rubio C, Puerto M, García-Rodríquez JJ, Lu VB, García-Martínez I, Alén R, Sanmartín-Salinas P, Toledo-Lobo MV, Saiz J, Ruperez J, Barbas C, Menchén L, Gribble FM, Reimann F, Guijarro LG, Carrascosa JM, Valverde ÁM. Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice. Mol Metab 2020;35:100954. [PMID: 32244182 DOI: 10.1016/j.molmet.2020.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
711 Shen SH, Zhong TY, Peng C, Fang J, Lv B. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats. BMC Complement Med Ther 2020;20:34. [PMID: 32024509 DOI: 10.1186/s12906-020-2835-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
712 Lee Y, Lai HTM, de Oliveira Otto MC, Lemaitre RN, McKnight B, King IB, Song X, Huggins GS, Vest AR, Siscovick DS, Mozaffarian D. Serial Biomarkers of De Novo Lipogenesis Fatty Acids and Incident Heart Failure in Older Adults: The Cardiovascular Health Study. J Am Heart Assoc 2020;9:e014119. [PMID: 32020839 DOI: 10.1161/JAHA.119.014119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
713 Mauricio D, Alonso N, Gratacòs M. Chronic Diabetes Complications: The Need to Move beyond Classical Concepts. Trends Endocrinol Metab 2020;31:287-95. [PMID: 32033865 DOI: 10.1016/j.tem.2020.01.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
714 Ruan J, Guo J, Huang Y, Mao Y, Yang Z, Zuo Z. Adolescent exposure to environmental level of PCBs (Aroclor 1254) induces non-alcoholic fatty liver disease in male mice. Environmental Research 2020;181:108909. [DOI: 10.1016/j.envres.2019.108909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
715 Guaraldi G, Milic J. Vitamin E as a 'bridge' therapy for nonalcoholic steatohepatits in HIV: what is waiting on the other side of the bridge? AIDS 2020;34:317-9. [PMID: 31876593 DOI: 10.1097/QAD.0000000000002413] [Reference Citation Analysis]
716 Yang Y, Du L, Hosokawa M, Miyashita K. Effect of Spirulina lipids on high-fat and high-sucrose diet induced obesity and hepatic lipid accumulation in C57BL/6J mice. Journal of Functional Foods 2020;65:103741. [DOI: 10.1016/j.jff.2019.103741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
717 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170] [Cited by in Crossref: 131] [Cited by in F6Publishing: 102] [Article Influence: 65.5] [Reference Citation Analysis]
718 Rezaei S, Sasani MR, Akhlaghi M, Kohanmoo A. Flaxseed oil in the context of a weight loss programme ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease: a randomised double-blind controlled trial. Br J Nutr 2020;123:994-1002. [DOI: 10.1017/s0007114520000318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
719 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Bilson J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020;158:1597-1610. [PMID: 31987796 DOI: 10.1053/j.gastro.2020.01.031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
720 Kim SH, Park HY, Lee HS, Jung KS, Lee MH, Jhee JH, Kim TH, Lee JE, Kim HJ, Kim BS, Park HC, Lee BK, Choi HY. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity. Sci Rep 2020;10:1025. [PMID: 31974458 DOI: 10.1038/s41598-020-57894-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
721 Grgurevic I, Podrug K, Mikolasevic I, Kukla M, Madir A, Tsochatzis EA. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Can J Gastroenterol Hepatol 2020;2020:9181368. [PMID: 32051820 DOI: 10.1155/2020/9181368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
722 Moroldo M, Munyaka PM, Lecardonnel J, Lemonnier G, Venturi E, Chevaleyre C, Oswald IP, Estellé J, Rogel-Gaillard C. Integrative analysis of blood and gut microbiota data suggests a non-alcoholic fatty liver disease (NAFLD)-related disorder in French SLAdd minipigs. Sci Rep 2020;10:234. [PMID: 31937803 DOI: 10.1038/s41598-019-57127-x] [Reference Citation Analysis]
723 Gore E, Bigaeva E, Oldenburger A, Jansen YJM, Schuppan D, Boersema M, Rippmann JF, Broermann A, Olinga P. Investigating fibrosis and inflammation in an ex vivo NASH murine model. Am J Physiol Gastrointest Liver Physiol 2020;318:G336-51. [PMID: 31905025 DOI: 10.1152/ajpgi.00209.2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
724 Shi T, Wu L, Ma W, Ju L, Bai M, Chen X, Liu S, Yang X, Shi J. Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine. Evid Based Complement Alternat Med 2020;2020:8749564. [PMID: 31998400 DOI: 10.1155/2020/8749564] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
725 Laitinen TT, Vahtera J, Pahkala K, Magnussen CG, Nuotio J, Hutri-Kähönen N, Kivimäki M, Lehtimäki T, Jokinen E, Laitinen T, Tossavainen P, Pentti J, Viikari JSA, Juonala M, Raitakari OT. Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study. Hepatology 2020;71:67-75. [PMID: 31169929 DOI: 10.1002/hep.30804] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
726 Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 28.5] [Reference Citation Analysis]
727 Hao F, Shi J, Chen Y, Gu X, Ma D. Integrated Analysis of a Noncoding RNA-Associated Competing Endogenous RNA Network in Non-Alcoholic Fatty Liver Disease. IEEE Access 2020;8:88977-89. [DOI: 10.1109/access.2020.2992109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
728 Singh A, Nath P, Singhal V, Anand D, Kavita, Verma S, Hong T. A New Clinical Spectrum for the Assessment of Nonalcoholic Fatty Liver Disease Using Intelligent Methods. IEEE Access 2020;8:138470-80. [DOI: 10.1109/access.2020.3011289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
729 Ninić A, Zdravković M, Radosavljević V, Gardijan V, Memon L, Vekić J, Spasojević-kalimanovska V. Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea. Arhiv za farmaciju 2020;70:319-31. [DOI: 10.5937/arhfarm70-27586] [Reference Citation Analysis]
730 Li K, Zhao B, Wei D, Wang W, Cui Y, Qian L, Liu G. miR‑146a improves hepatic lipid and glucose metabolism by targeting MED1. Int J Mol Med 2020;45:543-55. [PMID: 31894315 DOI: 10.3892/ijmm.2019.4443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
731 Hosseinabadi S, Rafraf M, Asghari S, Asghari-Jafarabadi M, Vojouhi S. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Complement Ther Med 2020;49:102290. [PMID: 32147076 DOI: 10.1016/j.ctim.2019.102290] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
732 Seko Y, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Mizuno N, Takemura M, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;21:E171. [PMID: 31881781 DOI: 10.3390/ijms21010171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
733 Wattacheril J. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:141-9. [PMID: 32033760 DOI: 10.1016/j.gtc.2019.10.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
734 Coilly A, Desterke C, Guettier C, Samuel D, Chiappini F. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Sci Rep 2019;9:19785. [PMID: 31874999 DOI: 10.1038/s41598-019-56235-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
735 Li L, Fu J, Liu D, Sun J, Hou Y, Chen C, Shao J, Wang L, Wang X, Zhao R, Wang H, Andersen ME, Zhang Q, Xu Y, Pi J. Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARγ expression. Redox Biol 2020;30:101412. [PMID: 31901728 DOI: 10.1016/j.redox.2019.101412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
736 Tong H, Zhang X, Tan L, Jin R, Huang S, Li X. Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases. Eur J Pharmacol 2020;870:172888. [PMID: 31866404 DOI: 10.1016/j.ejphar.2019.172888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
737 Käräjämäki AJ, Hukkanen J, Kauma H, Kesäniemi YA, Ukkola O. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study). Scand J Clin Lab Invest 2020;80:106-13. [PMID: 31851849 DOI: 10.1080/00365513.2019.1700428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
738 Mikolasevic I, Lukenda Zanko V, Jakopcic I, Domislovic V, Mijic A, Stevanovic T, Delija B, Bokun T, Dinjar Kujundzic P, Ostojic A, Filipec Kanizaj T, Grgurevic I, Krznaric Z, Stimac D, Targher G. Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. J Diabetes Complications 2020;34:107512. [PMID: 31882273 DOI: 10.1016/j.jdiacomp.2019.107512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
739 Du J, Ji Y, Qiao L, Liu Y, Lin J. Cellular endo-lysosomal dysfunction in the pathogenesis of non-alcoholic fatty liver disease. Liver Int 2020;40:271-80. [PMID: 31765080 DOI: 10.1111/liv.14311] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
740 Zhao Y, Xing H, Wang X, Ou W, Zhao H, Li B, Li Y, Duan Y, Zhuang L, Li W, Cheng D, Quan M, Zhang Y, Ji S. Management of Diabetes Mellitus in Patients with Chronic Liver Diseases. J Diabetes Res 2019;2019:6430486. [PMID: 31915709 DOI: 10.1155/2019/6430486] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
741 Cabré N, Luciano-Mateo F, Baiges-Gayà G, Fernández-Arroyo S, Rodríguez-Tomàs E, Hernández-Aguilera A, París M, Sabench F, Del Castillo D, López-Miranda J, Menéndez JA, Camps J, Joven J. Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;51:374-87. [PMID: 31825539 DOI: 10.1111/apt.15606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
742 Ando Y, Yamazaki M, Yamada H, Munetsuna E, Fujii R, Mizuno G, Ichino N, Osakabe K, Sugimoto K, Ishikawa H, Ohashi K, Teradaira R, Ohta Y, Hamajima N, Hashimoto S, Suzuki K. Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population. Sci Rep 2019;9:18856. [PMID: 31827150 DOI: 10.1038/s41598-019-55076-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
743 Liu W, Zheng KI, Pan X, Ma H, Zhu P, Wu X, Rios RS, Targher G, Byrne CD, Wang X, Chen Y, Zheng M. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2020;35:1057-64. [DOI: 10.1111/jgh.14894] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
744 Shili-Masmoudi S, Wong GL, Hiriart JB, Liu K, Chermak F, Shu SS, Foucher J, Tse YK, Bernard PH, Yip TC, Merrouche W, Chan HL, Wong VW, de Lédinghen V. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int 2020;40:581-9. [PMID: 31749300 DOI: 10.1111/liv.14301] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
745 Eslam M, Alvani R, Shiha G. Obeticholic acid: towards first approval for NASH. Lancet. 2019;394:2131-2133. [PMID: 31813639 DOI: 10.1016/s0140-6736(19)32963-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
746 Janssen A, Grobbee DE, Dendale P. Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease. Eur J Prev Cardiol 2020;27:1059-63. [PMID: 31801050 DOI: 10.1177/2047487319891783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
747 Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, Schattenberg JM. Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Dig Dis Sci 2020;65:2112-9. [DOI: 10.1007/s10620-019-05986-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
748 Ahadi S, Gharekhani A, Shiva A. Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. Arab Journal of Gastroenterology 2019;20:189-97. [DOI: 10.1016/j.ajg.2019.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
749 Kovacovicova K, Vinciguerra M. Inhibition of dipeptidyl peptidase 4 (DPP4) activates immune cells chemotaxis in hepatocellular carcinoma. Oncology Signaling 2019;2:1-3. [DOI: 10.1016/j.onsig.2019.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
750 Xiong Q, Wu Y, Yang M, Wu G, Wang Y, Wang H, Feng J, Song L, Tong B, He G, Xu Y. Nr2e1 ablation impairs liver glucolipid metabolism and induces inflammation, high-fat diets amplify the damage. Biomedicine & Pharmacotherapy 2019;120:109503. [DOI: 10.1016/j.biopha.2019.109503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
751 Berenguer M. The changing face of hepatology. JHEP Rep 2019;1:415-7. [PMID: 32039392 DOI: 10.1016/j.jhepr.2019.11.003] [Reference Citation Analysis]
752 Mikami K, Endo T, Sawada N, Igarashi G, Kimura M, Hasegawa T, Iino C, Tomita H, Sawada K, Nakaji S, Matsuzaka M, Torok NJ, Fukuda S. Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population. Cytokine 2020;126:154927. [PMID: 31756645 DOI: 10.1016/j.cyto.2019.154927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
753 Zhang P, Feng W, Chu X, Sun X, Zhu D, Bi Y. A newly noninvasive model for prediction of non-alcoholic fatty liver disease: utility of serum prolactin levels. BMC Gastroenterol 2019;19:202. [PMID: 31775658 DOI: 10.1186/s12876-019-1120-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
754 Singh A, Elboraie A, Lan N, Gupta M. Factors Associated with Deep Vein Thrombosis in Type 2 Diabetics with Biopsy-Proven Non-alcoholic Fatty Liver Disease. SN Compr Clin Med 2020;2:32-41. [DOI: 10.1007/s42399-019-00188-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
755 Chen Y, Huang Q, Ai P, Liu H, Chen X, Xu X, Ding G, Li Y, Feng X, Wang X, Ji L, Li D, Zhou Y. Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease according to Different Menstrual Status Groups. Can J Gastroenterol Hepatol 2019;2019:2763093. [PMID: 31871925 DOI: 10.1155/2019/2763093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
756 Wang L, Zhu X, Sun X, Yang X, Chang X, Xia M, Lu Y, Xia P, Yan H, Bian H, Gao X. FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c. Lipids Health Dis 2019;18:197. [PMID: 31729980 DOI: 10.1186/s12944-019-1132-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
757 Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:128-41. [PMID: 31696690 DOI: 10.3350/cmh.2019.0001n] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
758 Montesano A, Senesi P, Vacante F, Mollica G, Benedini S, Mariotti M, Luzi L, Terruzzi I. L-Carnitine counteracts in vitro fructose-induced hepatic steatosis through targeting oxidative stress markers. J Endocrinol Invest 2020;43:493-503. [PMID: 31705397 DOI: 10.1007/s40618-019-01134-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
759 Desterke C, Chiappini F. Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway. Int J Mol Sci 2019;20:E5594. [PMID: 31717414 DOI: 10.3390/ijms20225594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
760 Yoo JJ, Yoo YJ, Moon WR, Kim SU, Jeong SW, Park HN, Park MG, Jang JY, Park SY, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SG, Kim YS, Kim JH, Yeon JE, Byun KS. Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. Korean J Intern Med 2020;35:1346-53. [PMID: 31694366 DOI: 10.3904/kjim.2018.309] [Reference Citation Analysis]
761 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
762 Iruarrizaga-lejarreta M, Arretxe E, Alonso C. Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. Expert Review of Precision Medicine and Drug Development 2019;4:283-97. [DOI: 10.1080/23808993.2019.1685379] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
763 Meroni M, Longo M, Erconi V, Valenti L, Gatti S, Fracanzani AL, Dongiovanni P. mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients 2019;11:E2597. [PMID: 31671785 DOI: 10.3390/nu11112597] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
764 Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism 2019;101:154001. [PMID: 31672448 DOI: 10.1016/j.metabol.2019.154001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
765 Fan M, Choi YJ, Tang Y, Bae SM, Yang HP, Kim EK. Efficacy and Mechanism of Polymerized Anthocyanin from Grape-Skin Extract on High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease. Nutrients 2019;11:E2586. [PMID: 31717842 DOI: 10.3390/nu11112586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
766 Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad F, Kowdley KV, Alkhouri N. Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World J Hepatol 2019; 11(10): 710-718 [PMID: 31749901 DOI: 10.4254/wjh.v11.i10.710] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
767 Sinn DH, Kang D, Chang Y, Ryu S, Cho SJ, Paik SW, Song YB, Pastor‐barriuso R, Guallar E, Cho J, Gwak G. Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. Journal of Gastroenterology and Hepatology 2020;35:833-9. [DOI: 10.1111/jgh.14856] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
768 Khoo WY, Chrisfield BJ, Sae-Tan S, Lambert JD. Mitigation of nonalcoholic fatty liver disease in high-fat-fed mice by the combination of decaffeinated green tea extract and voluntary exercise. J Nutr Biochem 2020;76:108262. [PMID: 31759197 DOI: 10.1016/j.jnutbio.2019.108262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
769 Li X, Zeng F, Huang Y, Liu B. The Positive Effects of Grifola frondosa Heteropolysaccharide on NAFLD and Regulation of the Gut Microbiota. Int J Mol Sci 2019;20:E5302. [PMID: 31653116 DOI: 10.3390/ijms20215302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
770 Astuti SD, Victory VS, Mahmud AF, Putra AP, Winarni D. The effects of laser diode treatment on liver dysfunction of Mus musculus due to carbofuran exposure: An in vivo study. J Adv Vet Anim Res 2019;6:499-505. [PMID: 31819878 DOI: 10.5455/javar.2019.f374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
771 Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martinez JA, Zulet MA. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Nutrients 2019;11:E2543. [PMID: 31652512 DOI: 10.3390/nu11102543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
772 Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17:40-52. [PMID: 31641249 DOI: 10.1038/s41575-019-0212-0] [Cited by in Crossref: 106] [Cited by in F6Publishing: 91] [Article Influence: 35.3] [Reference Citation Analysis]
773 Cui Y, Chang R, Zhang T, Zhou X, Wang Q, Gao H, Hou L, Loor JJ, Xu C. Chinese Herbal Formula (CHF03) Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) Through Inhibiting Lipogenesis and Anti-Oxidation Mechanisms. Front Pharmacol 2019;10:1190. [PMID: 31680967 DOI: 10.3389/fphar.2019.01190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
774 Mollica G, Senesi P, Codella R, Vacante F, Montesano A, Luzi L, Terruzzi I. L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. Dig Liver Dis 2020;52:314-23. [PMID: 31607566 DOI: 10.1016/j.dld.2019.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
775 Nobili V, Mantovani A, Cianfarani S, Alisi A, Mosca A, Sartorelli MR, Maffeis C, Loomba R, Byrne CD, Targher G. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. Journal of Hepatology 2019;71:802-10. [DOI: 10.1016/j.jhep.2019.06.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
776 Huang X, Chen W, Yan C, Yang R, Chen Q, Xu H, Huang Y. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. Biomedicine & Pharmacotherapy 2019;118:109258. [DOI: 10.1016/j.biopha.2019.109258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
777 Labenz C, Prochaska JH, Huber Y, Nagel M, Straub BK, Wild P, Galle PR, Schattenberg JM. Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. Hepatol Commun 2019;3:1472-81. [PMID: 31701071 DOI: 10.1002/hep4.1428]